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ABSTRACT
Background: Transforming growth factor beta 1 (TGF-β1), a pro-fibrotic tumour-
derived factor, promotes myofibroblast differentiation in the tumour microenvironment
and is thought to contribute to the development of pro-tumourigenic cancer associated
fibroblasts (CAF). To date, the molecular mechanisms underlying CAF differentiation
are poorly characterised. Here, the contribution of a class of small non-coding RNA,
miRNA, to myofibroblastic CAF differentiation was examined. The expression profile of
miRNA in experimentally-derived CAF (eCAF) was determined compared to normal
fibroblasts and CAF derived from oral cancers, and the functionality of selected miRNAs
in the reprogramming of normal fibroblasts to eCAF or in tumour-derived CAF was
investigated.
Methods: NOF (normal oral fibroblasts) were treated with a range concentration of
TGF-β1 (0.05-5 ng/ml) for 24 h and 48 h. The expression of myofibroblast markers, α-
SMA and FN-EDA1, were determined using qRT-PCR and western blot. The formation
of stress fibres was assessed by fluorescence microscopy, and associated changes in
contractility assessed using collagen contraction assays. miRNA expression profiling in
NOF, eCAF, and tumour-derived CAF was carried out using tiling low density array
(TLDA) cards, with two distinct methods of analysis employed. Candidate miRNAs were
validated using qRT-PCR. miRNA inhibitors used in the loss-of-function experiments;
anti-miR-424-3p and anti-miR-145-5p while a pre-miR-424-3p used to overexpress miR-
424-3p.
Results: TGF-β1 induced a myofibroblastic, CAF-like, phenotype in NOF (termed eCAF)
as assessed by expression of molecular markers, the formation of stress fibres and
increased contractility. TLDA analysis and qPCR validation demonstrated that miR-424-
3p and miR-145-5p were upregulated in eCAF. Overexpression of miR-424-3p inhibited
xvii
TGF-β1-induced eCAF phenotype in NOF. Conversely, knockdown of miR-424-3p or
miR-145-5p had no effect on eCAF formation. Overexpression of miR-424-3p did not
inhibit basal myofibroblast phenotype of CAF or further TGF-β1-induced myofibroblast
phenotype in CAF. Neither inhibition of miR-424-3p nor miR-145-5p increased basal
myofibroblast phenotype of CAF. Inhibition of miR-424-3p decreased TGF-β1-induced
α-SMA stress fibre formation and TGF-β1-induced contractility in CAF. Inhibition of
miR-145-5p increased TGF-β1-induced gel contraction, but not other myofibroblast
phenotype, in CAF. Reanalysis of TLDA data using a more stringent approach identified
other potential miRNA candidates differentially expressed in eCAF and CAF, compared
to NOF. The miRNA expression profiles of tumour-derived CAF (two subtypes of OSCC)
was distinctly different from that observed in eCAF, suggesting a difference between
CAF and fibroblasts artificially induced to become CAF-like cells in vitro.
Conclusions: The findings suggest that miR-424-3p might partially participate in TGF-
β1-induced CAF-like myofibroblast differentiation. Other miRNA was identified which
showed differences in expression between NOF, eCAF and CAF which could be
functionally analysed in future studies. Collectively the data suggest that miRNA may
play a role in CAF development, and could provide translational benefits in cancer
therapy.
1CHAPTER 1: Introduction
21.1 Overview
Several lines of evidence demonstrate that altered stroma microenvironment
makes a significant contribution to the malignant progression of cancers including oral
squamous cell carcinomas (OSCC) (Sobral et al., 2011). The tumour microenvironment
contains a mixture of cancerous cells together with normal cell populations such as
fibroblasts, endothelial cells, inflammatory cells and non-cellular components including
extracellular matrix components (ECM) (Baglole et al., 2006; Bussard et al., 2016). The
majority of tumour stromal cells, in most cases, are activated fibroblasts which
commonly express alpha smooth muscle actin (α-SMA) and other myofibroblast markers
such as fibronectin extra domain A (FN-EDA1) (Sugimoto et al., 2006). These cells have
been referred interchangeably as carcinoma-associated fibroblasts, cancer-associated
fibroblasts but are often called myofibroblasts (Dewever and Mareel, 2003; Bussard et al.,
2016). TGF-β is the best characterised factor capable of inducing a myofibroblast
phenotype (Ronnov-Jessen and Petersen, 1993; Tuxhorn et al., 2002). However, other
growth factors and cytokines mediate myofibroblast differentiation including interleukin-
6 (IL-6), platelet-derived growth factor (PDGF) and hepatocyte growth factor (HGF)
(Kalluri, 2016). More recently, Activin A has been reported to provoke myofibroblast
differentiation. Nithiananthan and colleagues (2017) demonstrated that Activin A induces
dermal fibroblast activation by increasing α-SMA positive stress fibre formation
compared to unstimulated cells. Additionally, expression of α-SMA positive stress fibre
formation by Activin A in static conditions is similar to that fibroblasts stimulated with
TGF-β1.
MicroRNAs (miRNAs) are small noncoding RNA molecules that regulate target
gene expression at the posttranscriptional level and are found to be deregulated in many
cancer cells (Ambros, 2004; Schickel et al., 2008). miRNAs are involved in many
3cellular processes such as cell death, cell proliferation and differentiation (Bartel, 2009).
Interestingly, some of them have also been classified as oncomiRs and tumour
suppressors (Lee and Dutta, 2006). To date, it is not clearly understood whether miRNAs
are involved in myofibroblast differentiation in cancer since little is known about the
miRNA expression in the stroma microenvironment.
Previous studies have demonstrated that CAF might be a potential target in the
treatment of cancer (Micke and Ostman, 2004), due to the genetic stability of these cells
and their wide applicability in various tumour types. They regulate the make-up of the
tumour ECM and the crosstalk between cancer cells and CAF that favours the survival of
tumour cells (Thode et al., 2011). Therefore, with this in mind, a study might be
conducted to investigate the role of miRNAs in CAF differentiation. In addition, there
has been no report comparing miRNA expression profile between TGF-β1-treated NOF
with unstimulated NOF in the tumour microenvironment of OSCC. The role of selected
miRNA in this study will add a valuable knowledge on how miRNAs regulate CAF
differentiation in OSCC.
1.2 Cancer biology
Cancers are a group of diseases in which normal cells proliferate in an uncontrolled
fashion and spread throughout the body. Such cells can arise in a variety of tissues and
organs and each of these sites contains different cell types that may be affected. The
hallmarks of cancer, as reviewed by Hanahan and Weinberg (2011), are the minimum
sets of genotypes or phenotypes that a cancer cell must acquire to become malignant.
These are; (a) sustaining proliferative signalling, (b) evading growth suppressors, (c)
enabling replicative immortality, (d) resisting cell death, (e) sustained angiogenesis and
(f) tissue invasion and metastasis.
4Carcinogenesis is defined as a multi-step process which involves initiation,
promotion and progression (Figure 1.1). It is initiated in a single cell that is exposed to
various carcinogens e.g. tobacco smoke, resulting in irreversible changes that will permit
malignant transformation. Once a cell has been initiated, it can become a cancer cell if it
retains the ability to divide and if the cellular changes that occurred during initiation are
enhanced by promotion. A promotion stage occurs where growth enhancement can allow
it to form a tumour. Both events resulted in the accumulation of genetic modifications.
Finally, at progression stage, the tumour must corrupt the cells around it (the tumour
microenvironment) to allow it to develop its own blood supply (angiogenesis) in order to
survive.
1.2.1 Cancer prevalence
Cancer is a major public health problem worldwide. Head and neck cancers rank
sixth of cancer-related death in the world, with an estimated 500 000 cases annually
(Fanucchi et al., 2006). The National Cancer Registry of Malaysia reported that head and
neck cancer was the third most common cancer among males and accounted for 7.8 % of
the total cancers in males (Gerrad and Halimah, 2008). Melanesia, south-central Asia,
western and southern Europe and southern Africa are high-risk regions for oral cancer
while southern and eastern Europe, south America and western Asia are for laryngeal
cancer (Parkin et al., 2002). This cancer usually occurs over the age of 60 and is much
more common in men, although the incidence of the disease is rising amongst both
women and young people, most likely due to lifestyle changes (Mackenzie et al., 2000).
1.3 Head and neck cancer and its carcinogenesis
Head and neck cancer is a broad term that consists of heterogeneous groups of
tumours that arise in the oral cavity, pharynx, larynx and cervical oesophagus (Figure
5Figure 1.1: Carcinogenesis
A) Epithelial cells are separated by basement membrane from the stroma milieu. The
stromal compartment consists of fibroblasts, inflammatory cells, ECM and blood vessels.
B) During carcinogenesis, epithelial and stromal components undergo genetic
modifications that promote cell proliferation. Additionally, fibroblast becomes activated,
increases in inflammatory cells homing and formation of new blood vessels. C) The
stroma becomes reactive and epithelial cells proliferate uncontrollably. Moreover, ECM
components are degraded while the number of inflammatory cells and activated
fibroblasts increases, resulting in secretion of various growth factors. Angiogenesis is
maintained for tumour cells to survive and ultimately metastases to distant site (taken
from Mbeunkui and Johann, 2009)
61.2). In most of the cases, this type of cancer mainly presents as squamous cell
carcinomas, therefore collectively referred as head and neck squamous cell carcinoma
(HNSCC). Although disparate in site, these tumours sometimes share certain molecular
characteristics. It has been found that telomerase is reactivated in 90 % of cases of
HNSCC (McCaul et al., 2002). Meanwhile, inactivation of p16 and loss of 3p contribute
to HNSCC carcinogenesis (Rocco and Sidransky, 2001; Perez-Ordonez et al., 2006). p53
mutation and loss of heterozygosity of 17p are detected in 50 % of cases of HNSCC
(Balz et al., 2003). Cyclin-D1 overexpression and amplification of 11q13 are seen in
HNSCC which might contribute to tumour aggressive behaviour (Pignataro et al., 1998;
Cappacio et al., 2000). Poor prognosis was detected in patients with tumours
overexpressing epidermal growth factor receptor (EGFR). Proangiogenic factors
including vascular endothelial growth factor (VEGF) have found to be upregulated in
HNSCC (Smith et al., 2000). Taken together, these collective events, in concert with
changes in the tumour microenvironment, might govern the development of HNSCC.
1.3.1 Risk factors for HNSCC
The major risk factors of HNSCC are smoking and excessive alcohol
consumption (Rodriguez et al., 2004). Recently a new etiologic factor, human
papillomavirus (HPV), was found to be involved in specific subsets of HNSCC (D’Sauza
et al., 2007). High-risk HPV types such as HPV16 and HPV18 mediate their
carcinogenic effect through E6 and E7 oncoproteins, that inactivate the p53 and pRb,
respectively (Munger and Howley, 2002). HPV genomic DNA was detected in about 25
% of cases of HNSCC (Kreimer et al., 2005). In addition, HPV16 might not depend on
other carcinogens to cause HNSCC (D’Souza et al., 2007). Therefore, the interaction
between HPV and HNSCC is crucial especially for treatment, prognosis and prevention
of HNSCC. All cancers are caused by abnormalities in the genetic material of the
7Figure 1.2: Head and neck cancer
A schematic picture highlighting the organs in which head and neck cancer can possibly
originate from. Head and neck cancer is generally understood as cancer of heterogeneous
group of organs or tissues that originate in oral cavity, pharynx, larynx and cervical
oesophagus (taken from the National Cancer Institute:
https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)
8transformed cells. This can happen due to both external factors such as tobacco,
infectious organisms, chemicals, and radiation and internal factors such as inherited
mutations, hormones and immune conditions (American Cancer Society, 2011). These
factors may act together or in sequence to initiate or promote carcinogenesis. In the case
of Fanconi Anaemia, patients have mutations in the genes which play a role in the
maintenance of DNA stability; in addition to bone marrow failure they are also at high
risk to develop squamous cell carcinoma, especially in the oral cavity, compared to
others (Suarez et al., 2006). Therefore, individuals with cancer susceptibility syndromes
are high risk to get HNSCC. Several genetic variations in enzymes that function to
metabolise and detoxify the carcinogenic substances in cigarette smoke and alcohol are
found to increase cancer risk (Ruwali et al., 2009).
1.3.2 Treatments for HNSCC
With the advancements in research and development, a number of invasive and
non-invasive treatments for HNSCC have been in practice. Some of the most widely
practised treatments are listed below and in each case, therapy will be decided by
considering primary tumour site, stage, resectability, patient factors such as swallowing
and airway considerations, desire for organ preservation and comorbid illnesses (Argiris
et al., 2008). Treatment decisions for HNSCC are often complex due to the involvement
of specialists such as head and neck surgeons, medical oncologists, radiation oncologists,
plastic surgeons as well as dentists.
Surgery- It is a primary treatment for HNSCC but often limited to some extent such as
the anatomical extent of the tumour and desire to achieve organ preservation. HNSCC
metastasise to a lymph node in the neck via the lymphatic route. Therefore, the presence
of lymph nodes metastases and the level in the neck, as well as the number of involved
nodes and the presence of extranodal spread are important prognostic factors (Schaaij-
9Visser et al., 2010). At this stage, the neck should be treated. Surgical excision may be
achieved with functional preservation of the involved organ and good oncological results
for a small, transorally accessible cancers of the oral cavity, pharynx and larynx
(Lefebvre, 2006).
Radiotherapy- It is an essential part of surgery treatment of HNSCC. Radiotherapy itself
controls tumour growth for early stage glottic, base of tongue and tonsillar cancer
(Argiris et al., 2008). Advances in imaging and radiation delivery such as CT scan, MRI
or PET datasets have dramatically changed management approaches. The intensity of
radiotherapy beams can be optimised by computer-controlled treatment to deliver a high
dose of radiation to cancer cells while reducing the dose and toxic effect on healthy
tissues (Argiris et al., 2008). Advance in radiotherapy methods including heavy particle
radiation, proton therapy, brachytherapy and neutron beam radiation can be used, but
have not been validated in clinical trials (Ding et al., 2005).
Chemotherapy and novel agents- Chemotherapy plays an important role in HNSCC
treatment, from palliative care to curative programmes for locally advanced HNSCC
(Cohen et al., 2004). Different classes of agents such as platinum compounds,
antimetabolites as well as taxanes have shown promising activity against HNSCC
(Colevas, 2006). Platinum compounds including cisplatin are used in combination with
radiation or with other agents. Taxane-based combinations are effective in treating
locally advanced HNSCC (Argiris, 2005). EGFR inhibitors such as cetuximab have
emerged as a novel treatment for locally advanced HNSCC (Karamauzis et al., 2007). In
addition, the combination of EGFR with other molecular targeted agents has emerged as
a novel strategy (Argiris et al., 2008). However, the combination of these novel agents is
not yet regarded as a standard treatment for locally advanced HNSCC.
1.4 Tumour Microenvironment
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Stroma of the tumour microenvironment (reactive stroma) is fundamentally different
from the stroma of normal tissue. Genetic and epigenetic studies indicate that tumour
progression is not just determined by cancer cells themselves, but also tumour
microenvironment. Paget (1889) proposed “seed and soil” hypothesis; tumour cells (the
seed) require the host environment (the soil) for their optimal growth. The tumour
microenvironment is a complex network that comprises a multiple cell, soluble factors,
signalling molecules and ECM which directs tumour progression (Cukierman and Bassi,
2012). The multiple cells that collectively form the tumour microenvironment are
endothelial cells, pericytes, fibroblasts and inflammatory cells (Figure 1.3) (Joyce and
Pollard, 2009). Numerous studies have demonstrated that CAF promote tumour growth
and progression, although there exist conflicting reports. Paracrine interactions within the
tumour microenvironment are responsible for the complexity of the metastatic cascades
(Van Zijl et al., 2011). For example, matrix metalloproteinase (MMPs) secreted from
tumour cells can modify extracellular microenvironment by degrading ECM proteins,
cytokines and growth factors secretion including TGF-β (Egeblad and Werb, 2002). In
addition, MMPs and members of a disintegrin metalloproteases (ADAM) family can
cleave cell surface membrane receptors, thus releasing them into ECM (Zhou et al.,
2005).
1.4.1 Fibroblasts
As originally described by Tarin and Croft (1969), fibroblasts are non-vascular,
non-epithelial, non-inflammatory cells, embedded within the matrix of the connective
tissue. Morphologically, fibroblasts are spindle-like shape cells with the prominent actin
cytoskeleton and vimentin filaments (Kalluri and Zeisberg, 2006). Fibroblasts play role
in ECM deposition, regulation of epithelial differentiation, regulation of inflammation
and involvement in wound healing (Parsonage et al., 2005). They synthesise ECM
11
Figure 1.3: Tumour microenvironment
Various cell types within tumour microenvironment in addition to tumour cells. These
include cellular components such as endothelial cells, pericytes, CAF and non-cellular
components including ECM and various growth factors (taken from Joyce and Pollard,
2009).
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constituents including type I, type III and type V collagen and fibronectin (Tomasek et
al., 2002; Rodemann and Muller, 1991). In addition, they secrete type IV collagen and
laminin for basement membrane formation (Chang et al., 2002). Fibroblasts are crucial in
maintaining an ECM homoeostasis, by producing ECM-degrading proteases such as
MMPs (Simian et al., 2001).
Fibroblasts in normal stroma are considered inactive with negligible metabolic
activity at the molecular level. Therefore, they are assumed to be in the quiescent state. A
specific marker for quiescent fibroblast is still unknown, but fibroblast specific protein 1
(FSP-1) has been proposed as a possible candidate (Strutz, 1995). Fibroblasts play
important roles in wound healing in which they invade the lesions and generate ECM that
acts as a scaffold for tissue regeneration (Rasanen and Vaheri, 2010). These activated
fibroblasts become a specialised type of fibroblasts known as myofibroblasts which
acquired contractile stress fibres and express α-SMA and FN-EDA1 (Tomasek et al.,
2002). However, the mechanism of how these myofibroblasts revert to their original
phenotype is poorly understood, but it is believed that these myofibroblasts undergo a
specific type of programmed cell death called nemosis and removal by granulation tissue
(Desmouliere et al., 1995). The differences between quiescent fibroblasts and activated
myofibroblasts are listed in Table 1.1. Myofibroblasts in mammals are highly
heterogeneous with specific expression depending on where they are isolated in the tissue.
Therefore, none of the fibroblasts markers is both exclusive to fibroblasts or present in all
fibroblasts (Table 1.2).
1.4.2 Cancer associated fibroblasts
Unlike in normal stroma, fibroblasts in tumour stroma remain activated. These
activated fibroblasts are called cancer associated fibroblasts (CAF) (Tomasek et al.,
2002). In regards to phenotype and function, CAF can be distinguished from normal
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Quiescent or resting fibroblasts Activated fibroblasts
Morphologically bland (spindle-shaped) Morphologically active (cruciform or
stellate-shaped)
Metabolically indolent Metabolically active
G0/G1 arrest or slow cycling self-
renewal
Proliferative
Activated by growth factors Further activated by growth factors
FSP1+, α1β1 integrin+ αSMA+, PDGFRβ+, FAP+
Non-migratory Migratory
No ECM production ECM production and synthetic
phenotype
No active secretome Active and dynamic secretome
Epigenetically stable Epigenetically modified (e.g. RASAL1
hypermethylation)
Precursor for activated fibroblasts Precursor for chondrocytes, adipocytes,
myocytes and endothelial cells
Table 1.1: The differences between normal fibroblasts with activated fibroblast
Morphologically, fibroblasts appear as elongated cells with a prominent actin and
vimentin filaments. Phenotypically, activated fibroblast often express α-SMA (adapted
from Kalluri, 2016)
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Marker Function Fibroblast types in
which it is found
Other cell types in
which it is found
Vimentin Intermediate- filament-
associated protein
Miscellaneous Endothelial cells,
myoepithelial cells
and neurons
α-SMA Intermediate- filament-
associated protein
Myofibroblasts Vascular smooth
muscle cells,
pericytes and
myoepithelial cells
Desmin Intermediate- filament-
associated protein
Skin fibroblasts Muscle cells and
vascular smooth
muscle cells
FSP1 Intermediate- filament-
associated protein
Miscellaneous Invasive carcinoma
cells
Discoidin-
domain
receptor 2
Collagen receptor Cardiac fibroblasts Endothelial cells
FAP Serine protease Activated
fibroblasts
Activated
melanocytes
α1β1 integrin Collagen receptor Miscellaneous Monocytes and
endothelial cells
Prolyl 4-
hydroxylase
Collagen biosynthesis Miscellaneous Endothelial cells,
cancer cells and
epithelial cells
Pro-collagen
1α2
Collagen1 biosynthesis Miscellaneous Osteoblasts and
chondroblasts
Table 1.2: Activation markers
Several well-established markers for fibroblasts and their expression in other cell types
(adapted from Kalluri and Zeisberg, 2006).
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fibroblasts by differential expression of ECM components and growth factors as well as
their proliferation rate (Kalluri and Zeisberg, 2006). CAF are characterised by several
activation markers including α-SMA, fibroblast specific marker 1 (FSP-1), PDGF and
FAP (Garin-Chesa et al., 1990; Kalluri, 2016). CAF are often identified by their
expression of α-SMA (Ronnov-Jenssen et al., 1996; Gabbiani, 2003). In addition, FSP-1
is reported to be specific to CAF in vivo (Kalluri and Zeisberg, 2006). The previous study
has demonstrated that CAF in different tumours showed two major subsets. One subset
was FSP-1 positive but lack expression of α-SMA and PDGF while other, on the other
hand, FSP-1 negative with co-expressed α-SMA and PDGF (Sugimoto et al., 2006). CAF
were found to be one of the most prominent cell type within the tumour stroma of breast,
prostate and pancreatic cancers (Kalluri and Zeisberg, 2006; Pietras and Ostman, 2010).
The underlying mechanisms that mediate transition of normal fibroblasts to CAF are
unclear. Apart of TGF-β, various growth factors such as PDGF, insulin growth factor
(IGF) and granulocyte macrophage colony stimulating factor (GM-SCF) were suggested
to take part in CAF differentiation (DeWever and Mareel, 2003). Phenotypic features of
CAF can be induced by TGF-β in vitro which mediates fibroblast activation during
wound healing and organ fibrosis (Dumont and Arteaga, 2000).
1.4.3 Myofibroblasts or activated fibroblast-associated with wound healing
Wound healing is a sequence of events that lead to the repair of injured tissue.
Wound healing occurs in three phases; inflammatory, proliferative and remodelling
phases (Schilling, 1976). Homing of leukocytes including neutrophils, lymphocytes and
monocytes to the wound is important to clear dead cells (Kurkinen et al., 1980). This
phase is known as the inflammatory phase. While in the proliferative phase, collagen
deposition occurs as well as the formation of new vasculature (Hunt, 1998). The injured
tissue attracts various types of cell such as endothelial cells, pericytes, myofibroblasts
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and leukocytes (Witte and Barbul, 1997). In the remodelling phase, wound healing can
be accomplished by regeneration of same parenchymal cells or replacement of fibrous
extracellular matrix (Madden and Smith, 1970). After completing the wound healing
process, myofibroblasts revert to their original phenotype or undergo apoptosis by
granulation tissue (Desmouliere et al., 1995).
Myofibroblasts are most commonly present in tissue related with mechanical
strength such as the oral cavity, the skin, the gastrointestinal tract, the uterus, the testes
and the heart (Huang and Lee, 2003; Eyden, 2009). Morphologically, myofibroblasts
appears similar to both fibroblast and smooth muscle cells (Oda et al., 1988).
Myofibroblasts commonly expresses α-SMA, though this marker is expressed in smooth
muscle cells (Hinz et al., 2007; Eyden et al., 2009). However, myofibroblasts is negative
for heavy myosin chains, caldesmon and desmin (McAnulty, 2007; Schurch et al., 2007;
Eyden, 2008). They are also typically negative for cytokeratin, CD68, CD34 and CD31
(DeWever, 2008; Micke and Ostman, 2004). Myofibroblast differentiation is induced by
paracrine signalling by various factors including TGF-β, PDGF and IGF 11 (Powell et al.,
1999; Desmouliere et al., 2004; Micke and Ostman, 2004). Morphologically and
phenotypically differences between quiescent fibroblasts, wound healing associated
fibroblasts and CAF are shown in Figure 1.4.
1.4.4 Senescent fibroblasts
Cellular senescence or replicative senescence is termed as an event in which
proliferating cells undergo permanent cell arrest in response to oncogenic events. In 1965,
Hayflick and co-workers demonstrated that human fibroblasts had limited ability to
proliferate in culture; after many cell passages, cell proliferation was gradually decreased.
Many factors contribute to cellular senescence including DNA damage,
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Figure 1.4: Morphologically and phenotypically differences between quiescent
fibroblasts, wound healing associated fibroblasts and CAF
A) Quiescent fibroblasts are elongated-shaped single cells, B) During wound healing,
activated fibroblasts are stellate-shaped cells and express α-SMA. ECM remodelling
contributes to their contractility and various secretory molecules amplify their activation
and enhance proliferation, C) CAF may gain enhanced various secretory molecules and
specialised ECM remodelling, adding to the complexity of tumour microenvironment
(Kalluri, 2016).
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oncogene expression and physiological mitogenic signals. Cellular senescence acts as
tumour suppressive mechanism that prevents cells undergo neoplastic transformation
(Campisi, j, 2001; Redder, R, 2000). The hallmark of cellular senescence is growth arrest.
Senescent cells arrest growth at G1 phase of cell cycle, yet they remain metabolically
active (Herbig et al., 2004). Unlike quiescence cells, the growth of senescent cells is
permanently arrested as the proliferative ability of senescent cells cannot be stimulated
by known physiological stimuli. The characteristics of senescence growth arrest depend
on the species and genetic background of the cell itself. Senescent cells often express
cell-cycle inhibitors; the cyclin-dependent kinase inhibitors (CDK1s) p21 and p16
(Campisi, J, 2001; Braig and Schmitt, 2006). These CDKIs are involved in tumour
suppressor pathways that are governed by the p53 and pRB proteins. p53 and pRB act as
transcriptional regulators and the pathway they regulated are often interrupted in cancer
(Sherr and McCormick, 2002).
Several markers can distinguish senescent cells, both in culture and in vivo.
Nevertheless, none of them is specific to the senescent state and are normally used in
combination to increase confidence. The most common senescence marker was
senescence-associated β-galactosidase (SA-βgal) (Dimri et al., 1995). This marker can be
detected by histochemical staining in senescent cells. Recently p16 also can be used to
identify senescent cells (Krishnamurthy et al., 2006). p16 is expressed in many (not all)
senescent cells (Beausejour et al., 2003; Itahana et al., 2003). However, it also expressed
in some of the tumour cells, particularly those that have lost pRB function (Gil and Peters,
2006).
1.5 Roots of CAF
There is considerable controversy regarding the origin of CAF. It is possible that
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they come from multiple origins such as resident fibroblasts, pericytes, epithelial cells,
mesenchymal cells, endothelial cells as well as cancer cells (Figure 1.5) (Chirri and
Chiarugi, 2011). Thus, their multiple origins contribute to pleiotropic actions in tumour
microenvironment milieu.
1.5.1 CAF may derive from normal fibroblasts
CAF possibly originate from resident fibroblasts via mesenchymal-mesenchymal
transition (MMT) by cancer-derived growth factors including TGF-β (Kalluri and
Zeisberg, 2006). This notion was confirmed by data showing that human mammary
fibroblasts convert into CAF in a breast tumour xenograft model and this activation is
mediated by TGF-β (Kojima et al., 2010). CAF and tumour cells create a
cytokinenetwork, working directly on both cells. Additionally, CAF undergo frequent
genetic modification (Tsellou and Kiaris, 2008).
The evidence of genetic alteration in CAF is controversial and conflicting. Some
of the studies have identified a genetic alteration in CAF. This is exemplified in the work
conducted by Littlepage et al., (2005) that tumour enhancing characteristics of fibroblast
can be maintained without exposure to cancer cells. This indicates that genetic
modification may responsible for this stable phenotypes. Indeed, some studies have
reported a high frequency of genetic alterations in CAF including point mutations, loss of
heterozygosity (LOH) and changes in expression level of oncogenes and tumour
suppressors from various human cancers. Surprisingly, LOH frequency of 59.7 % and
66.2% was observed in BRCA1/2-related breast cancer stroma and in the epithelium,
respectively (Weber et al., 2006). Additionally, LOH frequency was identified in the
neoplastic epithelial breast (25-69%) and stromal compartment (17-61%) (Kurose et al.,
2001). Taken together, the frequency of LOH in stroma was similar to that
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Figure 1.5: Multiple origins of CAF within the tumour microenvironment
CAF may arise from resident fibroblasts, pericytes, epithelial cells, mesenchymal cells,
endothelial cells and carcinoma cells via various types of mesenchymal transition process
(taken from Chirri and Chiarugi, 2011).
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observed in epithelial components. Moreover, LOH signature of CAF is strongly
associated with tumour grade in women diagnosed with sporadic breast tumours (Fukino
et al., 2004). However, one study did not find genetic alterations in CAF isolated from
fresh breast cancer biopsies using SNP array analysis (Allinen et al., 2004). Similarly,
CAF neither show any somatic genetic alterations nor p53 protein expression in
pancreatic cancer (Walter et al., 2008).
1.5.2 CAF may originate from bone marrow-derived MSCs
CAF may also originate from bone marrow-derived mesenchymal stem cells
(MSCs). Both cell types have similarities in the expression of surface markers such as
CD29, CD90, CD44, CD73, CD106 and CD117 as well as α-SMA and vimentin. MSCs
have capability to differentiate into various cell types including bone, fat, cartilage and
muscle in physiological and pathological processes (Bergfeld and DeClerck, 2010;
Dominici et al., 2006). MSCs exhibit homing and engraftment at injury sites in many
conditions, particularly in tissue repair and inflammation (Hall et al., 2007). Similar to
inflammatory cells in tissue repair, the recruitment of MSCs at the tumour site is
mediated by various cytokines and growth factors (Spaeth et al., 2008). A study carried
out by Spaeth and colleagues (2009) showed that labelled MSCs were localised within
the tumour mass and differentiated into CAF. In addition, Direkzi and co-workers (2004)
transplanted green fluorescent protein (GFP) α-SMA + MSCs-derived male patient into a
female recipient and found that 25% of cells labelled with GFP in the total CAF
population. Additionally, osteopontin is able to convert MSCs into CAF. Collectively,
these studies indicate that MSCs may act as a potential source for CAF.
1.5.3 CAF may derive from epithelial cells
Alternatively, CAF may originate from epithelial cells via epithelial-
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mesenchymal transition (EMT) (Radisky et al., 2007). This idea arises from the evidence
that epithelial cells undergo DNA oxidation and mutation when exposed to MMP-driven
oxidative stress, thereby undergoing specialised EMT in which they become CAF
(Spaeth et al., 2009). EMT is an event in which epithelial cells with tight junctions
become mesenchymal cells with a loose cell-cell adhesion (Hay, 1995). Conversion of
epithelial cells into CAF is a special case of EMT (Forino et al., 2006). This transition
generates CAF instead of cancer cells. Iwano et al., (2002) found that 30 % of CAF in
the kidney are derived from kidney tubular epithelial cells. Indeed, genetic analysis
showed that CAF isolated from human breast cancer biopsies were derived from the
epithelial tumour cells (Peterson et al., 2003). Even though cancer cells are unable to
generate the majority of CAF by EMT, other cells such as normal epithelial cells can act
as additional source of CAF through EMT in response to certain stimuli from the
microenvironment (Iwano et al., 2002; Direkze et al., 2004; Direkze and Alison, 2006).
1.5.4 CAF from endothelial cells through endothelial-mesenchymal transition
(EndMT)
Proliferating endothelial cells might become CAF via endothelial-mesenchymal
transition (EndMT) process by the loss of endothelial markers such as CD31 under
stimulation of TGF-β (Zeisberg et al., 2007). This type of EndMT expresses both FSP-1
and down-regulation of CD31/PECAM (Potenta et al., 2008). During this process,
resident endothelial cells disorganise the cell layer and invade the underlying tissue due
to loss of E-cadherin (Potenta et al., 2008).
1.5.5 CAF from cancer cells
Cancer cells can directly generate CAF through EMT process (Radisky et al.,
2007). This process allows cancer cells to behave mesenchymal-like phenotype,
23
characterised by increased in invasiveness. EMT is induced by many factors including
TGF-β and is mediated by targeted downstream molecules such as Snail, Slug and Twist
(Medici et al., 2008).
1.6 Role of CAF in tumorigenesis
CAF affect tumour growth in many ways. Initially, CAF suppress tumour growth
by inhibiting early stages of tumour progression through the formation of gap junctions
between activated fibroblasts. But, later on, CAF promote tumorigenesis by secreting
pro-tumourigenic factors (McAnulty, 2007). Two different pathways are established in
the crosstalk between cancer cells and stromal cells. In the efferent pathway, cancer cells
cause a reactive response in stroma via secretion of various growth factors and cytokines
while in the afferent pathway, the stroma influences cancer cells’ behaviour in an
analagous way (Figure 1.6; described in more detail in section 1.6.2) (Giannoni et al.,
2010).
1.6.1 CAF support tumour growth by secretion of growth factors, cytokines and
proteases
Tumour cell proliferation is important in order to maintain continuous growth and
metastatic properties. CAF directly stimulate cancer cell proliferation by secreting
various growth factors, hormones and cytokines such as TGF-β and hepatocyte growth
factor (HGF) (Chirri and Chiarugi, 2011). Parallel to this notion, Kuperwasser and
colleagues (2004) showed that overexpression of these two growth factors in mouse
fibroblasts is able to induce the initiation of breast cancer when co-injected with normal
epithelial cells. In addition, FSP-1 secreted by CAF is important in altering tumour
microenvironment which favours cancer progression. Metastatic cancer cells transplanted
into FSP-1 knockout mice are less likely to form a tumour than when co-injected with
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Figure 1.6: Crosstalk between CAF and tumour cells
Cancer cells induce CAF via secretion of various growth factors and cytokines which, in
turn, sustain tumour progression by promoting ECM remodelling (taken from Giannoni
et al., 2010).
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FSP-1 positive fibroblasts (Grum-Schewensen et al., 2005). Stromal cell-derived factor 1
(SDF-1) derived from CAF is able to promote angiogenesis via binding of SDF-1β or
CXCL12 to its receptors, CXCR4 which highly expressed on the cancer cells (Goh et al.,
2007). Apart from those growth factors, IGF-1 also plays important role in cancer growth.
For example, melanoma cells are unable to produce IGF-1 by themselves, thus they rely
on surrounding fibroblasts which express N-cadherin to stimulate their growth (Li et al.,
2003). Of note, CAF can respond to androgen produced by lung and prostate cancer cells
to produce growth factors that mediate proliferation of epithelial cells (Cunha et al.,
2002). CAF also secrete some metabolites such as pyruvate that governs the growth of
cancer cells (Koukourakis et al., 2006).
1.6.2 CAF regulate motility and stemness
Both clinical and experimental data support the hypothesis that CAF mediate cell
motility and metastases to the distant site (Joyce and Pollard, 2009). Two signals are
established in the crosstalk between cancer cells and CAF; efferent signal and afferent
signal. In efferent signal, several factors secreted by cancer cells such as TGF-β, IL-6,
PDGF and VEGF stimulate a response in activated stromal cells. These factors influence
fibroblast differentiation and proliferation. In turn, the reactive stromal cells secrete
multiple factors including TGF-β, HGF and SDF-1 that influence cancer cells. This
signal is known as an afferent signal. CAF and tumour cells create a paracrine network,
working directly with each other. The involvement of soluble mediators secreted by CAF
influences the progression of cancer cells. In vitro coculture studies showed that CAF
stimulated by TGF-β increase growth of breast cancer cells and squamous cell carcinoma
(Lewis, et al., 2004; Casey et al., 2008). Additionally, conditioned media from gastric
cancer cells induces IL-6 secretion by fibroblasts through IL-1. IL-6 acts in a paracrine
manner, promoting the proliferation of gastric cancer cells through STAT3 signalling
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(Kinoshita et al., 2013). Some studies demonstrated that CAF can induce a cancer stem
cell (CSC) phenotype. Vermeulen and co-workers (2010) demonstrated that HGF
secreted by CAF enhanced Wnt signalling activity in colon cancer cells, thereby
stimulated the CSC features. Additionally, CAF were able to enhance the stem cell-
specific phenotype by increasing the CCL-2 expression in breast cancer cells (Tsuyada et
al., 2012). CAF influence homing and self-renewal capability of cancer cells by
increased expression of cancer stem cell markers such as CD44 (Mani et al., 2008).
Indeed, this induction of cancer stem cells phenotype has been related to EMT through
over-expression of either Snail or Twist transcription factors.
1.6.3 Regulation of cancer metabolism
The mechanism of how CAF may regulate tumour metabolism is described in
Figure 1.7 (Koppenol et al., 2011). The difference between normal and cancer cells is
glucose metabolism. Cancer cells use glucose by aerobic glycolysis while normal cells
catabolize glucose by oxidative phosphorylation (Jones and Thompson, 2009). Increased
glucose consumption produces more intermediate glycolytic metabolites and ATP from
glycolysis. Following glycolysis, pyruvate mainly converted into lactate in the cytoplasm
by lactate dehydrogenase (LDH) (so-called Warburg effect). The Warburg effect coupled
with an increased glucose intake facilitates the growth of cancer cells by generating
pyruvate (glycolytic intermediate). This product is more likely secreted rather than being
oxidised through mitochondrial metabolism. Aerobic glycolysis and LDH are over-
expressed in Caveolin-1 (Cav-1) deficient stromal cells of breast cancer (Pavlides et al.,
2009). Furthermore, a loss of Cav-1 is correlated with tumour metastases and poor
prognoses in breast cancer. In contrast to Warburg effect, Koukourakis et al., (2006)
proposed that tumour stroma acts as a major buffer of acidity and recycles products of
aerobic glycolysis (pyruvate) to sustain its anabolism and growth. These contrast findings
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Figure 1.7: Metabolic interactions between cancer cells with CAF
Cancer cells force CAF to undergo aerobic glycolysis that ultimately produces energy-
rich nutrients (lactate or pyruvate). This product was used by cancer cells in Krebs cycle
for ATP production (taken from Koppenol et al., 2011).
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need further confirmation especially in an in vivo model.
1.6.4 CAF involvement in invasion and metastasis
CAF are able to act as modulators of tumour cell invasion and as regulators for
the tumour to metastasise to distant sites. CAF participate in tumour metastases through
cell-cell interactions and paracrine signalling (Gupta and Massague, 2006). However, it
is also demonstrated that CAF use physical movement; they create a tunnel through the
matrix, making a path that allows cancer cells to follow behind (Gaggioli et al., 2007).
This mechanism poses the role of CAF in ECM remodelling through the secretion of
various proteases and metalloproteinases. Moreover, Duda et al., (2010) proposed that
the stromal cells might travel with tumour cells in the bloodstream, thus protecting
tumour cells from apoptosis. CAF have increased ability to degrade matrix, and express
palladin which is able to promote in vitro and in vivo invasion of pancreatic cancer cells
(Goicoechea et al., 2014). The ECM remodelling by MMPs is one of the important steps
in tumour progression. In normal tissues, the balance between MMPs and their inhibitors
keeps ECM well-organized. However, in tumours, fibroblasts play a major role by
secreting various matrix degrading proteases as well as their activators, urokinase
receptor (uPA). The tissue inhibitors of metalloproteinases (TIMPs) can downregulate
MMPs activity. In addition, TIMPs can modulate other growth factors without inhibition
of the MMPs, suggesting that TIMPs may be involved in some oncogenic signal (Flavell
et al., 2008). Many MMPs (not all) play important roles in cancer metastases. For
example, high levels of MMP2 production in stromal cells indicates pathological
neoangiogenesis of glioma (Takahashi et al., 2002). Up-regulation of MMP1 is
associated with poor prognosis in breast cancer as it cleaves protease-activated receptor-1
(PAR1) on the cancer cell surface, thereby stimulating growth and invasion of cancer
cells (Poola et al., 2005).
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Over the last decades, a large amount of evidence from many different studies
demonstrated that CAF produce soluble factors that cause cancer cell migration. For
example, HGF, a chemotactic factor released by CAF binds to cMET receptor on the
tumour cells, thereby stimulating tumour progression and growth (De Veirman et al.,
2014). Karnoub et al., (2007) reported that CCL5 is involved in breast cancer metastases.
Stanniocalcin 1 (STC1), a protein secreted by CAF stimulates colon cancer cells
metastases (Peña et al., 2013). Collectively, these data show that CAF as prominent
stromal cell component of tumours create optimal conditions for secondary tumour
development.
1.6.5 CAF interact with immune cells in the tumour microenvironment
Pro-inflammatory cytokines secreted by cancer cells and CAF attract excessive
immune cells such as leukocytes, monocytes, macrophages and mast cells to the cancer
region (Raz & Erez, 2013). CCL2 secreted by CAF showed a role in
monocyte/macrophage recruitment in several types of cancer, including lymphoma,
breast and melanoma cancer (De Veirman et al., 2014). In addition, several factors
secreted by CAF such as IL-6, IL-4, IL-8 and FAP are involved in macrophage
differentiation or M2 polarisation, creating an immunosuppressive microenvironment.
Once macrophages reach the tumour, they become tumour associated macrophages
(TAMs) which further influence growth and metastatic properties of cancer cells (Lin &
Pollard, 2007).
1.7 TGF-β and myofibroblasts recruitment
1.7.1 TGF-β signalling
TGF-β superfamily contains over 30 members including three isoforms, TGF-β1,
β2 and β-3 that have different potencies but similar properties in vivo and in vitro and
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among of these, TGF-β1 is most related to fibrosis and myofibroblasts differentiation
(Ask et al., 2008). TGF-β is secreted to ECM as inactive latent complexes consisting of
bioactive TGF-β, the latency-associated product and the latent TGFβ-binding-protein 1
(Rifkin, 2005). TGF-β is activated by various proteases and ECM proteins including
plasmin, MMP2, MMP9, integrin αvβ6 and thrombospondin (Annes et al., 2003). TGF-β
binds to two transmembrane serine/threonine kinase receptors (TβRI & II), thereby
activating downstream molecules, particularly Smads and small G-proteins (Derynck et
al., 2001). Smad comprises of three classes; the receptor-activated Smads (R-Smads,
Smad1, 2, 3, 5 and 8), the common Smads (co-Smad, Smad4) and the inhibitory Smads
(iSmads, Smad6 and 7). In TGF-β signalling, the receptor complex binds to Smad2 and 3,
which are phosphorylated in their C-terminal tail by the active TβRI. A trimeric complex
comprises of the phosphorylated R-Smads, co-Smad and Smad 4 and was transported
into the nucleus. This complex recognises specific Smad binding elements located in the
enhancer or promoter regions of target genes. TGF-β1 mediates conversion of normal
fibroblasts into myofibroblasts. TGF-β1 induces myofibroblast phenotype of MRC-5
human fetal lung fibroblasts, leading to upregulation of miR-21 expression in the
myofibroblasts (Yao et al., 2011). TGF-β1 treatment caused upregulation of miR-21
expression in primary rat adventitial fibroblasts compared to untreated fibroblasts (Wang
et al., 2012). TGF-β is important for N-cadherin expression through a JNK-dependent
signalling (De Wever et al., 2004). Of note, TGF-β is the only growth factor that able to
transdifferentiate fibroblasts into CAF in vivo and in vitro as assessed by abundant
expression of α-SMA (Tuxhorn et al., 2002). Lewis et al., (2004) demonstrated that
conditioned media from SCC induces myofibroblast differentiation associated with TGF-
β1 treatment. Further, by Matrigel assay, they showed that these activated myofibroblasts
produce higher levels of HGF, thereby increasing migration of SCC. Moreover, TGF-β1
produced by CAF is able to increase colony formation in soft agar compared to normal
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fibroblast from prostate tissue.
Initially, TGF-β functions as a tumour suppressor by inhibiting early stages of
carcinogenesis but, later on, promotes cancer progression and metastases (Arkhurst,
2002). However, the underlying molecular mechanisms are not clear. Under normal
conditions, the antiproliferative effect of TGF-β on epithelial cells might limit the growth
of normal epithelium and the formation of cancer (Siegel and Massague, 2003). On the
contrary, TGF-β facilitates EMT of cancer cells, thus promoting invasiveness and
metastasis. High levels of TGF-β1 in tumours is due to an increase in the release of
active TGF-β1 from its latent complex that is commonly found in ECM of stromal cells
(McCawley et al., 2000). Taken together, the role of TGF-β in cancer cells is complex
and multifaceted. Therefore, its function should be interpreted with caution.
1.7.2 Canonical TGF-β signalling in myofibroblasts differentiation
Smad signalling was implicated to be involved in myofibroblast differentiation by
early studies using knockout models, where mice null for Smad3 was protected from
fibrosis in various experimental models (Bujak et al., 2007; Flanders et al., 2002; Zhao et
al., 2002). Intriguingly, the proximal promoter of α-SMA contains at least two Smad
binding elements (SBEs) and mutation of SBEs prevents TGF-β1 induced activation of
this promoter (Hu, Wu and Phan, 2003). Thus, most studies so far, have demonstrated
Smad3 as the main Smad mediator of fibrosis associated with TGF-β signalling (Hu et al.,
2003; Qiu, Feng and Li, 2003; Duan et al., 2014). However, other studies showed that
both R-Smads are involved in myofibroblasts differentiation (Evans et al., 2003). Smad2
and Smad3 are both activated downstream of TβR1 and share similar sequence
homology. But these proteins differ in their ability to bind DNA. Unlike Smad3, Smad2
does not binds directly to DNA, thus requires additional co-factors to regulate target
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genes (Yagi et al., 1999). In line with this, Smad2 and Smad3 null mice show different
phenotypes in disease. Smad3 mutant caused colon cancer to metastasise to distant site
(Zhu et al., 1998). Smad2 signalling determines anterior-posterior polarity of the early
mouse embryo (Waldrip et al., 1998).
Active Smad complexes can interact with other transcription factors and co-
activators in the nucleus that further define target gene competency for expression in a
cell. More studies emphasised the interaction between pSmad2/3 and β-catenin at
specific cis-elements of fibrotic target genes (Akhmetshina et al., 2012; Chen et al., 2011;
Shafer and Towler, 2009). Upon Wnt signalling activation, β-catenin, the effector of the
canonical Wnt signalling pathway, accumulates in the nucleus and binds to the TCF/LEF
family of transcription factors (Clevers and Nusse, 2012). The TGF-β and β-catenin
signalling pathways display synergistic effects on myofibroblast differentiation and α-
SMA expression (Carthy et al., 2012; Chen et al., 2011). Zhou et al (2012) demonstrated
that TGF-β signalling can activate β-catenin to form a complex with pSmad3 and the
histone acetyl-transferase CREB-binding protein (CBP) at the α-SMA promoter.
Furthermore, specifically blocking the interaction of β-catenin with CBP prevents TGF-
β-induced expression of α-SMA and fibrosis in vivo, suggesting β-catenin connect
Smad3 to the catalytic activity of CBP (Hao et al., 2011; Henderson et al., 2010).
Other crosstalk that exists in Smad signalling is TGF-β-hippo pathways
interaction. Some studies showed that YAP and TAZ, the hippo pathway effectors,
interact with Smads to control Smad nuclear retention and TGF-β induced cellular
responses (Narimatsu et al., 2015; Varelas et al., 2008). YAP/TAZ accumulates in the
nucleus by activated TGF-β signalling (Grannas et al., 2015). Inhibition studies of these
effectors block the nuclear translocation of active pSmad2/3 complexes, thus inhibit the
expression of fibrotic genes associated with TGF-β including α-SMA, COL1A1 and
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CTGF (Piersma et al., 2015; Szeto et al., 2016). Liu and coworkers (2015) demonstrated
that YAP/TAZ accumulated in the nuclei of α-SMA positive fibroblasts of lung fibrosis.
1.7.3 Non-Smad signalling: RHO pathway links TGF-β mediated actin
polymerisation in myofibroblast differentiation
One of the myofibroblast phenotypes induced by TGF-β is a reorganisation of the
actin cytoskeleton and formation of focal adhesion complexes. TGF-β induces these
phenotypes, at least in part, through activation of Rho GTPase pathway. The Rho
GTPase act as molecular switches, exist in GDP-bound (inactive state) while GTP-bound
(active state) and interact with downstream effectors to transmit their signal (Van Aelst
and D’souza-Schorey, 1997). TGF-β induces activation of Rho GTPases in various cell
types including fibroblasts (Vardouli, Moustakas and Stournaras, 2005), with several
studies emphasised on Rho A (Johnson et al., 2014; Manickam et al., 2014). The
mechanism of Rho activation by TGF-β is poorly understood. However, it was postulated
to be non-Smad signalling, at least initially, but requires the activity of Tβ1R (Fleming et
al., 2009; Sandbo et al., 2011). The activated Rho GTPase trigger a cascade involving
Rho coiled-coiled kinase (ROCK) 1-mediated LIM-kinase 2 activation and inactivation
of the actin microfilaments and the formation of stress fibres (Vardouli et al., 2005).
Both a rapid and delayed activation of Rho Kinase pathway has been observed in
response to TGF-β (Edlund et al., 2002; Sandbo et al., 2011; Vardouli et al., 2005).
Furthermore, the delayed activation correlates to the prominent stress fibres formation
after 18-24 h of TGF-β stimulation and subsequent α-SMA expression. The delayed
activation of Rho kinase was postulated to involve a biphasic signalling pathway;
initially dependent on Smad signalling but later dependent on cofilin phosphorylation
downstream of ROCK (Edlund et al., 2002; Sandbo et al., 2011). Inhibition of ROCK
signalling by pharmacological inhibitor (Y27632) prevents stiffness-induced α-SMA
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expression and stress fibres formation in lung myofibroblasts (Htwe et al., 2017).
Inhibition of actin polymerisation by cytochalasin D prevents myofibroblast
transformation of lung fibroblasts (Ni et al., 2013). Inhibition of focal adhesion kinase
(FAK) activity by FAK inhibitor attenuates myofibroblast differentiation of cardiac
fibroblast (Zhang et al., 2017). Collectively, inhibition of Rho kinase signalling prevents
myofibroblast phenotype in various tissue fibrosis.
1.7.4 Non-Smad signalling: MAPK pathway and TGF-β induced myofibroblasts
As reviewed by Zhang et al., (2017), TGF-β activates a member of MAPK
signalling (ERK, c-Jun amino terminal kinase and p38 MAPK) upon receptor-ligand
binding. In myofibroblast differentiation, a rapid phosphorylation of ERK1/2 and p38
MAPK have been observed in TGF-β-treated human tenon fibroblasts with p38 showing
a biphasic and sustained signal (Carthy et al., 2015; Meyer-Ter-Vehn et al., 2006). Fra 2,
a member of the Fos family of AP1 transcription factors, is believed to be involved in the
ERK1/2 activation induced by TGF-β. Pre-incubation of human breast fibroblasts with
Fra 2-targeting siRNA inhibits the myofibroblast markers associated with TGF-β such as
calponin and SM-22α compared to control siRNA (Carthy et al., 2015). However, the
exact mechanism on how MAPK signalling links to Smad signalling remains unclear.
The pathways that involve in TGF-β-induced myofibroblasts differentiation are
illustrated in Figure 1.8.
1.8 Drug resistance induced by tumour stromal cells
Therapeutic resistance is the significant reason for cancer treatment failure, including
in HNSCC. Stromal cells including CAF may influence the treatment sensitivity of
tumour cells. Several lines of evidence demonstrate that the tumour microenvironment
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Figure 1.8: TGF-β signalling in myofibroblasts differentiation
TGF-β activates Smad and non-Smad signalling which contribute to the myofibroblasts
phenotype. The Smad pathway is characterised by the binding of Smad transcriptional
complexes to the Smad binding elements in the specific site of target genes. TGF-β
induces non-Smad MAPK signalling via Fra 2, a member of Fos family of AP1
transcription factors (taken from Carthy et al., 2015).
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confers chemotherapy resistance by releasing soluble factors. Johansson and coworkers
(2012) demonstrated that co-culture of HNSCC cell lines with CAF in the presence of
cetuximab resulted in an increased proliferation rate of tumour cells and elevated
expression of MMP-1. Additionally, the CAF-induced resistance was partly abolished by
adding MMP-1 inhibitor into co-culture, suggesting the role of MMP-1 in the
development of drug resistance. HGF levels secreted by the stromal cells of melanoma
correlates with poor response to anti-cancer drugs (Straussman et al., 2012). The cellular
(CAF) and non-cellular (ECM) of tumour microenvironment contribute to the anti-
apoptotic property of tumour cells (Sebens and Schafer, 2012). The tumour
microenvironment also hampers chemotherapy treatments by causing the tumour to
develop drug resistance through metabolic effects (Pietras and Ostman, 2010). Moreover,
other studies demonstrated that stromal cells promote mitochondrial metabolism in
carcinoma cells (Martinez-Outschoorn et al., 2010; Martinez-Outschoorn et al., 2011).
For instance, fibroblasts induce resistance to tamoxifen in breast cancer by amplifying
mitochondrial metabolism in cancer cells (Martinez-Outschoorn et al., 2011).
Additionally, stromal cells induce resistance to cytotoxic chemotherapy such as
doxorubicin and docetaxel through lactate production (Martinez- Outschoorn et al. 2011;
Rong et al., 2013). Parallel with this finding, Tavares-Valente and colleagues (2013)
demonstrated that lactate release from stromal cells causes a low pH in the tumour
microenvironment and this low pH is associated with resistance to paclitaxel and
doxorubicin in MCF-7 cells.
1.9 Therapeutic implications
Increasing evidence shows that cancer progression is greatly influenced by its
microenvironment, not merely on cancer cells. The concept of targeting CAF as a
therapeutic implication is intriguing, however, several obstacles should be overcome.
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Successful therapy must solely target the cancer components while avoid targeting the
surrounding normal stromal cells such as endothelial cells and inflammatory cells.
Moreover, several factors such as insufficient vascular structures, pH alterations and
hypoxia may hamper the delivery of agents to the stroma. Therefore, effective
approaches are needed to identify the novel targets and successful delivery methods.
There are several promising drugs targeting CAF. VEGF inhibitors specifically target the
endothelial cells, one of the origins of CAF (Xing et al., 2010). Tenascin-C is highly
expressed in CAF and able to promote metastases in colon cancer (De Wever et al.,
2004). Anti-tenascin antibody, 81C6 is now in a clinical trial (phase II) for brain tumour
patients (Reardon et al., 2006). FAP is abundantly expressed in CAF compared to normal
fibroblast. Thus, an antibody called sibrotumab is under clinical trials for colon cancer
patients (Scott et al., 2003). CTGF is highly expressed in CAF and it promotes
tumorigenesis in prostate cancer (Yang et al., 2005). Therefore, CTGF inhibitors might
be a promising target for cancer therapy. Further understanding of CAF themselves and
their pathological role in tumour microenvironment milieu will lead to the development
of promising novel agents for cancer therapy.
1.10 MicroRNAs
They are many types of endogenous RNA molecules exist; small transfer RNA
(tRNA), ribosomal RNA (rRNA), small nucleolar RNA (snoRNA), small interfering
RNA (siRNA) and microRNA (miRNAs). miRNAs are small noncoding RNAs of ~ 22
nucleotides in length that negatively regulate gene expression at the post-transcriptional
level. miRNAs regulate cell differentiation since they affect the expression of many
genes. Furthermore, they are deregulated in cancer cells (Schickel et al., 2008).
Generally, it is not clear whether miRNAs are involved in the conversion of normal
fibroblasts to CAF. In addition, little is known about miRNAs expression in tumour
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stroma, particularly in oral cancer. One study demonstrated that miR-145 was down-
regulated in oral fibroblast treated with cigarette smoke condensate (Pal et al., 2013).
1.10.1 Expression and function of miRNAs
The expression and function of miRNAs involve a complex set of proteins
(Meltzer, 2005). miRNAs commonly located in a non-coding region or in introns of
protein coding-genes (Chen, 2005). The mechanism of miRNAs biogenesis and function
is described in Figure 1.9 by Barca-Mayo and Lu (2012).
Briefly, a relatively large primary miRNA (pri-miRNA) is produced when the
miRNAs gene is transcribed by RNA Polymerase II. This pri-miRNA is cleaved by
Ribonuclease III or Drosha to form a precursor miRNA (pre-miRNA) molecule. Then,
pre-miRNA is transported to the cytoplasm by Exportin 5 for further steps. In the
cytoplasm, the pre-miRNA is converted into short RNA duplex of 18-24 nucleotides in
length by Dicer. In most cases, one strand is degraded while the other one is incorporated
into the RNA-induced silencing complex (RISC). The RISC complex caused miRNA to
bind to the 3’ UTR region of mRNA target, leading to degradation of miRNA or
inhibition of mRNA translation. Of note, miRNAs might play a role in cell proliferation
and apoptosis, thus it is not surprisingly that miRNAs might cause tumorigenesis (Catto
et al., 2011).
1.10.2 MicroRNAs and cancer
While most microRNA studies have focused on the tumour cell, little is known
about microRNA expression in the tumour microenvironment. As mentioned above, the
microRNAs are usually deregulated in many cancers. Differential expression of
microRNAs in various cancer cells can be identified by high output technologies
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Figure 1.9: Biosynthesis and function of miRNAs
A pri-miRNA is transcribed from miRNA gene by RNA polymerase II and is cleaved by
Drosha to produce pre-miRNA. A pre-miRNA is transported into the cytoplasm by
Exportin 5. In the cytoplasm, the pre-miRNA is cleaved by Dicer to produce a miRNA
duplex. The mature miRNA strand incorporates into the RISC and bind to a specific site
of mRNA target. The miRNA complex induces either mRNA degradation or translational
repression (taken from Barca-Mayo and Lu, 2012).
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including microarray and PCR approaches. For example, down regulated of miR-15a and
miR-16-1 in prostate cancer cells and these miRNAs target their downstream molecule,
BCL-2 (Calin et al., 2002; Cimmino et al., 2005). Let-7 family, tumour-suppressor
miRNA is found to be down-regulated in several cancers such as lung and gastric cancer
(Takamizawa et al., 2004). In addition, decreased expression of this miRNA cause
increased expression of Ras oncogene in some human lung tumours and is associated
with poor prognosis (Johnson et al., 2005). Previous studies have shown that oncogenic
miRNAs involved in the pathogenesis of some tumours. Overexpression of these
miRNAs inactivates tumour suppressor genes. For example, overexpression of miR-155
in breast, lung and colon cancers (Yanaihara et al., 2006; Volinia et al., 2006).
Additionally, overexpression of miR-21 has been shown in glioblastoma cell lines (Chan
et al., 2005). Taken together, altered miRNAs expression could be involved in the
initiation of tumour process.
1.10.3 miRNA in tumour microenvironment (CAF)
Accumulating data indicate that microRNAs are involved in the dramatic changes
in the tumour microenvironment, mainly in CAF, which enhances the progression of the
tumour (Aprelikova et al., 2012). To date, there have been no reports regarding
differential miRNA expression profiling in CAF, particularly in HNSCC. A recent study
demonstrated that miR-21 expression in CAF is associated with poor prognosis in
pancreatic ductal adenocarcinoma (Kadera et al., 2013). Overexpression of miR-21
promotes CAF formation in cultured human fibroblast foreskin (Li et al., 2013). Yang
and colleagues (2014) demonstrated that miR-106b is upregulated in CAF compared with
normal fibroblasts established from patients with gastric cancer. Additionally, the
expression level of miR-106b is associated with poor prognosis of patients. miR-200
family including miR-200c is down-regulated in CAF compared to normal fibroblast in
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breast cancer (Zhao et al., 2012). This miRNA has been shown to regulate EMT and
cancer cell migration by targeting tumour suppressor E-Cadherin (Gregory et al., 2008).
miR-31 is down-regulated in CAF of endometrial cancer compared to normal fibroblast
and is associated with increased tumour cell motility (Aprelikova et al., 2010). Taken
together, global gene expression profiling of the stromal compartment, mainly fibroblasts
have been shown to effectively predict clinical outcome and therapy response (Finak et
al., 2008; Farmer et al., 2009).
1.10.4 miRNA in fibrosis
Fibrosis is the formation of excess fibrous connective tissue in an organ that
ultimately resulted in an imbalance of metabolism of ECM molecule. Fibrosis is
probably to result from both; an increased synthesis and decreased degradation of ECM
components. For example, MMPs that degrade ECM may be elevated while their
inhibitors, TIMPs may be down-regulated. Thus, abnormalities in multiple pathways
involved in tissue repair and inflammation can lead to the development of fibrosis.
Extensive tissue remodelling and fibrosis can eventually lead to a number of organ
failure. Several of evidence that suggest miRNAs are involved in the process of fibrosis
in several organs including heart, lung and kidney.
Cardiac fibroblasts are abundant cell type in the heart and crucial in the regulation of
cardiac ECM metabolism (Sounders et al., 2009). Excess deposition of ECM components
in the heart is associated with various cardiovascular diseases such as hypertension,
myocardial infarction and cardiomyopathy and miRNAs are believed to involve in the
modulation of these conditions (Diez, 2009; Mishra et al., 2009). miR-28 was selectively
expressed in cardiac fibroblasts and overexpression of miR-28 was observed in heart
failure of human, mice and rats (Thum et al., 2008). Van Rooij et al (2008) demonstrated
that the miR-29 family was down-regulated in murine and human hearts during
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myocardial infarction.
Pulmonary fibrosis is characterised by excessive deposition of collagen and other
ECM proteins within the pulmonary interstitium. In addition, it is commonly associated
with the upregulation of TGF-β (du Bois, 2010). Pottier and co-workers (2009)
demonstrated that TGF-β caused downregulation of miR-155 expression in human lung
fibroblasts. Additionally, studies using a bleomycin-induced mouse model of lung
fibrosis demonstrated that upregulation of miR-155 was correlated with the degree of
lung fibrosis in C57BL/6 and BALB/C mice (Pottier et al., 2009).
Diabetic nephropathy is characterised by progressive fibrosis in the renal glomerulus
and tubulo-interstitial region (Brosius, 2008). Treatment of TGF-β in cultured human and
mouse mesangial cells caused upregulated of miR-377 expression (Wang et al., 2008).
1.10.5 Role of miRNAs in tumour microenvironment
1.10.5.1 CAF differentiation
Mitra and co-workers (2012) demonstrated that miR-155 was upregulated in both
fibroblasts isolated from ovarian cancer tissue and in experimentally induced CAF.
Upregulation of miR-31 and miR-221 were reported in breast CAF (Zhao et al., 2012).
However, downregulation of some miRNAs may induce a CAF myofibroblast phenotype.
The expression of miR-31 and miR-214 were downregulated in CAF ovarian (Mitra et al.,
2012). Additionally, they demonstrated that triple transfection of NOF with anti-miR-31,
anti-miR-214 and pre-miR-155 promotes fibroblast migration and invasion of co-
cultured HeyA8 and SKOV3ip1 cells. Triple transfection of CAF with pre-miR-31, pre-
miR-214 and anti-miR-155 reverses these pro-tumourigenic properties of co-cultured
ovarian cancer cells to levels similar to those NOF co-cultured with ovarian cancer cells.
Tang and colleagues (2016) demonstrated that miR-200 downregulation contributes as a
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regulator of CAF differentiation in breast cancer.
1.10.5.2 EMT and ECM remodelling
In order to metastasize to a distant site, cancer cells must break the basement
membrane which separates epithelial cells from the stroma. Under normal condition,
epithelial cells form a strong connection to each other by gap junction involving E-
cadherin, thus limit their migration. Taking this advantage, cancer cells undergo EMT
and suppress E-cadherin expression, thus detach from the epithelial layer to metastases
(Thiery et al., 2009). Furthermore, cancer cells undergoing EMT are fundamentally
different in gene expression profiles and are stem-like cells e.g. self- renewal capability
(Mani et al., 2008). Therefore, as mentioned before, EMT is a crucial process for cancer
cells stemness. A mountain of evidence suggests that miRNAs are involved in regulating
the EMT process. The first group of miRNAs that regulate EMT are the miR-200 family
(miR-200a, miR-200b, miR200c, miR-141 and miR-429) and miR-205 (Zhang et al.,
2014). These two families were deregulated in various tumours to facilitate EMT
progression. Furthermore, suppression of these miRNAs cause increased expression of
the transcription factor ZEB family, which modulate the expression of E-cadherin in
cancer cells (Gregory, 2008; Korpal et al., 2008; Burk et al., 2008). Since then, some
additional miRNAs have been found to regulate EMT process by targeting EMT-related
transcription factors. For example, miR-34, miR-9 and miR-30a modulate Snail1
expression (Kim et al., 2011; Liu et al., 2012), miR-124, miR-203 and miR 204/211
regulate Snail2 (Xia et al., 2012; Zhang et al., 2011; Wang et al., 2010) whereas miR-
214, miR-580 and Let 7d target Twist1 (Li et al., 2012; Nairismagi et al., 2012; Chang et
al., 2011). Additionally, miR-138, miR-215 and miR-708 downregulate Zeb2 (Liu et al.,
2011; White et al., 2011; Saini et al., 2011).
MMPs are important in ECM remodelling by cancer cells. MMPs are produced
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by various cells such as macrophages, mast cells and fibroblasts as well as certain
epithelial cells under the appropriate stimuli (Overall and Kleifeld, 2006). It has been
demonstrated that some miRNAs affect the expression of MMPs. miR-29b suppresses
the expression of prometastatic regulators including MMP2 and MMP9, thereby
modifying the tumour microenvironment and reduce metastasis by altering collagen
remodelling, proteolysis and angiogenesis (Chou et al., 2013). Conversely, upregulation
of miR-21 cause increased expression of various MMPs including MMP2 and MMP9
through suppression of PTEN in hepatocellular carcinoma cells and the MMP inhibitors
RECK and TIMP3 in glioblastoma cells (Gabriely et al., 2008; Meng et al., 2007).
Additionally, decrease expression of miR-138 induced RhoC expression and increase
MMP2/MMP9 production in cholangiocarcinoma (Wang et al., 2013).
Taken together, these findings show that many miRNAs involved in EMT and
ECM remodelling whereby cancer cells take advantage of tumour microenvironment to
facilitate their metastases using these processes.
1.10.5.3 Hypoxia and angiogenesis
In primary tumour, cancer cells proliferate rapidly with outgrowing of its blood
supply, leaving many tumour cells in regions deprived of adequate oxygen supply
compared to normal tissues. Therefore, to adapt and survive this hypoxic environment,
cancer cells have to modify their intrinsic gene expression and form a new vasculature to
get enough nutrients and oxygen. Hypoxia-inducing factors (HIFs) are the transcription
factors that respond to hypoxia. HIFs arrange a signalling cascade to promote tumour
growth and angiogenesis (Semenza, 2012). The most common miRNAs-inducing
hypoxia is miR-210. Upregulation of miR-210 under hypoxia is correlated with
metastases in breast cancer, melanoma, pancreatic cancer, and ovarian cancer (Ho et al.,
2010; Giannakakis et al., 2008; Camps et al., 2008). Theoretically, miR-210 targets
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MAX dimerization protein (MNY), a MYC antagonist which allows cancer cells to
divert the hypoxia-induced cell cycle arrest (Zhang et al., 2009). miR-210 regulates the
mitochondrial metabolism of cancer cells through glycolysis by suppressing the
expression of iron-sulfur cluster scaffold homolog (ISCU) and cytochrome c oxidase
assembly protein (COX10) (Chen et al., 2010). miR-424 is also believed as hypoxia-
induced miRNAs by suppression of the scaffolding protein cullin 2 (CUL2), which is
important to assemble the ubiquitin ligase system, thus stabilise the HIF-α and promote
angiogenesis (Ghosh et al., 2010). Collectively, these findings have delineated the role of
several miRNAs related with HIF signalling to control oxygen homoeostasis inside
tumours. Regardless of these findings, recent understanding of the role of hypoxia-
induced miRNAs remains limited. Taken together, the communication between miRNA-
containing microvesicles with various cell types delineates an additional mechanism of
microenvironmental regulation of miRNAs involved membrane and secreted proteins.
1.10.6 Role of miR-424
To date, little is known about the effects of miR-424 in cancer as well as in the
stromal microenvironment, particularly in CAF. miR-424 is believed to involve in
maintaining physiological vasculature (Kim et al., 2013; Chamorro-Jorganes et al., 2011)
and differentiation of blood cells (Rosa et al., 2007). While in cancer, miR-424
expression possibly induces EMT as effectively as miR-200c in prostate cancer (Banyard
et al., 2013). Low expression of miR-424 correlates with poor prognosis and lymph node
metastasis in cervical cancer (Xu et al., 2012).
miR-424 is a member of the miR-16 family, which includes miRNA-
15/16/195/424/497. Despite different genomic locations, these miRNAs have a ‘seed
region’ in the 5’UTR which resulted in some overlapping miRNA targets (Forrest et al.,
2010). MiR-16 family regulates multiple cell cycle genes such as CCND1, CCNE1 and
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targets several oncogenes including BCL-2 in various types of cancer (Liu et al., 2008).
However, Cimmino and colleagues (2005) demonstrated that miR-16 negatively
regulates BCL-2. miR-195 regulates pro-apoptotic activity through targeting BCL-2
expression in colorectal cancer (Huang et al., 2010). Additionally, ectopic expression of
miR-195 cause down-regulation of cell cycle-related genes such as CCNE1 and CHK1 as
well as an accumulation of cells at GI phase (Linsley et al., 2007). Similar to miR-195,
ectopic expression of miR-497 blocked cell cycle at G1 stage and induced apoptosis in
breast cancer (Li et al., 2011). Taken together, these findings suggest that miR-16 family
has a similar cluster of gene regulation. miR-424 is relatively known as hypoxia-induced
miRNA. Ghosh and co-workers (2010) demonstrated that hypoxia-induced miR-424
regulates HIF-α isoforms and promotes angiogenesis. miR-424-5p expression was
decreased in liver cancer tissue compared to that normal liver tissue and this
downregulation was associated with advance disease progression in liver cancer patients
(Zhang et al., 2014). Conversely, Wu and co-workers (2013) demonstrated that miR-
424-5p was significantly upregulated in pancreatic cancer. To date, there is no published
study, which has explored the role of miR-424 in CAF of OSCC. Recent study
demonstrated that miR-424 downregulates isocitrate dehydrogenase 3α (IDH3α) in CAF
isolated from colon cancer tissue (Zhang et al., 2015). miR-424 potentiates TGF-β-
induced myofibroblast differentiation through EMT in human lung epithelial cells (Xiao
et al., 2015).
1.10.7 miR-145 and tumour microenvironment
miR-145 is a 22 nt in length and located on chromosome 5(5q32-33), well-known
cancer associated cancer region (Zhang, 2009; Le Beau et al., 1989). miR-145 is co-
transcribed with miR-143 and commonly refers as a miR-143/miR-145 cluster (Cordes et
al., 2009). miR-145 is a well-established tumour suppressor was found to be
47
downregulated in various types of cancers including bladder, breast and colon cancer
(Ichimi et al., 2009; Sempere et al., 2007; Schepeler et al., 2008). The mechanism
underlying this downregulation remains unknown. miR-145 involved in regulation of
various cellular processes including cell cycle and apoptosis by targeting multiple
oncogenes (Zhang, 2009). Additionally, downregulation of miR-145 is associated with
poor prognoses for many cancers and have been considered an ideal biomarker in cancer
therapy. miR-145 is downregulated in the saliva of the patients with OSCC compared
with healthy patients (Zahran et al., 2015).
p53 is a tumour suppressor that controls various cellular pathways. Recently, p53
regulates some of the miRNAs such as miR-192/215, miR-34 and miR-145 (Hermeking,
2007; Barlev et al., 2010). Sachdeva et al (2009) demonstrated p53 regulates the miR-
145 promoter activity by directly binding to the p53 response elements-2 (p53RE-2),
thereby increases miR-145 expression. Downregulation of miR-145 was demonstrated in
prostate cancer tissue and various types of cancer cell lines associated with p53
mutations (Suh et al., 2011). Till now, many oncogenic genes have been identified as
targets for miR-145, which involves in various biological pathways proliferation,
invasion and metastases (Fuse et al., 2011; Miles et al., 2012; Noh et al., 2013). miR-145
inhibits cancer cell proliferation by targeting growth factor-related genes including
EGFR (Fuse et al., 2013). miR-145 regulates some genes-related to invasion and
metastases such as MUC1, FSCN and SOX9 (Guo et al., 2013; Miles et al., 2012; Noh et
al., 2013). Apart from that, miR-145 regulates cell differentiation by targeting core
reprogramming factors such as OCT4, SOX2 and KLF4 (Xu et al., 2009; Hu et al., 2012).
In addition, miR-145 could inhibit angiogenesis process by targeting VEGF and HIF-1α
(Fan et al., 2012; Zou et al., 2012).
Recently, the roles of miR-145 in the tumour microenvironment, particularly in
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the myofibroblast differentiation has gained a lot of attentions. miR-145 was reported to
promote myofibroblast phenotype in cardiac and pulmonary fibrosis (Wang et al., 2015;
Yang et al., 2013). Microarray data showed a significant downregulation of miR-145 in
CAF isolated from invasive bladder tumours and normal fibroblast from foreskin
(Enkelmann et al., 2011). However, these data not correlate with validation data from
qRT-PCR. Additionally, miR-145 was shown to regulate scarring of skin tissues and
TGF-β1-induced myofibroblast differentiation compared to untreated fibroblasts (Gras et
al., 2015). Collectively, these data suggest that miR-145 plays a role in fibroblast
transdifferentiation. Pal et al., (2013) demonstrated that miR-145 was downregulated in
normal oral fibroblasts in response to cigarette smoke, which promotes migration of
OSCC cancer cell lines. This finding highlighted that miR-145 is involved in stromal-
epithelial interactions.
1.10.8 miRNA and cancer-related extracellular vesicles
Recent works have demonstrated the role of miRNAs in cellular communication.
miRNAs have been detected as circulating biomarkers for various cancers such as breast,
pancreatic, colon and lung (Roth et al., 2010; Kawaguchi et al., 2013; Cheng et al., 2011).
These circulating miRNAs are generated from cancer cell debris through apoptosis or
necrosis and from miRNA-containing extracellular vesicles including exosomes,
microvesicles and apoptotic bodies (Valadi et al., 2007). Vesicles released from cells are
vary from 30 nm to 5 µm in diameter and are collectively called extracellular vesicles.
However, exosomes have been extensively studied amongst vesicles as direct carriers of
miRNAs mediating cellular communication (Kosaka and Ochiya, 2011). Recent studies
have demonstrated that certain miRNAs in this form could influence tumour progression
via cancer cell-stroma interactions. For example, in breast cancer cells, miR-210 can be
released via nSMase2-dependent exosomal secretion pathway and transported to
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endothelial cells, thereby served as angiogenic miRNA in recipient endothelial cells
(Kosaka et al., 2013). On the other hand, miRNAs also can be transported from stromal
cells to cancer cells. In coculture experiment, MiR-233 can be transmitted to breast
cancer cells from TAMs. Of note, miR-233 is highly expressed in IL-4-TAMs, not in
breast cancer cells (Yang et al., 2011). Conversely, transmission of miR-233 from
macrophages to hepatocellular carcinoma cells is associated with cellular contact and gap
junction, not exosomes. Additionally, miR-1 was shown to mediate extracellular vesicles
function. Overexpression of miR-1 in glioblastoma cells decreased in vivo tumour growth
and angiogenesis associated with extracellular vesicle transport of miR-1 (Bronisz et al.,
2014).
1.10.9 miRNAs therapies
The rationale of using miRNAs as a therapeutic approach is because 1) miRNAs
play important role in basic biological processes and deregulated in various cancer 2) the
cancer phenotype can be reversed by targeting miRNAs expression (Calin et al., 2002;
Motoyama et al., 2008). To date, two main approaches have been taken; miRNA
inhibition therapy (anti-miR) 2) miRNA replacement therapy (mimic miRNA). Anti-
miRs are generated to inhibit endogenous miRNAs that have a gain-of-function in
diseased tissues while mimic miRNAs are generated to restore miRNA that have a loss of
function.
Anti-miRs approach targets a single gene product such as small molecule
inhibitors and short interfering RNAs (siRNAs). Additionally, miRNA sponges and
antisense oligonucleotide (ASOs) are also been used as miRNA inhibition therapy. Anti-
miRs disrupt the RISC complex, thereby prevent the degradation of mRNA. miRNA
sponges have been developed to repress the activity of miRNA families sharing a
common seed sequence. Therefore, the disadvantage of miRNA sponges is the limited
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homogeneity of transcripts expression resulted in unwanted side effects (Zhang and
Wang, 2013). There are hurdles that hamper miRNA-based therapy, especially in vivo
study. In general, RNAs have low stability in vivo. Therefore, miRNA introduced into
mice is quickly cleared (30 min) from circulatory system (Trang et al., 2011).
Unmodified RNA will be degraded by RNAses and rapid renal excretion (Czauderna et
al., 2003). Thus, the plasma half-life of RNAs needs to be increased for miRNA-based
therapy. This can be achieved by higher miRNA stability or protection from RNAses.
miRNA stability can be improved by chemically modified oligonucleotides such as
locked nucleic acid (LNA) nucleotides (Wahlestedt et al., 2000), 2’-O-methyl-
oligonucleotides (2’-O-MOE) (Yoo et al., 2004) and peptide nucleic acid (PNA) (Hyrup
and Nielsen, 1996).
miR-21 is an oncomiRs and highly expressed in solid tumours and
haematological diseases (Folini et al., 2010; Lakomy et al., 2011). Inhibition of miR-21
is able to decrease cell proliferation and increased apoptosis in breast and glioblastoma
cancer cells (Mei et al., 2010; Corsten et al., 2007). Inhibition of miR-21 increased
expression of PTEN and decreased tumour cell proliferation, migration and invasion in
hepatocellular carcinoma cells (Meng et al., 2007).
On the other hand, miRNA mimics are used to restore miRNA that have a loss
function by using the oligonucleotide mimics containing the same sequence as the mature
endogenous miRNA. Similar to siRNAs, miRNA mimics can be delivered using the
same technologies. Therefore, miRNA mimics therapy will face less of a delivery
obstacle compared to anti-miRs. Furthermore, miRNA mimics are expected to be more
specific and well-tolerated in normal cells. This notion is based on the fact that miRNA
mimics have the same sequence as the naturally occurred miRNA and target the same
genes. The fact that most of the normal cells already express the targeted miRNA,
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delivery of miRNA mimics to normal cells is unlikely cause an adverse effect. This is
because the cellular pathways targeted by the mimic are already activated or inactivated
by the endogenous miRNA.
The Let-7 family is one of the tumour suppressor miRNAs and commonly
downregulated in the tumour (Barh et al., 2010). Administration of Let-7 either Let-7
mimic or a virus leads to strong inhibition of tumour growth in human non-small cell
lung cancer xenografts (Trang et al., 2010). This collective evidence suggests that
inhibition of overexpressed oncomiRs or substitution of tumour suppressive miRNAs
will become a promising strategy for cancer therapy.
1.11 Aims and hypotheses of the study
As mentioned above, the interaction between stroma and tumour cells contributes to
tumourigenesis and it is recognised that inflammatory cells, epithelial cells as well as
CAF are involved in promoting tumour growth. Fibroblasts play a pivotal role in
maintaining tissue homoeostasis and wound healing. However, the mechanism
underlying conversion of fibroblasts into CAF is poorly understood. Recently, miRNA
research has become a rising topic in cancer biology. Several studies have revealed
miRNA expression profiling in various cancer cells including HNSCC. But, the study of
miRNA in tumour stroma is still limited, leading to a paucity of information of how
miRNA contribute to malignancy in tumour-stroma interaction. Additionally, it is not
clear whether endogenous miRNAs are involved in the conversion of fibroblasts to CAF.
Therefore, we hypothesise that miRNAs are involved in the reprogramming of normal
fibroblasts to experimentally-derived CAF (eCAF). The present study aimed to
determine the miRNA expression profile in eCAF and tumour-derived CAF, and to study
the functions of candidate miRNA identified using this approach. To do this, a number of
specific aims were addressed as stated below;
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1) To characterise the CAF-like myofibroblastic phenotype of stromal oral
fibroblasts to utilise later to study miRNA involvement in the development of
CAF
2) To determine the miRNA expression profiles of eCAF and further examine the
role of selected miRNAs in eCAF and tumour-derived CAF
3) To profile the expression of miRNA using a global miRNA profiling strategy to
identify novel miRNA regulations of CAF-like differentiation in eCAF or CAF
development in tumour-derived CAF (isolated from two subtypes of OSCC)
Thus, the model for miRNA-induced normal oral fibroblasts into eCAF here opens the
possibility of a treatment approach targeting the tumour stroma with miRNA mimics and
miRNA inhibitors. The workflow for the study is presented in Figure 1.10.
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Figure 1.10: A summary of experimental design
Briefly, cells were treated with TGF-β1 (0.05-5 ng/ml) for 24 and 48 h. Fibroblasts
differentiation markers such as α-SMA and FN-EDA1 were determined by qPCR. The
optimal concentration and time point were used for subsequent experiments including α-
SMA protein expression, stress fibre formation, collagen contraction as well as miRNAs
expression profiling. Selected miRNAs were validated by qPCR, followed by
transfection of cells with selected miRNAs. The responses of transfected cells with or
without TGF-β1 were evaluated using the same experiments.
54
CHAPTER 2: Materials and
methods
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2.1 Materials and Chemicals
2.1.1 Chemicals and Reagents
All chemicals and reagents used in this study are listed in Table 2.1
Name Supplier
Acetic acid Fisher Chemical, UK
Acrylamide 40% solution Fisher-Scientific, UK
Ammonium Persulphate 99+% ACROS Organics, USA
Bovine Serum Albumin (BSA) Fisher-Scientific, UK
CL-Xposure™ film Thermo Scientific, USA
Complete ULTRA tablets, mini EDTA-
free
Roche, UK
Cowbelle ® Dried skimmed milk ALDI, UK
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, USA
Dulbecco’s Modified Eagle’s Medium
(DMEM)
Sigma-Aldrich, USA
DMEM (10X) Sigma-Aldrich, USA
Ethanol Fisher-Scientific, UK
EZ run pre-stained protein ladder Fisher-Scientific, UK
Fetal Bovine serum (FBS) Sigma-Aldrich, USA
Hydrochloric acid (HCl) Fisher Chemical, UK
Isopropanol Fisher-Scientific, UK
KlerAlcohol Denatured Ethanol (IMS) CamLab Limited, UK
L-glutamine BD worldwide, UK
Methanol Fisher-Scientific, UK
Nupage antioxidant Life Technologies, UK
Nupage LDS sample Life Technologies, UK
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Oligofectamine Life Technologies, UK
Penicillin/streptomycin BD worldwide, UK
Radioimmunoprecipitation assay (RIPA)
buffer
Sigma-Aldrich, USA
Rat tail collagen from tendon Roche, UK
Recombinant TGF-β1 R&D Systems, USA
Reduced serum-OptiMem medium Life Technologies, UK
Sodium dodecyl sulphate (SDS) Fisher-Scientific, UK
Sodium Hydroxide (NaOH) Sigma-Aldrich, UK
Tetramethylethylenediamine (TEMED) Applichem, Germany
Trypan blue 0.4% Life Technologies, UK
Tween-20 Fisher-Scientific, UK
Vectashield mounting medium for
fluorescence with DAPI
Vector Laboratories Inc, USA
Virkon (Rely+On™) DuPont™, UK
Table 2.1 List of chemicals and reagents
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2.1.2 Consumables
Table 2.2 shows a list of all consumables used in this study
Name Supplier
6-well plates Greiner Bio-one, UK
24-well plates Greiner Bio-one, UK
Cell scraper Zellschaber Greiner Bio-one, UK
Cryovials Greiner Bio-one, UK
Glass coverslips (diameter of 13 mm) VWR International, UK
IBlot gel transfer stack nitrocellulose Life Technologies, UK
PCR plates Qiagen, Germany
Round-bottom tubes Becton Dickinson, USA
Serological pipette (5, 10 and 25 ml) Fisher-Scientific, UK
Tubes (15 ml and 50 ml) Becton Dickinson, USA
Table 2.2 List of consumables
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2.1.3 Kits
Table 2.3 shows a list of all commercial kits used in this study
Name Supplier
BCA Protein Assay Thermo Scientific, UK
High Capacity cDNA Reverse Transcription Life Technologies, UK
MirVana™ miRNA isolation Life Technologies, UK
PCR master mix, no UNG Life Technologies, UK
Pierce ECL WB Thermo Scientific, UK
Power SYBR© green PCR master mix Life Technologies, UK
Preamplification master mix Life Technologies, UK
RNeasy® Mini Kit Qiagen, Germany
Taqman Universal PCR Master Mix Thermo Fisher Scientific, UK
Table 2.3 List of commercial kits
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2.1.4 Laboratory equipment
All laboratory equipment used in this study are listed in Table 2.4
Name and Brand Supplier
Belly dancer-Stuart SRT6 Biocote ESP Chemical Inc, UK
Class 2 MSC Walker Safety Cabinets Scientific-Lab Supplies, UK
Compact X4 Xograph imaging system Xograph Healthcare Inc, UK
Fridge/Freezer Proline, UK
Galaxy R Co2 Incubator Scientific-Lab Supplies, UK
IBlot TM Life technologies, UK
Integra pipet boy 2 Sigma-Aldrich, UK
JB series water bath Scientific-Lab Supplies, UK
Neubauer improved optic labor Fisher-Scientific, UK
Nikon Eclipse TS100 inverted
microscope
Nikon, Japan
Real-time PCR machine (Fast Real-time
PCR System)
Applied Biosystems, USA
Spectrophotometer (NanoDrop) Thermo-Scientific, UK
Thermal cycler PCR machine (GeneAmp
PCR System 9700)
Applied Biosystems, USA
Table 2.4 List of laboratory equipment used
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2.1.5 Antibodies
All antibodies used in this study are listed in Table 2.5
Name Supplier
Anti-mouse Horseradish peroxidase
(HRP) antibody (anti-mouse IgG)
Cell Signaling Technology, USA
Monoclonal α-smooth muscle actin
antibody, mouse
Sigma-Aldrich, USA
Mouse β-actin antibody Sigma-Aldrich, USA
Monoclonal anti-actin, α-smooth muscle
FITC antibody in mouse
Sigma-Aldrich, USA
Monoclonal anti-fibronectin antibody,
mouse
Sigma-Aldrich, USA
Table 2.5 List of antibodies used
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2.1.6 Primers
All primers used in this study are listed in Table 2.5
Name Sequence Supplier
U6 Forward 5’ CTCGCTTCGGCAGCACA 3’ Sigma-Aldrich, USA
U6 Reverse 5’ AACGTTCACGAATTTGCGT 3’ Sigma-Aldrich, USA
α-SMA Forward 5’ GAAGAAGAGGACAGCACTG 3’ Sigma-Aldrich, USA
α-SMA Reverse 5’ TCCCATTCCCACCATCAC 3’ Sigma-Aldrich,USA
Fibronectin 1 with
EDA (FN-EDA1)
Forward
5’ TGGAACCCAGTCCACAGCTATT 3’ Sigma-Aldrich, USA
Fibronectin 1 with
EDA (FN-EDA1)
Reverse
5’ GTCTTCCTCCTTGGGGGTCACC 3’ Sigma-Aldrich, USA
B2M Control Mix
(20X mix of probe
with forward and
reverse primers)
Pre-designed probe and primer sets Life Technologies,
UK
Collagen 1a
(COLA1) Forward
5’ GTGGCCATCCAGCTGACC 3’ Sigma-Aldrich, USA
Collagen 1a
(COLA1) Reverse
5’ AGTGGTAGGTGATGTTCTGGGAG
3’
Sigma-Aldrich, USA
miR-424-3p CAAAACGUGAGGCGCUGCUAU Life Technologies,
UK
miR-145-5p GUCCAGUUUUCCCAGGAAUCCCU Life Technologies,
UK
miR-424-5p CAGCAGCAAUUCAUGUUUUGAA Life Technologies,
UK
Table 2.6 List of primers used
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2.1.7 Oligonucleotides
All oligonucleotides used in this study are listed in Table 2.7
Name Part number Supplier
Negative premiR control #2 AM17111 Life technologies, UK
premiR miRNA precursor 424-
3p
AM17100 Life Technologies, UK
mIRCURY LNA™ miRNA
power inhibitor 424-3p
4100783-101 Exiqon, UK
mIRCURY LNA miRNA power
inhibitor 145-5p
4101574-101 Exiqon, UK
mIRCURY LNA power
Negative control A
199006-101 Exiqon, UK
mIRCURY LNA power
Negative control B
199007-101 Exiqon, UK
Table 2.7 List of miRNA mimics and inhibitors used
63
2.2 Cell Culture
2.2.1 Normal buccal oral fibroblasts (NOF)
Three types of NOF cultures were used throughout this study. NOF1, NOF2 and NOF5
cultures were obtained from Prof EK Parkinson (QMUL) and ethics approval had also
been obtained (Lim et al., 2011). NOF804 and CAF003 were kindly provided by Dr.
Helen Colley. All cells were maintained in DMEM medium. Cell passages from 1 to 7
were used in this study.
2.2.2 Reagents for cell culture work
2.2.2.1 Dulbecco’s Modified Eagle’s Medium
DMEM was purchased as ready-to-use without L-glutamine and antibiotics.
2.2.2.2 Foetal Bovine Serum (FBS)
The serum was aliquoted into sterile 50 ml tubes and kept at -20 0C.
2.2.2.3 Dulbecco’s Phosphate-buffered Saline (DPBS)
DPBS without calcium chloride and magnesium chloride was purchased as ready-to-use.
2.2.2.4 Penicillin/ streptomycin stock solution (100X)
An antibiotic stock solution containing 10 000 U/ml penicillin and 10 mg/ml
streptomycin was purchased as ready-to-use. The solution was diluted in DPBS and
aliquoted into sterile 1.5 ml tubes before being stored at -20 0C.
2.2.2.5 Trypsin/EDTA solution (1x)
Cultured cells were detached from the flask surface using trypsin from porcine free-
parvovirus. Trypsin-EDTA solution was purchased as ready-to-use and aliquoted into 15
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ml tubes and stored at -20 0C.
2.2.2.6 Complete growth medium
A complete growth medium was used in this study to culture and maintain the cell
cultures. The medium consists of DMEM solution supplemented with 10 % (v/v) FBS,
L-glutamine and 100 U/ml penicillin and 100 µg/ml streptomycin. The medium was
stored at 4 0C.
2.2.2.7 Assay medium (serum starvation and TGF-β1 treatment)
The assay medium used was DMEM medium without FBS. To prepare 100 ml assay
medium, 1 ml L-glutamine and 1 ml penicillin/streptomycin stock solution were mixed
with 98 ml of DMEM medium. The medium was kept at 4 0C.
2.2.2.8 Cryoprotectant medium
This medium contained 10 % (v/v) dimethyl sulphoxide (DMSO) in FBS and was used
to store ampoules of cells in liquid nitrogen. The cryoprotectant medium (20 ml) was
prepared by mixing 2 ml DMSO in 18 ml FBS. This medium was prepared fresh and
kept cold prior to use.
2.2.2.9 Trypan blue 0.1 % (w/v) solution
Trypan blue solution (20 ml) was prepared by diluting 5 ml ready-made 0.4 % (w/v)
Trypan blue in 15 ml DPBS. The solution was kept at room temperature until use.
2.2.3 Culture procedures and conditions (routine cell culture)
All tissue culture procedures were carried out under sterile conditions (Class ll biohazard
cabinet) and aseptic technique was used in order to avoid any contamination. Good cell
culture practice (GCCP) guidelines were exercised during the whole process.
65
2.2.3.1 Thawing of cells from frozen storage
A frozen ampoule of cells was retrieved from the liquid nitrogen storage vessel and was
left at room temperature for approximately 1 min before being transferred to a 37 0C
water bath for 1-2 min to thaw the cells fully. The ampoule was then wiped with a gauze
sprayed with 70 % (v/v) IMS prior to opening. The entire content of the ampoule was
gently pipetted into a 15 ml centrifuge tube containing 6 ml of DPBS and 1 ml pre-
warmed growth medium. The content was centrifuged at 1000 rpm for 1 min to remove
the DMSO. The cell pellet was then re-suspended in 5 ml of pre-warmed growth medium.
The cell suspension was then slowly pipetted into a 25-cm2 tissue culture flask. The cell
morphology was observed using an inverted phase contrast microscope to check for cell
viability. The culture flask was incubated in a humidified atmosphere containing 5 %
CO2 at 37 0C. The growth medium was replaced every 2-3 days.
2.2.3.2 Sub-culturing of cells
Cells were passaged at intervals of 2-3 days (80-90 % confluence). Subculturing was
performed by removal of the medium from the flask. The adherent cells were first rinsed
with 2 ml DPBS. After removal of the DPBS, 1 ml trypsin-EDTA solution was added
into the flask. The flask was incubated at 37 0C for approximately 5 min in the CO2
incubator for detachment of the adherent cells from the flask. The flask was gently
shaken to ensure complete detachment of cells and observed under the inverted
microscope until the cell layer was dispersed. One ml of fresh medium was added into
the flask to inactivate the trypsin activity and followed by repeated gentle pipetting to
break apart the clusters of cells. The medium (containing cells) was aspirated and
transferred to a sterile 15 ml centrifuge tube. The tube was centrifuged at 1000 rpm for 5
min. The supernatant was then removed and the cell pellet was re-suspended in 5 ml
growth medium. The mixture containing cells was aspirated and dispensed into 3-4 new
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flasks. The medium volume in each new flask was made up to 5 ml by adding fresh
growth medium and the cultures were incubated in humidified atmosphere containing 5
% CO2 at 37 0C.
2.2.3.3 Determination of cell number/concentration
Cell counting was performed by Trypan blue dye exclusion to ensure uniformity of the
number of viable cells to be added to each flask. Cells were grown in 75-cm2 tissue
culture flasks to obtain stock cultures. The cells were collected as described in Section
2.2.3.2 and re-suspended in 2-5 ml growth medium (depending on the size of the pellet).
Cell suspension (10 µl) was then added to 90 µl Trypan blue solution in 1.5 ml tube. The
mixture was then mixed well and left for 1 min at room temperature. The number of
stained and unstained cells was determined using a haemocytometer. Living cells exclude
the dye, whereas dead cells take up the blue dye. The number of viable cells was
estimated as follows:
Number of viable cells/ml = n X dilution factor X 104
5
n = total number of the cell in five squares
2.2.3.4 Freezing down of cells
When required (in order to maintain low passage stocks of primary fibroblasts) cells
were frozen down when they reached 70 % confluence. Normally, three or four flasks of
cells of the same passage were processed for batch freezing. Cells were detached from
flasks using trypsin/EDTA solution as described in Section 2.2.3.2. The cells were then
pelleted by centrifugation at 1000 rpm for 2 min to remove the trypsin/EDTA solution.
The supernatant was then removed and 10 ml of cryoprotectant medium (Section 2.2.2.8)
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was added slowly to resuspend the pelleted cells. The cell suspension was then dispensed
into 6 cryovials labeled with cell name, passage number, and date. The vials were placed
in a Mr. Frosty for 24 or 48 h at -800C before being moved into a cryobox where they
finally stored in liquid nitrogen in the vapour phase.
2.3 Preparation of collagen
Rat tail collagen (10 mg) was dissolved in 3.3 ml of sterile 0.2 % acetic acid, which
results in a final concentration of 3 mg/ml. The collagen then was stored at 4 0C.
2.4 Preparation of TGF-β1 stock solution
TGF-β1 was supplied in crystalline form and with a purity of more than 99.9 %. The
stock solutions of 20 µg/ml were prepared by dissolving 2 µg of TGF-β1 in 0.1 ml of 4
mM HCl. The solution was mixed well and aliquoted into sterile microcentrifuge tubes
and stored at -20 0C. The working solution of TGF-β1 (0, 0.05, 0.5 and 5 ng/ml) was
prepared from stock solutions of 20 µg /ml fresh in assay medium prior to use.
2.5 Gene expression of α-SMA and FN-EDA1
2.5.1 Treatment of cells
Cells (2.5 x 105/well) were seeded into 6-well plates and incubated overnight in 5 % CO2
at 37 0C for cell attachment. The cells were serum starved overnight and were treated on
the following day with a range of concentrations of TGF-β1 (0, 0.05, 0.5 and 5 ng/ml) for
24 or 48 h.
2.5.2 Extraction of total cellular RNA
The MirVana miRNA isolation kit was used for total RNA extraction according to the
manufacturer’s instructions. Briefly, growth medium in culture flasks containing TGF-
β1-treated or untreated cells at 24 and 48 h was aspirated and the cells were collected as
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described in Section 2.2.3.2. The cells were pelleted by centrifuging at 1000 rpm (168 x
g) for 5 min, and pellets lysed with 300 µl of Lysis/Binding solution. The resultant
mixture was vortexed to completely lyse the cells and obtain a homogenous lysate.
miRNA Homogenate Additive (30 µl) was added to the cell lysate and vortexed to mix.
The mixture was incubated on ice for 10 min. Following incubation, 300 µl of Acid-
Phenol:Chloroform was added to the lysate. The mixture was vortexed for 30 s to mix
and centrifuged for 5 min at 10 000 x g at room temperature to separate the aqueous
(upper) and organic phases. The aqueous phase was removed carefully without disturbing
the organic phase and was transferred into a fresh microcentrifuge tube. Ethanol (100 %;
375 µl) at room temperature was added into the aqueous phase and vortexed to mix. A
filter cartridge was placed into the collection tube for each sample. The mixture was
added to the filter cartridge and was centrifuged for 30 s at 10,000 x g to pass the mixture
through the filter. The flow-through was discarded and the filter cartridge was placed on
same collection tube for washing step. Wash solution 1 (500 µl) was added to the filter
cartridge and was centrifuged for 30 s at 10 000 x g to pass the solution through the filter.
The flow-through was discarded from the collection tube and the filter cartridge was
replaced into the same collection tube. Wash Solution 2/3 (500 µl) was added into the
filter cartridge and the solution was drawn through the filter cartridge as in the previous
step. The washing step was repeated using 500 µl of Wash Solution 2/3 and the solution
was drawn through the filter as in the previous step. The filter cartridge was placed in the
same collection tube and was centrifuged for 1 min at 10,000 x g to remove residual fluid
from the filter. The filter cartridge was transferred into a fresh collection tube and 20 µl
of pre-heated (95 0C) nuclease free water was added to the center of the filter cartridge
and centrifuged for 30 s at 10,000 x g to recover the RNA. The eluate (containing the
RNA) was collected and stored at -80 0C.
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2.5.3 Measurement of RNA concentration and purity
RNA purity and concentration were measured using a spectrophotometer (Nanodrop)
according to the manufacturer’s instructions. For the blank, 2 µl of RNase-free water was
pipetted onto the pedestal. The pedestal was then wiped and 2 µl of the samples were
then pipetted onto the pedestal. The RNA concentration was recorded in ng/µl. The
A260:A280 reading was recorded and A260:A280 ratio values of 1.8 to 2.0 were deemed to be
of sufficient purity for RNA. An OD 260/280 ratio between 1.8 to 2.0 is considered as a
good RNA quality (Sambrook et al., 2001).
2.5.4 Synthesis of the first-strand cDNA
The High-Capacity cDNA reverse transcription kit was used for cDNA synthesis
according to the manufacturer’s instructions. Briefly, all reagents were pulsed in a
microcentrifuge for 10-15 sec. The RT master mix (20 µl reaction) was prepared in
which the mixture contained 1 µl of Multiscribe Reverse Transcriptase, 2 µl of 10X RT
buffer, 2 µl of 10X RT Random primers, 0.8 µl of 25X dNTP mix (100 mM) and 4.2 µl
of nuclease-free water. Then, 10 µl of RT mixture was added to each RNA sample (100
ng diluted to 10 µl in nuclease-free water) in a PCR tube. The mixture was briefly
centrifuged and placed in a thermal cycler. As for a control, a no RT control was
performed containing of RNA sample with all other reagents except RT enzyme. The
reaction mixture was started by incubating at 25 0C for 10 min and was terminated by
heating at 85 0C for 5 min. The cDNA products were stored at -20 0C.
2.5.5 Quantitative real-time RT-PCR (qPCR)
Primers for quantitative real-time reverse transcription polymerase reaction qRT-PCR
were designed using Primer Blast (NCBI; https://blast.ncbi.nlm.nih.gov/Blast.cgi).
Briefly, primers were dissolved in TE buffer at 100 µM and then diluted to 5 µM in
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sterile distilled water. The final concentration of all the primers used was 0.25 µM. Real-
time PCR was performed with a 10 µl reaction mixture containing 5 µl Power SYBR
Green PCR master mix, 0.5 µl forward and reverse primers, 3.5 µl nuclease-free water
and 0.5 µl cDNA sample. The primer pair for human small nuclear RNA U6 was used as
an endogenous control. Previous data accrued in the lab had demonstrated the suitability
of this as a reference gene for TGF-β1-induced differentiation of NOF. For each primer
pair, a no-template control (NTC) was included to control for possible contamination of
reagents. The mixture was assembled in 96 well optical reaction plates and the plates
were sealed with optical adhesive film. Each gene and cDNA was analyzed in triplicate.
The reaction plates were placed on 7900 HT fast real-time PCR. The reaction involved
an initial heating for 2 min at 500C to eliminate carryover contamination, followed by a
denaturing step at 95 0C for 15 s and annealing/elongation at 60 0C for 1 min. Reactions
were run for 40 cycles. The amplification plot and CT values produced were analyzed by
linear regression analysis using SDS Manager programme.
2.5.6 qRT-PCR analysis
Relative quantitation of targets in different samples was calculated by the ∆∆Ct method
(Livak and Schmittgen, 2001). The amplification of the reference gene must be the same
as the efficiency of the target (Melling, 2015). Relative expression levels between the
treated samples and untreated samples can be calculated by arithmetic formulas. The
treated sample and untreated sample are compared to a reference gene to normalize for
variation in sample quality and quantity. These normalized values are known as ∆Ct
values are then used to calculate ∆∆Ct values as follows:
∆Ct values for the treated samples and untreated samples:
∆Ct treated = Ct target treated –Ct reference treated
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∆Ct untreated = Ct target untreated –Ct reference untreated
∆∆Ct value for each of the treated samples:
∆∆Ct treated sample = ∆Ct treated sample - ∆Ct untreated sample
RQ = 2-∆∆Ct
Fold difference = Log 2 (RQ) = -∆∆Ct
2.6 Stress fibre formation assay
2. 6.1 Treatment of the cells
Cells (2.5 x 105 /well) were seeded onto glass coverslips and incubated overnight in 5 %
CO2 at 37 0C for cell attachment. Cells were serum starved overnight and were treated on
the following day with 5 ng/ml of TGF-β for 48 h.
2.6.2 Immunocytochemistry
Cells grown on coverslips (as described in 2.6.1) were washed twice with DPBS for 5
min and fixed using 100 % methanol for 20 min at room temperature. Following
incubation, the fixative was removed and the cells were washed using DPBS for 5 min.
Then, the cells were washed with 0.5 ml 4 mM of sodium deoxycholate. The cells were
permeabilized using the same solution for 10 minutes. Non-specific antigens were then
blocked in a solution of 2.5 % of BSA in DPBS for 30 min. After that, cells were
incubated with 25 µl of FITC-conjugated anti α-SMA antibody (dilution 1:100)
overnight at 4 0C and protected from light. The primary antibody was aspirated and
coverslips washed twice with DPBS for 10 min before being mounted on slides using
mounting medium containing DAPI (Vector Laboratories) and the edges were sealed
with nail polish. The slides were viewed under a fluorescence microscope at 40x or 100x
magnification and the images were photographed using Pro-plus 7 imaging software.
Cells were observed under a fluorescence microscope using a bandpass FITC filter
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(excitation 490 nm, emission > 520 nm) to view the green fluorescence of α-SMA
positive cells. Nuclei were visualised using a DAPI filter with excitation at 365 nm and
emission at 480 nm. Three independent experiments were carried out.
2.7 Contraction assay
Cells (2.5 x 105 cells/well) were seeded in 150 µl of DMEM containing 10 % FBS.
Meanwhile, 75 µl of collagen (3 mg/ml) was mixed with 10X solution of DMEM. The
mixture was mixed with cells immediately. Then, 0.1 mM NaOH was added into the
mixture until the colour changes to a slight pink. After that, 300 µl of the collagen
mixture containing cells was seeded in each well of 24-well plates. The mixture was
incubated for 45 min at 37 0C. Following incubation, 500 µl DMEM containing 10 %
FBS was added to each well. The plates were incubated for another 4 h at 37 0C before
the media were removed without disturbing the collagen lattice. Finally, 500 µl of serum
free media was added to each well and incubated overnight at 37 0C. The next day, the
media were removed from each well and the collagen lattice was carefully detached
using a scalpel. Then, the lattice was treated with 500 µl of serum free media containing
5 ng/ml of TGF-β1 for 48 h. The lattices were photographed with a digital camera and
the surface area for each lattice was calculated using the Image J. For each lattice,
collagen contraction was determined in triplicate and the experiments were repeated at
least three times.
2.8 Western blot
2.8.1 Treatment of cells
Cells (5 x 105/flask) were seeded in culture flasks and incubated in 5 % CO2 incubator
for cell attachment. The cells were serum starved overnight and were treated on the
following day with 5 ng/ml of TGF-β1 for 48 h.
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2.8.2 Protein extraction
Cells were washed twice with cold DPBS and lysed using RIPA buffer containing 1X
complete EDTA-free protease inhibitor. Cells lysates were vortexed briefly, incubated on
ice for 30 min and then centrifuged for 15 min at 14 000 rpm at 40C. The supernatants
were collected and kept at -80 0C until required.
2.8.3 Protein quantification
Protein quantification was carried out using the Pierce BCA kit. Briefly, 10 µl of each
sample or protein standard (2, 1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.025, 0 mg/ml of BSA)
were mixed with 200 µl BCA working reagent (consisting of 50 parts reagent A and 1
part of reagent B). The samples were mixed well and incubated at 37 0C for 30 min. Each
sample and standard were run in triplicate. Following incubation, the optical density of
the samples and standards were measured by spectrophotometer at a wavelength of 562
nm. The protein concentration of samples was determined from a standard curve on the
basis of absorption at 562 nm of the BSA standards.
2.8.4 SDS polyacrylamide gel electrophoresis
Proteins were separated with a 12 % resolving gel consisting of 3 ml of 40% (w/v)
acrylamide, 4.3 ml distilled water, 4 ml of 1.5 M Tris-HCl pH 8.8, 0.16 ml of 10% (w/v)
SDS, 0.005 ml of TEMED and 0.35 ml of 10% ammonium persulphate. The catalyst
ammonium persulphate and TEMED were added last to initiate polymerization. The
mixture was immediately poured into the gel cassettes to approximately three-quarters of
the total height of the cassettes. Immediately after pouring the gel mixture, a small
colume of isopropanol was added into the cassettes to cover the gels. The gels were
allowed to solidify for 10 min. The 4 % stacking gels contained 1 ml of 40% (w/v)
acrylamide, 2.5 ml of 0.5 M Tris-HCl pH 6.8, 0.1 ml of 10% (w/v) SDS, 6.3 ml of
distilled water, 0.01 ml of TEMED and 0.1 ml of 10% ammonium persulphate. Before
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pouring the mixture, the isopropanol was removed by filter paper from the gel. The
mixture was immediately poured into the top of the cassettes and a sample comb inserted,
before allowing the gels to polymerize.
2.8.5 Loading the samples onto the gel
Briefly, 30 µl of the mixture contained 20 µg of samples, 7.5 µl of 4X LDS sample, 3 µL
of 1X reducing agent and 13.8 µl of distilled water was prepared and heated for 5 min at
95 0C. Then, 20 µl of protein samples were loaded into the wells. Five microlitres of pre-
stained protein markers were electrophoresed alongside the samples. 1X Running buffer
consisted of 25 mM Tris, 192 mM glycine and 0.1% SDS. The gels were electrophoresed
with 1X Running buffer at 120 V for 1 h.
2.8.6 Blot transfer
The iBlot™ filter paper was soaked in distilled water. Meanwhile, iBlot ™ anode stack
was placed on the blotting surface of iBlot™ apparatus. Then, the pre-run gel was placed
on nitrocellulose membrane of the anode stack. The gel was rolled by blotting roller to
remove any trapped bubbles. The pre-soaked filter paper was placed on the gel and rolled
with a roller to remove any bubbles. After that, the iBlot cathode™ stack was placed on
top of it. Again, the bubbles were removed by blotting roller. Lastly, the disposable
sponge was placed on the cathode stack and the blotting was performed for 7 min at 23 V.
2.8.7 Ponceau S staining
The membranes were soaked with Ponceau S solution and washed at least two times with
distilled water, to visualise protein transfer to the nitrocellulose membrane.
2.8.8 Blocking the membrane
The membranes were blocked by using 5 % non-fat milk and 3 % BSA. The blocking
buffer was prepared by dissolving 2.5 g of non-fat milk and 1.5 g BSA in 50 ml 0.1 %
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TBS-Tween-20 (TBST). The membranes were blocked with this solution overnight on an
orbital shaker at 4 °C.
2.8.9 Incubation with the primary antibody
The blocking buffer was discarded and the membranes were washed with TBST for 5
min. The membranes were incubated overnight with α-SMA or β-actin antibody diluted
in blocking buffer on an orbital shaker at 40C. The recommended dilution for α-SMA
antibody was 1:1000 while for β-actin antibody was 1: 10 000.
2.8.10 Incubation with the secondary antibody
Following overnight incubation, the primary antibodies were discarded and membranes
were washed three times for 10 min in TBST. Then, the membranes were incubated with
anti-mouse antibody conjugated to horseradish peroxidase (HRP) (1:3000) for 1 h at
room temperature on an orbital shaker.
2.8.11 Stripping and reprobing of membranes
Membranes were incubated with 50 ml of stripping buffer made up from 62.5 mM Tris
pH 6.7, 2 % of SDS and 100 mM of 2-βmercaptoethanol at 50 0C for 30 min. Membranes
were washed four times with TBS-Tween at 15 min intervals and reprobed as in Section
2.8.9 and Section 2.8.10.
2.8.12 Film development
The membranes were incubated in Pierce ECL substrate working solution containing
equal parts of Detection reagent 1 and 2. The membranes were incubated with the
working solution for 1 min at room temperature. The blots were placed in the clear
plastic wrap and excess working solution was removed using an absorbent tissue. Then,
the protected membranes were placed on X-ray cassette and exposed to X-ray film in a
dark-room. The film was developed using film developer.
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2.8.13 Densitometry
Quantification of protein bands from western blot was carried out using Image J analysis
software. The original blot picture was converted to an 8-bit image. The boxes were
drawn using the same size around each band. The area of each analyzed lane corresponds
to the pixel density of the band. The final step is to calculate the relative protein
quantification by adjusting the size of the bands relative to loading control bands.
2.9 MicroRNAs expression profiling
RNA was extracted as described in Section 2.5.2. The RNA purity and concentration was
measured as described in Section 2.5.3.
2.9.1 Taqman Tiling Low-Density Array (TLDA)
MicroRNA expression profiling was performed by using Megaplex™ pool kit. The RT
reaction master mix was prepared according to Table 2.8. The mixture was mixed well in
sterile PCR tubes and was incubated on ice for 5 min. The tubes were placed on thermal
cycler and the reverse transcription was performed as follows: 160C for 2 min, 420C for 1
min and 500C for 1 s for 40 cycles and then incubation at 850C for 5 min. The Megaplex
products were kept at -800C. TLDA consists of two arrays, each array containing 384
wells of pre-designed Taqman probes and exon-spanning primers including two
endogenous controls and a negative control.
2.9.2 Pre-amplification of cDNAs
The pre-amplification reaction mix contained 12.5 µl of 2X TaqMan preamp master mix,
2.5 µl of Megaplex pre-amp primers pool A or pool B, and 7.5 µl of nuclease-free water.
The mixture was mixed well in sterile PCR tubes and incubated on ice for 5 min. The
tubes were placed on thermal cycler and the pre-amplification was performed by heating
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RT reaction mix components Volume for one sample (µl)
Megaplex RT primers (pool A or pool B) 0.80
dNTPs with dTPP (100 mM) 0.20
MultiScribe Reverse Transcriptase (50 U/µl) 1.50
10X RT buffer 0.80
MgCl2 (25 mM) 0.90
RNase inhibitor (20 U/µl) 0.10
Nuclease-free water 0.20
Total RNA (3 ng) 3.0
Total 7.5
Table 2.8: List of RT reaction mix components
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the samples at 950C for 10 min, followed by 12 cycles of 950C for 15 s and 600C for 4
min and finally heated at 950C for 10 min. Following pre-amplification, 75 µl of 0.1 X
TE pH 8.0 was added to each tube. The tubes were briefly centrifuged to mix them. The
pre-amplification products were kept at -800C.
2.9.3 TaqMan microRNA array
The PCR reaction mix contained 450 µl TaqMan Universal PCR Master Mix, no UNG, 9
µl diluted pre-amplification product and 441 µl of nuclease-free water. The mixture was
briefly centrifuged to mix them well. Finally, 100 µl of the mixture was added into each
port of TaqMan MicroRNA array plate. The plates were briefly centrifuged and sealed
well. The reaction involved an initial heating for 2 min at 500C to eliminate carryover
contamination, followed by a denaturing step at 950C for 15 s and annealing/elongation
at 600C for 1 min. Reactions were run for 40 cycles.
2.10 Validation of miRNA expression by qRT-PCR
2.10.1 microRNA reverse transcription reaction
RNA was extracted as described in Section 2.5.2. The RNA purity and concentration was
measured as described in Section 2.5.3. The expression of specific miRNAs of interest
was validated using TaqMan MicroRNA assay. The RT master mix was prepared
according to Table 2.9 and dispensed into each PCR tube. The mirRT reaction was
performed under optimised cycling condition, starting by incubating at 25 0C for 10 min
and was terminated by heating at 85 0C for 5 min.
2.10.2 Targeted microRNA quantitation
The reaction mix contained 5 µl of 2X Taqman® Universal PCR master mix, no UNG,
0.5µl of probe and 3.7µl of nuclease-free water. Following that, 0.8 µl of diluted preamp
product or miRT product was added to the well. The plate was briefly centrifuged at
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RT reaction mix components Volume per reaction (µl)
dNTPs with dTPP (100 mM) 0.15
MultiScribe Reverse Transcriptase (50 U/µl) 1.00
10X RT buffer 1.50
5X probe 3.00
RNase inhibitor (20 U/µl) 0.19
Nuclease-free water 4.16
Total RNA (10 ng) 5.00
Total 15.0
Table 2.9: Reaction mix for targeted miRNA Transcription
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1000 rpm for 2 min. The reaction mix was run on a thermal cycler with an initial heating
for 2 min at 500C to eliminate carryover contamination, followed by a denaturing step at
950C for 15 s and annealing/elongation at 600C for 1 min. Reactions are run for 40 cycles.
RNU48 was used as a miRNA endogenous control as it is a small nuclear RNA shown
previously in the lab to be uniformly and robustly expressed in fibroblasts and
myofibroblasts.
2.11 Transfection of anti-miR microRNA inhibitors and pre-miRNAs
Untransfected or transfected cells (2.5 x 105/well) were seeded onto a 6-well plate which
gives around 60-70 % confluency and incubated overnight in 5 % CO2 incubator for cell
attachment. The concentration for all oligonucleotides used in this study was 50 nM
(Kabir et al., 2016). Anti-miR-145-5p, anti-miR-424-3p and pre-miR424-3p were
transiently transfected into the cells using Oligofectamine reagent while anti-miR
negative control A and negative pre-miR #2 were used as controls. 5 ul of
Oligofectamine was added into Opti-MEM medium to a final volume of 50 ul. 50 nM of
synthetic precursor miRNA or miRNA inhibitor were mixed with Opti-MEM to a final
volume of 50 ul. The transfection mixture and anti-miR or pre-miR mixture was
incubated together for 30 min at room temperature. Prior to transfection, cells were
washed twice with 500 ul of Opti-MEM medium and washed cells were added 800 µl of
Opti-MEM medium. After incubation, the transfection mixture-miRNAs was mixed with
100 ul of Opti-MEM medium. Then, the transfection mixture-miRNAs (200 µl) was
added to the washed cells and incubated for 4 hrs in 5 % CO2 incubator at 37 0C.
Following incubation, transfection mixture-miRNAs was removed and was replaced with
fresh DMEM culture and further incubated for 48 h. The cells were subjected to serum
starvation overnight and TGF-β1 treatment for another 48 h.
2.12 Statistical analyses
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The experiments carried out in the present study were repeated three times to calculate
the mean of each sample tested. The Shapiro-Wilk (n < 50) normality test by Graph Pad
Prism 7 was done to determine data distribution. However, this test is less powerful to
detect normal distribution in a small sample size. The significant differences in the mean
of treated and untreated cells were calculated using unpaired, equal variance of Student
T-test, performed using Graph Pad Prism 7. The error bars on graphs represent the
standard error of mean (SEM) unless otherwise stated.
2.13 Ethical approval
The isolation and use of human primary buccal fibroblast (NOF804) and CAF003
isolated from OSCC have been ethically reviewed and approved by Sheffield Research
Ethics Committee with reference number 09/H1308/66 and 13/NS/0120.STH17021,
respectively. CAF isolated from genetically stable OSCC (BICR70, BICR73, BICR59)
and CAF isolated from genetically unstable OSCC (BICR31, BICR18, BICR3) had been
reviewed and ethically approved (Lim et al., 2011).
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CHAPTER 3: Characterisation of
the CAF-like myofibroblastic
phenotype in oral fibroblasts
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3.1 Aim and objectives
Over the years, increasing evidence has shown interactions between cancer cells
with stroma and how this interaction can influence cancer cell biological behaviour
(Goubran et al., 2014). CAF, one of the predominant cells of tumour stroma, have been
shown to impact many aspects of tumour progression (e.g cancer cell invasion, ECM
remodelling, angiogenesis and inflammatory cell infiltrate) in various malignancies
(Pietras and Ostman, 2010). In OSCC, the presence of CAF is positively correlated with
invasive phenotype (Fujii et al., 2012), presence of cancer recurrence (Kellermann et al.,
2007), and poor prognoses of the patients (Dhanda et al., 2014). The origins of CAF in
vivo are unclear, but increasing of evidence suggests at least a proportion of them arise
from differentiation of resident fibroblasts. The molecular mechanisms underlying this
differentiation remain largely unknown, however several recent studies in other cancers
have implicated the involvement of miRNAs (Mitra et al., 2012; Shen et al., 2016).
Therefore, understanding the molecular mechanism of CAF-myofibroblastic
differentiation holds promise as a source of novel approaches to inhibit the pro-
tumourigenic properties of CAF.
The work outlined in this chapter aimed to characterise the response of NOF to
TGF-β1 stimulation. TGF-β1, a profibrotic cytokine with pleiotropic functions within the
tumour microenvironment (Bowen et al., 2012), has been used to convert the oral
fibroblast into myofibroblast in previous studies (Smith et al., 2006; Marsh et al., 2011;
Sobra et al., 2011). Here, the aim was to verify and further characterise the response of
NOF to TGF-β1 with the specific aim of developing a model of CAF (cancer-associated
fibroblast)-like myofibroblastic differentiation (henceforth termed eCAF) to utilise later
in the project to study the contribution of miRNA to the development of CAF. To
achieve the aim, a number of specific objectives were addressed as stated below:
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1. To determine the appropriate TGF-β1 concentration and treatment time for
activation of NOF into eCAF.
2. To determine the gene expression of myofibroblastic CAF markers, α-SMA and
FN-EDA1, in untreated and TGF-β1-treated NOF by qPCR.
3. To determine the protein abundance of α-SMA in untreated and TGF-β1-treated
NOF cells by western blot.
4. To study cytoplasmic stress fibre formation in untreated and TGF-β1-treated
NOF by fluorescence microscopy.
5. To study the contractility of untreated and TGF-β1-treated NOF by collagen
contraction assay.
3.2 Results
3.2.1 TGF-β1 induces α-SMA expression in eCAF
Dose response and time course experiments were carried out to optimise the
appropriate TGF-β1 concentration and time point required for primary fibroblast
activation to a myofibroblastic, CAF-like phenotype (henceforth referred to as
experimentally-derived CAF; eCAF). Since CAF are commonly characterised by the
expression of α-SMA as well as FN-EDA1, these markers were used experimentally to
examine activation of normal resting oral fibroblasts to eCAF. Optimisation of TGF-β1
treatment was carried out by using a dose and time-response experiment. Three primary
oral fibroblast cultures; NOF1, NOF5 and NOF804 (derived from different subjects to
assess heterogeneity of response), were treated with TGF-β1 at concentrations ranging
from 0.05-5 ng/ml for 24 h and 48 h (these concentrations were selected from searching
the literature, e.g. Walker et al., 2004, and from data previously accrued in the lab
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(Melling, Abidin et al, in revision)).
As shown in Figure 3.1, TGF-β1 induced expression of α-SMA in a dose- and time-
dependent manner in all cultures with maximum α-SMA expression occurring at 48 h
post-treatment at a concentration of 5 ng/ml. The increase in α-SMA expression was 5
±1.9-fold (at 0.05 ng/ml of TGF-β1) and 5.1±1.4-fold (at 0.5 ng/ml of TGF-β1) in NOF1
cells and reached 20±4-fold at 5 ng/ml of TGF-β1 at 24 h, compared to untreated controls.
TGF-β1 increased expression of α-SMA at 48 h by 4±1.2-fold and 12±3.9-fold at 0.05
ng/ml and 0.5 ng/ml of TGF-β1, respectively. Treatment with the highest concentration
of TGF-β1 increased α-SMA expression by 29±4.1-fold at 48 h (Figure 3.1). Similar to
NOF1 cells, TGF-β1 at 24 h induced α-SMA expression by 5±0.9-fold and 12±2.3 -fold
at 0.05 and 0.5 ng/ml in NOF5 cells, respectively. However, the induction of α-SMA at 5
ng/ml of TGF-β1 at 24 h was not as great as NOF1 (13±2.4 -fold), but a significant
induction (55±3-fold; p <0.005) in expression of α-SMA compared to untreated cells was
observed at 48 h (Figure 3.1). Likewise, TGF-β1 induced α-SMA expression in NOF804
cells, a primary fibroblast culture isolated independently (in Sheffield, rather than NOF1
and NOF5 which were isolated at Queen Mary, University of London). At 24 h TGF-β1
significantly induced 5±0.4 -fold and 7±0.7-fold increases in α-SMA expression at 0.05
and 0.5 ng/ml, respectively. The expression level of α-SMA slightly increased at 5 ng/ml
compared to 0.5 ng/ml at 24 h (9±0.5-fold). Treatment with TGF-β1 produced a
proportional increase in α-SMA expression at 48 h with the 5 ng/ml dose significantly
increasing expression by 16±1.0 -fold (p<0.0001) compared to untreated controls.
Nevertheless, the increase in expression of α-SMA at 5 ng/ml is not as remarkable in
NOF804 as for NOF5 and NOF1 at 48 h. In spite of the observed heterogeneity between
the responses of cultures from different subjects, overall the results indicate that 5 ng/ml
is the optimal concentration of TGF-β1
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Figure 3.1: α-SMA expression reaches a peak at 48 h after 5 ng/ml of TGF-β1
treatment
Cells were seeded, serum starved and treated with TGF-β1 (0.05-5 ng/ml) or serum-free
medium (untreated), for (A) 24 h and (B) 48 h. After that, cells were subjected to RNA
extraction and cDNA preparation. The expression of α-SMA was determined using
qPCR and U6 was used as a reference gene. Each data represents the mean ± SEM from
three independent experiments. Statistical significance was determined using two-tailed
Student T-test with *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001 compared to
untreated.
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and 48 h as an optimal time point to induce a CAF-like cell phenotype. This TGF-β1
concentration and time point was also used in the previous studies to induce fibroblast
conversion into myofibroblast in vitro (Yao et al., 2011; Chen et al., 2011; Ina et al.,
2012). Thus, this concentration and time point was used for subsequent experiments.
From the body of literature, it is likely that the TGF-β1 concentration used in this study
are within the physiological range fibroblasts may be exposed to in vivo; 2 ng/ml (Yang
et al., 2013) and 8 ng/ml (Li et al., 2013).
3.2.2 FN-EDA1 expression is increased in eCAF
In order to further characterise the response of NOF to TGF-β1, expression of
another myofibroblast marker, extra domain A-containing fibronectin (FN-EDA1), a
matrix protein, was also determined in this study. This marker has also been detected in
CAF (Serini et al., 1998). Each primary oral fibroblast culture was treated with different
concentrations of TGF-β1 (0.05-5 ng/ml) for 24 h and 48 h, as described in the previous
section. Similar to α-SMA, TGF-β1 induced FN-EDA1 expression in all cultures, with
the highest expression observed at 48 h at 5 ng/ml. As shown in Figure 3.2, expression of
FN-EDA1 increased in all cultures at 24 h and 48 h. TGF-β1 significantly induced FN-
EDA1 expression in NOF1 cells with 2±1.8-fold (0.05 ng/ml), 3±2.6-fold (0.5 ng/ml)
and 6±2.6-fold (5 ng/ml) changes at 24 h. At 48 h, TGF-β1 significantly induced FN-
EDA1 expression (12±5.0-fold) at a concentration of 5 ng/ml. In NOF5, TGF-β1
significantly induced expression of FN-EDA1 with 2±0.1 -fold (0.05 ng/ml), 3±1.6-fold
(0.5 ng/ml) and 4±1.1-fold (5 ng/ml) increases at 24 h, and further significantly increased
FN-EDA1 expression at the highest concentration (5 ng/ml) with 12±2.1-fold (p <0.0001)
at 48 h (Figure 3.2). The induction of FN-EDA1 expression by TGF-β1 at 5 ng/ml was
lower in NOF804 cells at 48 h compared to both NOF1 and NOF5 (Figure 3.2). The FN-
EDA1 expression level fluctuated upon treatment with TGF-β1 at 24 h;
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Figure 3.2: FN-EDA1 expression reaches a peak at 48 h of TGF-β1 treatment
Cells were seeded, serum starved and treated with TGF-β1 (0.05-5 ng/ml) or serum-free
medium for untreated, for (A) 24 h and (B) 48 h. After that, cells were subjected to RNA
extraction and cDNA preparation. The expression of FN-EDA1 was determined using
qPCR and U6 was used as a reference gene. Each data represents the mean ± SEM from
three independent experiments. Statistical analysis was determined using two-tailed
Student T-test with *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001 compared to
untreated.
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3±0.3-fold (0.05 ng/ml), 2±0.4-fold (0.5 ng/ml), 3±1.5-fold (5 ng/ml). At 48 h, TGF-β1
significantly induced FN-EDA1 expression at 0.5 ng/ml and 5 ng/ml (4.5±1.3 -fold and
4±0.8-fold expression of untreated cells, respectively). Unlike NOF1 and NOF5, the
induction of FN-EDA1 expression did not display a dose-dependent response in NOF804.
3.2.3 TGF-β1 increases protein abundance of α-SMA in eCAF
Next, α-SMA abundance was also quantified at the protein level. Two primary
oral fibroblasts were treated with 5 ng/ml TGF-β1 for 48 h (determined as the optimal
concentration of TGF-β1 and optimal time point). Protein extracts were prepared from
the cells and analysed by western blot with an anti-α-SMA antibody as described in
Section 2.8. The results of western blot analyses of TGF-β1 treatment of NOF5 and
NOF804 cells are shown in Figure 3.3. The α-SMA antibody recognized a single protein
band of ~42 kDa. The intensity of this protein band was much greater after stimulation of
both cells with 5 ng/ml of TGF-β1 compared to untreated cells. An equal amount of β-
actin (42 kDa) was detected in the sample analysed which confirmed that equal amounts
of protein had been loaded in each lane (Figure 3.3). Image J software was used to
quantify the band densities. The densities of the bands corresponding to α-SMA were
divided by the densities of the bands representing the internal control, β-actin, to adjust
for any differences in the amount of sample loaded in each well. The effect of TGF-β1
stimulation was expressed as the fold difference between the treated and untreated
samples. As shown in Figure 3.3, TGF-β1 caused statistically significant 2±0.1-fold (p <
0.05) and a 6±0.1-fold (p <0.05) increases in α-SMA protein in NOF804 and NOF5,
respectively. Additionally, α-SMA was detected at protein level in unstimulated cells,
suggesting a low level of basal activation of α-SMA.
3.2.4 TGF-β1 induces stress fibre formation in eCAF
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Figure 3.3: TGF-β1 treatment transformed normal fibroblasts into eCAF
Cell lysates were immunoblotted against α-SMA and β-actin (A) Western blot bands (B)
α-SMA band densities were quantified by Image J analysis and normalized to total β-
actin. Total protein lysates (20µg) were resolved by 12 % SDS-PAGE and transferred
onto nitrocellulose membrane for immunoblotting. Each data represents the mean ± SEM
from three independent experiments. Statistical analysis was determined using two-tailed
Student T-test with *p < 0.05.
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It has been demonstrated that in α-SMA-positive fibroblasts, the formation of
stress fibres was more prominent compared with α-SMA-negative fibroblasts (Hinz et al.,
2001). Treatment of 5 ng/ml of TGF-β1 provokes α-SMA-positive stress fibre formation
in human primary lung fibroblast compared to unstimulated fibroblasts (Yao et al., 2011).
Thus, immunocytochemistry was conducted to next determine whether TGF-β1 was able
to induce α-SMA-positive stress fibre formation in primary oral fibroblasts. NOF were
seeded onto coverslips, serum starved and were treated with 5 ng/ml of TGF-β1 for 48 h
(the dose and time identified as generating the maximal dose of α-SMA expression in
Section 3.2). The cells were fixed with methanol, permeabilised and α-SMA was
visualised using a FITC conjugated monoclonal anti-SMA antibody. Fluorescence
microscopic analysis demonstrated that TGF-β1 increased the number of α-SMA positive
cells (green) in all cultures (Figure 3.4 (A). However, not all the different cultures of
NOF responded equally to TGF-β1; NOF5 appears unresponsive and NOF1 shows
diffuse staining (even some nuclear). Only NOF804 displayed a vivid staining of stress
fibres compared to both NOF1 and NOF5 (Figure 3.4 (B). Staining of NOF804 cell with
α-SMA-conjugated FITC was better than NOF1 and NOF5 due to more experience with
the fluorescence microscope. None of the untreated cells had detectable stress fibres.
3.2.5 TGF-β1 enhances contraction of eCAF
The incorporation of α-SMA in stress fibres is associated with increases in
contractility (Arora and McCulloch, 1994; Hinz et al., 2001). Myofibroblasts acquire a
contractile phenotype to promote wound closure, before re-epithelisation (Skalli and
Gabbiani, 1988). Therefore, the contractile ability of fibroblasts is considered one of the
hallmarks of the myofibroblast phenotype, and by extension the CAF phenotype.
Collagen gel contractility assays are commonly used to study cellular contraction in vitro
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Figure 3.4: Stress fibre formation in NOF in response to TGF-β1
(A) Stress fibres formation in NOF1, NOF5 and NOF804 after treated with 5 ng/ml of
TGF-β1 for 48 h, (B) NOF804 shows clear stress fibres formation after TGF-β1
treatment and this image was produced by digital zoom of the image at 40x
magnification. Cells were seeded onto coverslips and treated with TGF-β1. The
coverslips were washed with PBS, fixed in 100 % methanol for 20 min and
permeabilised with 4 mM sodium deoxycholate for 10 min. Then, the coverslips were
blocked with 2.5 % (v/w) BSA in PBS for 30 min. Cells were observed under a
fluorescence microscope after being stained with the α-SMA-FITC antibody (green) and
Dapi (blue). The images were taken using fluorescence microscope and were processed
using Pro-plus 7 imaging software. The images are representative of three independent
experiments except for NOF1 for which n=1.
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(Bogatkevich et al., 2001). While α-SMA expression is a quantitative measure at cellular
level, the gel contractility assay is a functional analysis method measuring the magnitude
of contractility. A gel collagen contractility assay was therefore performed to determine
whether TGF-β1 treatment of primary oral fibroblasts can promote increased generation
of contractile force. To do this, two primary oral fibroblast cultures (unfortunately it was
not possible to generate data for this experiment from NOF1 cells as the cells died) were
resuspended in collagen mixed with media (1:1) and added to a 24-well plate as
described in Section 2.7. The cells were treated with 5 ng/ml of TGF-β1 for 48 h. Cells
cultured with 10 % FBS were used as a positive control. Following incubation, the
collagen lattices were detached from the edge of wells. The gels were photographed and
the area of gel surface was measured with Image J software. A decrease in lattice area
correlates with an increase in contractility (Bell et al., 1979; Yang et al., 2015).
As shown in Figure 3.5, TGF-β1 significantly enhances contraction of NOF5 and
NOF804 cells compared to untreated controls. Treatment of NOF5 cells with TGF-β1
significantly decreased lattice surface area (157±8.7 mm2; p <0.001) compared to
untreated cells (267±5.5 mm2). While TGF-β1 stimulates remarkable gel contraction in
NOF804 with decreased lattice surface area (208±4.1 mm2) compared to untreated cells
(382±5.5 mm2).
3.3 Discussion
Myofibroblasts are characterised by expression of activation markers, α-SMA
(Honda et al., 2010), collagen 1A1 (COL1A1) and other matrix proteins (Pan et al.,
2013), as well as the presence of cytoplasmic stress fibres and enhanced contractility.
However, some fibroblasts exhibit some features of myofibroblast phenotype without
expressing α-SMA or cytoplasmic stress fibres. These cells, which are thought to be en
route to complete myofibroblast differentiation, termed proto-myofibroblast (Tomasek et
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Figure 3.5: The effects of TGF-β1 on collagen gel contractility of NOF5 and
NOF804 cells
(A) Images of detached lattices at 48 h, (B) the collagen gel contractility were assessed
by measuring the gel surface area (n = 3 replicates/group). Cells were counted and mixed
with 1:1 collagen mixture of collagen with 10x DMEM. pH was neutralised using NaOH
and gel was set to polymerise for 45 min. Growth medium was added to the cells and
after 4 h was replaced with serum free medium. The gels were detached from the side of
the wells and were subjected to TGF-β1-treatment. Cells were cultured in growth
medium as a positive control. The images are representative of three independent
experiments. Statistical analysis was determined using Two-tailed Student T- test with
***p < 0.001 and ****p < 0.0001 compared to untreated.
95
al., 2002). Myofibroblasts are activated fibroblasts found in wound healing or fibrosis,
while CAF are activated fibroblasts found in tumour. Activated fibroblasts are commonly
express α-SMA, therefore α-SMA marker is likely the one really consistent feature of
CAF. The myofibroblast differentiation model was used to confirm that the phenotype
assessed in this study were CAF-like myofibroblastic cell.
TGF-β1 is reported to induce conversion of resting fibroblasts into myofibroblasts in
vitro (Kalluri and Zeisberg, 2006). However, the mechanisms underlying this conversion,
and particularly the relevance of this to CAF development, are poorly understood. In
vitro studies have demonstrated that TGF-β1 causes conversion of normal primary breast
fibroblasts into CAF (Ronnov-Jessen and Petersen, 1993). Thus, TGF-β1 treatment of
primary oral fibroblasts from healthy subjects was used in this study to establish an
experimental model of CAF (eCAF) and to later in the study use this model to examine
the contribution of miRNA to CAF development.
In this study, the optimal TGF-β1 dose for inducing eCAF was determined to be 5
ng/ml at 48 h. TGF-β1 induced upregulation of α-SMA at both the mRNA and protein
level. The magnitude of induction of α-SMA expression by TGF-β1 differed between
different cultures. This might be due to the TGF-β1 freshness (although great care was
taken over storage conditions) as well as the passage number of fibroblast used in the
experiments (efforts were made to use a small number of passages). Cell-to-cell variation
might also contribute to the differences of α-SMA expression in NOF upon TGF-β1
treatment. Single cells in a tissue contain a diverse population of cells characterised by
different morphologies, functions and gene expression profiles (Yuan et al., 2017).
Myofibroblasts derived from various origins showed different level of α-SMA expression,
as do myofibroblasts arising from same origin or same microenvironment conditions (Xu
et al., 1997; Dugina et al., 1998; Hinz et al., 2001). The induction of α-SMA protein
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level by TGF-β1 was not greater as mRNA level in NOF cultures. This might due to
post-transcriptional and post-translational modifications of TGF-β1 in regulating α-SMA
expression in fibroblasts. A similar trend of α-SMA protein abundance in response to
TGF-β1 were observed in other previous phD project (Melling, 2015). Additionally, a
reduction of α-SMA protein level was observed after 48 h when fibroblasts transfected
with α-SMA siRNA, indicating a short α-SMA half-life in fibroblasts (Melling, 2015). α-
SMA mainly expressed in normal adult smooth muscle and temporary expressed during
development of skeletal muscle and cardiac (Ruzicka & Schwartz, 1988; Woodcock-
Mitchell et al., 1988). Even though it is a differential marker for smooth muscle cells, its
expression also detected in myofibroblasts (Darby et al., 1990; Roy et al., 2001).
Collectively, these findings showed that α-SMA expression is the hallmark of
myofibroblast and CAF differentiation. However, how it regulates fibroblast
differentiation is still unclear.
TGF-β1 treatment is reported to cause fibroblasts to alter their ultrastructure with
an increase in cytoskeletal stress fibre formation (Vaughan et al., 2000). TGF-β1
stimulation enhanced α-SMA-rich stress fibres formation in all NOF cultures. As stated
in Section 3.2.4, there was technical issue regarding the staining of NOF5 with α-SMA-
conjugated FITC, thus reflects little stress fibre formation compared to the remarkable
induction of α-SMA at mRNA level. The α-SMA stress fibre formation can be quantified
by fluorescence intensity per cell by Image J, however, the analysis could not be
performed due to the images taken were at 40x magnification, resulting an overlapping
stress fibre formation compared to images at 100x magnification which only focus on
single cell.
TGF-β1 also induced upregulation of other myofibroblast differentiation marker,
FN-EDA1 at transcript levels. Fibronectin (FN) is a 440 kDa dimeric glycoprotein and a
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major component of ECM. It plays a role in differentiation, adhesion, and migration. FN
presents in two main forms; plasma and cellular. Plasma FN is mainly secreted by
hepatocytes while cellular FN is abundantly secreted by activated fibroblasts (Muro et al.,
2003). FN is composed of three different types of homologous; type 1, type II, and type
III (Hynes, 1990). It has two alternatively spliced domains which are EDA and EDB
(Kornblihtt et al., 1996). Only cellular FN has EDA and EDB (Vartio et al., 1987; Ina et
al., 2012). Both isoforms are mainly expressed in embryonic tissue and rarely found in
normal adult tissue. Nevertheless, FN-EDA are re-expressed in various fibrotic and
pathological processes, including wound healing (Ffrench-constant et al., 1989; Ina et al.,
2012). Although FN-EDA1 promotes myofibroblast differentiation, the mechanism
behind it is still unclear. It would be interesting to determine other CAF markers such as
FAP, if more time had given. However, none of the markers are exclusive to CAF due to
their heterogeneous nature and the expression of many of these markers by other cell
types (for example pericytes).
In this study, TGF-β1 promoted fibroblast contraction in NOF cultures. The
matrix reorganization that occurs during floating collagen lattice contraction is similar to
what occurs during the early phases of wound closure (Tomasek et al., 2002). In floating
and unattached gels, any tension that caused fibroblast contraction is transferred to the
gel matrix, resulting in gel contraction. In this condition, fibroblast is not under
continuous tension and stress fibre formation is not observed (Bell et al., 1979).
Conversely, fibroblasts populated in collagen lattice are attached and unable to contract,
thus the formation of stress fibres is seen (Farsi and Aubin, 1984). Subsequent release of
the lattices from attachment cause actin stress fibre disassembly (Tomasek et al., 1992).
These results suggest that the transmission of tension to fibroblast is crucial to induce
actin cytoskeleton, thereby promoting myofibroblast phenotype (Hinz et al., 2001a).
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Induction of α-SMA expression by TGF-β1 at transcript levels was greater in NOF5
compared to NOF804, however, less magnitude of contraction was seen compared to
NOF804. It is possible that batch or freshness of TGF-β1 and the fibroblast passage
number used in this study contribute to these differences. However, evidence in literature
of quantitative correlation between α-SMA mRNA level with the contraction magnitude
is limited, suggesting the involvement of other factors, which may also contribute to the
lack of correlation observed. Furthermore, although the collagen contractility model
provides a simple, yet effective way to study fibroblasts contraction and is widely used,
some limitations exist. This assay provides a semi-quantitative measurement of
contraction and able to quantify contraction of populations of cells, not of individual cells.
Other method such as Traction force microscopy (TFM) is used to measure the
contraction of single cells by observing collagen gel embedded with multiple
fluorescence microbeads (Dembo and Wang, 1999; Butler et al., 2002).This method is
technically challenging and measurements of contraction do not provide a true cell
contraction model, however. TGF-β1 induced α-SMA expression and FN-EDA1,
followed by an increase in collagen contractility in diabetic renal fibrosis (Ina et al.,
2012). Hinz and colleagues (2001b)) demonstrated that α-SMA modulates fibroblast
contractile activity and plays an important role in focal adhesion maturation (Hinz et al.,
2003).
Alternatively, the statistical analysis for α-SMA and FN-EDA1 transcript levels
in NOF cultures could have been done with analysis of variance (ANOVA) by using
Tukey’s test as a post-hoc test. T-test is a special type of ANOVA that commonly used to
compare two different means while ANOVA compares more than two groups of mean.
3.4 Summary
Fibroblasts are the most numerous cellular constituent within the tumour
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microenvironment. Activated fibroblasts have been reported to play a role in promoting
stromal remodelling and disease progression (Kalluri and Zeisberg, 2006). Although
there are many potential sources of CAF within the tumour microenvironment, it is likely
that myofibroblastic differentiation of resident fibroblasts accounts for at least some of
this population. In this chapter, normal buccal fibroblasts were exposed to factor that are
known to promote myofibroblast phenotype in vitro in order to model myofibroblastic
CAF surrounding tumours for subsequent miRNA profiling and mechanistic studies. In
this study, the optimal TGF-β1 dose for inducing differentiation of normal oral
fibroblasts to a myofibroblastic CAF-like phenotype (experimental CAF; eCAF) was
determined to be 5 ng/ml at 48 h. TGF-β1 treatment of normal primary oral fibroblasts
induces the expression of α-SMA as well as promoting FN-EDA1 expression. TGF-β1
also enhances the formation of α-SMA-rich stress fibre in eCAF. In addition, TGF-β1
promotes contractility of collagen in eCAF. These findings suggest that TGF-β1
successfully converts NOF into eCAF and this differentiation model was used later to
study any involvement of miRNAs in the development of CAF.
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CHAPTER 4: Examination of the
roles of miR-424-3p and miR-145-
5p in eCAF differentiation
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4.1 Aim and objectives
The previous chapter demonstrated that TGF-β1 treatment of normal human
primary fibroblasts resulted in differentiation to a myofibroblastic eCAF. The aim of this
chapter was to profile the expression of miRNAs in eCAF. To do this, the following
objectives were addressed:
1) to determine the differential miRNAs expression of eCAF using TaqMan tiling
low density array (TLDA) and validation of selected miRNAs by qRT-PCR.
2) to examine a role selected miRNAs may play in this TGF-β1-induced
differentiation by doing loss-of-function and/or gain-of-function experiments in
NOF or tumour-derived CAF.
4.2 Results
4.2.1 miRNAs are differentially expressed in eCAF (a preliminary study)
As described detail in Chapter 1, miRNAs are small noncoding RNA molecules
(~22 nucleotides) that regulate gene expression at posttranscriptional level (Scaria et al.,
2007). miRNAs relatively bind to 3’-untranslated region of target mRNA, stimulating
degradation or translational inhibition (Breving et al., 2010). miRNA bind 7-8mer
sequences which may be present in more than one transcript, and also tolerate a degree of
base mismatch, resulting in the ability of a single miRNAs to repress the expression of a
number of genes (Nam et al., 2014). It is thought that, rather than this resulting in non-
specific gene expression regulation, this confers on miRNA the ability to target several
genes within the same functional pathway, resulting in profound phenotypic changes
despite relatively mild effects on the expression of individual genes. This enables a
relatively small number of miRNA to play important roles in critical cellular processes,
such as differentiation.
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Relatively little is known about the role of miRNAs in regulating myofibroblast
differentiation in response to TGF-β1, particularly in the context of tumour-stromal
interactions. miRNAs are thought to play a role in regulating TGF-β1 signalling; most
members of the TGF-β1 pathway are known or predicted to be targeted by one or more
miRNAs (Butz et al., 2012). Furthermore, TGF-β1 directly regulates the biogenesis of
miRNAs through Smads (Zhong et al., 2010), suggesting the existence of feedback loops.
To determine TGF-β1-induced eCAF differentiation was associated with changes
in miRNA expression, three primary NOF cultures were seeded, serum starved and
treated with or without 5 ng/ml of TGF-β1 for 48 h. RNA was isolated from untreated
and TGF-β1-treated NOF was used for cDNA synthesis. The cDNA samples were
amplified to enhance the sensitivity of the qRT-PCR in detecting the low abundance of
miRNAs. Pre-amplified cDNA was subjected to TLDA analysis (Section 2.9.3) and the
data obtained were analysed using DataAssist software v2.0. TLDA cards contained 384-
wells per card (2 cards) pre-loaded with miRNA targets, including endogenous controls.
In this study, approximately 700 miRNA were differentially expressed in eCAF
compared to normal fibroblasts when fold change of <1 is considered downregulated and
fold change >1 is considered upregulated (Appendix 1). To identify differentially
expressed miRNA to take forward for further study, the fold change of each miRNA
were determined using DataAssist software v2.0. For the analysis, the maximum Ct cut-
off value of miRNAs was set at 34; Ct value more than 34 are excluded from the analysis.
As shown in Figure 4.1, miR-145-5p, miR-424-5p and miR-424-3p were
upregulated 3.1-fold, 1.5-fold and 3.2-fold in NOF1 following TGF-β1-induced
myofibroblast differentiation compared to unstimulated cells, respectively. Similarly,
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Figure 4.1: Expression of miR-145-5p, miR-424-5p and miR-424-3p are deregulated
in eCAF
Three primary NOF cultures were seeded and serum starved for overnight. Following
that, fibroblasts were treated with or without TGF-β1 FOR 48 h. RNA was extracted and
was used for cDNA synthesis. cDNA was amplified by PCR and the pre-amplified
products were used for TLDA analysis by qRT-PCR. The data obtained from qRT-PCR
were analysed using DataAssist v2.0 software. The fold difference between the treatment
group and the untreated group are plotted. N=1 for TLDA.
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miR-145-5p, miR-424-5p and miR-424-3p were found to be highly upregulated in NOF5
after TGF-β1 treatment with 16-fold, 158-fold and 18-fold increases over unstimulated
cells, respectively. TGF-β1 treatment upregulated miR-424-3p expression (78-fold) and
miR-424-5p expression (2.3-fold) while miR-145-5p was downregulated by 0.3-fold in
NOF804 over unstimulated cells. Thus, miR-424-5p, miR-424-3p and miR-145-5p were
chosen for validation. In this preliminary study, an attempt to validate some of the other
miRNA that highly upregulated in eCAF from both cultures was unsuccessful (data not
shown). This might be due to false positives having been identified as a result of only
performing one repeat of the TLDA analysis - this deficiency is addressed in Chapter 5.
4.2.2 Validation of selected miRNAs expressed in eCAF
The selected miRNAs were further verified by qRT-PCR. To do this, independent
RNA samples treated in the same way as the samples used for TLDA were used to
generate specific miR-145-5p, miR-424-5p, miR-424-3p and RNU48 cDNA. They were
used in a qRT-PCR reaction using stem-looped primers designed to amplify miR-145-5p,
miR-424-5p, miR-424-3p and RNU48. RNU48 was used as reference gene. The qRT-
PCR analysis demonstrated that the expression levels of certain selected miRNAs more
or less similar with the values observed in the TLDA experiment for NOF1 (Figure 4.2
(A)) and NOF5 (Figure 4.2 (B)), although the magnitude of change observed in some
cases differed; for example, the increase in expression level of miR-424-3p detected by
qRT-PCR (5.2-fold) was lower than that detected by TLDA (78-fold) (Figure 4.2 (C) and
Figure 4.2 (D)).
4.2.3 Overexpression of miR-424-3p attenuates TGF-β1-induced α-SMA and FN-
EDA1 markers, not COL1A1 marker in NOF
As NOF5 grew slowly and subsequently died, data for the subsequent
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Figure 4.2: Validation of miRNA expression in eCAF by qRT-PCR
Fibroblasts were seeded and serum starved overnight. Following that, fibroblasts were
treated with or without 5 ng/ml of TGF-β1 for 48 h. RNA was extracted from untreated
and TGF-β1-treated NOF and was used for specific miRNA cDNA synthesis. The
expression of miRNAs relative to RNU48 (reference control) was determined by qRT-
PCR in (A) NOF1, (B) NOF5 and (C) NOF804. (D) Comparison of the fold changes
observed in TLDA and by qRT-PCR. Each reaction was performed in triplicate and data
are presented as means ± SEM from three independent experiments for qRT-PCR. Dash
lines indicate no data for that miRNA. N=1 for TLDA.
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experiments could not be generated for this culture. Thus, NOF804 was mainly used in
this study. The validation data showed that miR-424-3p was upregulated in eCAF.
Therefore, miR-424-3p was selected for further examination. To gain further insight into
the effect of TGF-β1-induced miR-424-3p upregulation in the eCAF, one primary NOF
culture (NOF804) was transiently transfected with a synthetic precursor miR-424-3p
(pre-miR-424-3p) oligonucleotide for 48 h to overexpress mature miR-424-3p. A non-
targeting precursor miRNA was used as a negative control and mock (transfection
reagent only) also included in this experiment. The miRNA mimic concentration (50 nM)
was selected based on the concentration frequently used in the literature (Liu et al., 2012)
and previously optimised in the laboratory (Kabir et al., 2016). The transfected NOF
were serum starved overnight and treated with TGF-β1 or left untreated for 48 h. After
the treatment, NOF were harvested for RNA extraction, followed by cDNA synthesis.
qRT-PCR was performed on cDNA using primers specific for α-SMA, FN-EDA1,
COL1A1 and B2M as a reference gene. B2M was used as the reference gene, as it
showed the least variable in CT values between samples, compared to U6 (Appendix 2).
As shown in Figure 4.3, TGF-β1 treatment significantly enhanced α-SMA
transcript levels in fibroblasts transfected with mock (36.9±14.1-fold), pre-miR negative
control (35.1±10.6-fold) and pre-miR-424-3p (23.5±9.5-fold). Interestingly,
overexpression of miR-424-3p caused a significant reduction in TGF-β1-stimulated α-
SMA expression by ≈ 69 % (compared to treated-pre-miR negative control) and by ≈ 65
% (compared to treated mock). Next, other myofibroblast differentiation markers were
assessed to investigate whether miR-424-3p was able to alter other myofibroblast
differentiation markers besides α-SMA. In agreement with data shown in Chapter 3
(section 3.2.2), FN-EDA1 transcript levels were significantly increased in transfected
NOF treated with TGF-β1; increases of 24.9±9.8-fold (mock), 27.1±9.1-fold (pre-miR
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Figure 4.3: Overexpression of miR-424-3p attenuates TGF-β1 induced α-SMA
expression in NOF
NOF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. The transfected NOF were serum starved overnight before being treated with or
without TGF-β1 for 48 h. Following treatment, NOF were harvested and subjected to
RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was done using
primers designed to amplify αSMA. B2M was used as a reference gene. Each data
represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated pre-miR negative control. Statistical analysis
was determined using two-tailed Student T-test with *p <0.05. If not shown by a bar, the
significance is compared to the untreated equivalent transfection, or pre-miR negative
control, in the case of untreated pre-miR.
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Figure 4.4: Overexpression of miR-424-3p attenuates TGF-β1 induced FN-EDA1
expression in NOF
NOF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. The transfected NOF were serum starved overnight before being treated with or
without TGF-β1 for 48 h. Following treatment, NOF were harvested and subjected to
RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was done using
primers designed to amplify FN-EDA1. B2M was used as a reference gene. Each data
represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated pre-miR negative control. Statistical analysis
was determined using two-tailed Student T-test with *p < 0.05. If not shown by a bar, the
significance is compared to the untreated equivalent transfection, or pre-miR negative
control, in the case of untreated pre-miR.
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negative control) and 18.9±6.5-fold (pre-miR-424-3p) were observed (Figure 4.4).
Similar to the effects observed on α-SMA expression, overexpression of miR-424-3p
significantly attenuated the TGF-β1-mediated increase in FN-EDA1 expression, 19-fold
(compared to ≈27-fold of treated pre-miR negative control) and ≈19-fold (compared to ≈
25-fold of treated mock). As shown in Figure 4.5, TGF-β1 caused an increase in
COL1A1 transcript levels in mock (11.9±12.4-fold), pre-miR negative control (7.9±4.6-
fold) and pre-miR 424-3p (9.4±6.6-fold). However, none of these changes reached
significance (p<0.05). Moreover, overexpression of miR-424-3p did not alter TGF-β1-
modulated COL1A1 gene expression in NOF, compared to TGF-β1-treated pre-miR
negative control. The data above suggest that miR-424-3p has the ability to modulate α-
SMA and FN-EDA1 expression but not COL1A1.
4.2.4 Overexpression of miR-424-3p had no effect on TGF-β1-induced α-SMA
protein abundance in NOF
As shown in Chapter 3, TGF-β1 treatment induces α-SMA protein abundance in
NOF. To investigate the effect of miR 424-3p on TGF-β1-induced α-SMA protein
abundance, NOF were transiently transfected with pre-miR negative control or pre-miR
424-3p for 48 h. NOF were serum starved overnight and treated with TGF-β1 or left
untreated for 48 h. Cells were harvested and subjected to protein extraction. The total
protein lysates were used for immunoblotting. TGF-β1 caused a small increase in α-SMA
protein abundance in mock (1.5 ±0.5-fold), pre-miR negative control (1.3±0.4-fold) and
pre-miR-424-3p (1.4±0.2-fold) (Figure 4.6). However, none of these reaches statistical
significance (p<0.05). Overexpression of miR-424-3p slightly increased TGF-β1-induced
α-SMA protein abundance in NOF, compared to treated pre-miR negative control.
However, this did not reach significance value tested.
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Figure 4.5: Overexpression of miR-424-3 had no effect on TGF-β1 induced COLIA1
expression in NOF
NOF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. Transfected NOF were serum starved overnight before being treated with or
without TGF-β1 for 48 h. Following treatment, NOF were harvested and subjected to
RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was done using
primers designed to amplify COL1A1. B2M was used as a reference gene. Each data
represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated pre-miR negative control. Statistical analysis
was determined using two-tailed Student T-test, as the significance is compared to the
untreated equivalent transfection, or pre-miR negative control, in the case of untreated
pre-miR. No significant difference between pre-miR negative control compared to pre-
miR 424-3p in TGF-β1-treated NOF.
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Figure 4.6: Overexpression of miR 424-3p had no effect in TGF-β1-induced α-SMA
protein abundance in NOF
NOF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. Then, NOF were serum starved overnight and treated with or without TGF-β1 for
48 h. NOF were harvested and used for protein extraction. Total protein lysates were
used for immunoblotting using antibodies from mouse α-SMA and β-actin as a loading
control. (A) a representative of protein bands for immunoblot from three independent
repeats, (B) the quantified amount of protein in each sample using Image J software.
Each data represents the mean ± SEM from three independent experiments. Statistical
analysis was determined using two-tailed Student T-test, as the significance is compared
to the untreated equivalent transfection, or pre-miR negative control, in the case of
untreated pre-miR. No significant difference between pre-miR negative control compared
to pre-miR 424-3p in TGF-β1-treated NOF.
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4.2.5 Overexpression of miR-424-3p had no effect on TGF-β1-induced α-SMA
positive stress fibres formation in NOF
In the previous chapter, it was demonstrated that TGF-β1 induces the formation
of stress fibres in NOF. To determine the effect of TGF-β1- induced miR-424-3p
upregulation on these stress fibre, NOF were seeded onto coverslips and transiently
transfected with pre-miR negative control or pre-miR-424-3p for 48 h before being
treated with TGF-β1 or left untreated for 48 h. TGF-β1 treatment significantly increased
the formation of α-SMA positive stress fibres, by mean relative fluorescence per cell in
mock (7.1±1.1-fold), pre-miR negative control (7.0±0.3-fold) and pre-miR-424-3p
(5.7±0.7-fold) (Figure 4.7 (B)). Overexpression of miR-424-3p caused no change in the
formation of TGF-β1-induced α-SMA positive stress fibres formation, compared to
treated pre-miR negative control, but this did not reach statistical significance (p<0.05)
(Figure 4.7 (A)).
4.2.6 Overexpression of miR-424-3p significantly decreased TGF-β1-induced gel
contraction in NOF
To further investigate the role of miR-424-3p in myofibroblast phenotype, a gel
collagen contractility assay was performed to examine the effect of overexpression of
miR-424-3p on TGF-β1-induced contractility in NOF. NOF were transiently transfected
with pre-miR negative control or pre-miR 424-3p for 48 h. Transfected NOF were
resuspended in a mixture of rat tail collagen 1 with DMEM (1:1). The mixture was
allowed to polymerize, then treated with TGF-β1 or left untreated for 48 h. As shown in
Figure 4.8, TGF-β1 significantly induced gel contraction in mock (224±29.5 mm2), pre-
miR negative control (237±29.9 mm2) and pre-miR-424-3p (286±39.9 mm2).
Interestingly, overexpression of miR-424-3p significantly reduces TGF-β1’s ability to
induce contraction of gels, indicated by decrease in gels surface area by ≈ 83 %
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Figure 4.7 Overexpression of miR-424-3p did not prevent the formation of TGF-β1-
induced α-SMA positive stress fibres in NOF
NOF were seeded onto coverslips overnight and transiently transfected with pre-miR
negative control or pre-miR-424-3p for 48 h. Following that, NOF were serum starved
overnight and treated with or without TGF-β1 for 48 h. The coverslips were washed with
DPBS prior to fixation with 100 % methanol for 20 min. Then, they were permeabilised
in 4 mM sodium deoxycholate for 10 min before being blocked with 2.5 % (w/v) BSA in
DPBS for 30 min. The coverslips were incubated with a primary FITC-conjugated α-
SMA antibody overnight at 4 0C. Following incubation, they were washed with DPBS
and were mounted with Dapi. The coverslips were viewed under a fluorescence
microscope using Pro-Plus 7.0 imaging software at 100x magnification (using oil
immersion). (A) Representative images of stress fibre formation from three independent
repeats. (B) The mean fluorescence intensity per cell ± SEM from three independent
experiments was quantified using Image J software. Statistical analysis was determined
using two-tailed Student T-test with *p < 0.05 and **p < 0.005. If not shown by a bar,
the significance is compared to the untreated equivalent transfection, or pre-miR negative
control, in the case of untreated pre-miR.
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Figure 4.8: Overexpression of miR-424-3p prevents TGF-β1-induced contractility in
NOF
NOF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. Following incubation, the NOF were harvested, counted (2.5 x 105 cells/well) and
resuspended in a mixture of rat tail collagen 1 (in 0.1 M acetic acid) and DMEM (1:1).
The pH was neutralised with 1M NaOH and the mixture was aliquoted into wells (300
µl/well) and left to polymerise in an incubator at 37 0C with 5 % CO2. After the gels had
polymerised, media were added to each well and incubated for 4 h in the incubator. After
that, the media were replaced by serum-free media for overnight. The gels were detached
from the sides of the wells with a scalpel and treated with TGF-β1 or left untreated for 48
h. The images were taken at 48 h and the gel contraction was determined by measuring
the surface area of the gels with Image J software. (A) a representative of gels containing
transfected NOF after 48 h of TGF-β1 treatment. (B) the quantified of gels contraction,
as a surface area (mm2) compared to untreated pre-miR negative control. Each data
represents the mean ± SEM from three independent experiments. Statistical analysis was
determined using two-tailed Student T-test with **p < 0.005 and ****p < 0.0001. If not
shown by a bar, the significance is compared to the untreated equivalent transfection, or
pre-miR negative control, in the case of untreated pre-miR.
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(compared to TGF-β1-treated pre-miR negative control) and by ≈ 78 % (compared to
treated-mock).
4.2.7 Knockdown of miR-424-3p or miR-145-5p had no effect in TGF-β1-induced
fibroblast differentiation markers in NOF
Preliminary study showed that miR-145-5p was downregulated in eCAF. Thus an
attempt to inhibit its expression was examined at this section. To investigate further
whether inhibition of miR-424-3p and miR-145-5p affected TGF-β1-induced
myofibroblast phenotype, one primary NOF culture was transiently transfected with a
synthetic miR-424-3p inhibitor or miR-145-5p inhibitor for 48 h. A non-targeting
miRNA inhibitor was used as a negative control and mock consisted of transfection
reagent only. As stated in Section 4.3, similar concentration of miRNA inhibitors (50 nM)
was used in this study. TGF-β1 was added after overnight serum starvation for 48 h.
NOF were harvested and used for total RNA extraction, followed by cDNA synthesis
using random hexamers. Fibroblast differentiation markers were determined using
primers designed to amplify α-SMA, FN-EDA1, COL1A1 and B2M as reference gene by
qRT-PCR.
Treatment with TGF-β1 increased α-SMA transcript levels in fibroblasts
transfected with mock (64.5±29.8-fold; significant), negative control inhibitor (45.0±8.9-
fold; significant), miR-145-5p (50.2±35.2-fold; not significant) and miR-424-3p inhibitor
(49.8±14-fold; significant) (Figure 4.9). The α-SMA is slightly increased by 4 fold, not
significant (p<0.05) when NOF were exposed to the miR-424-3p inhibitor and TGF-β1 in
combination, compared to treated negative control inhibitor. Knockdown of miR-145-5p
caused a small increase by 5 fold but not significant (p<0.05) of TGF-β1-modulated α-
SMA gene expression, compared to treated negative inhibitor.
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Figure 4.9: Neither inhibition of miR-424-3p nor miR-145-5p had an effect on TGF-
β1-induced α-SMA expression in NOF
NOF were transiently transfected with negative control inhibitor, miR-424-3p inhibitor
or miR-145-5p for 48 h. The transfected NOF were serum starved overnight before being
treated with or without TGF-β1 for 48 h. Following treatment, NOFs were harvested and
subjected to RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was
done using primers designed to amplify αSMA. B2M was used as a reference gene. Each
data represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated negative control inhibitor. Statistical analysis
was determined using two-tailed Student T-test with *p <0.05. If not shown by a bar, the
significance is compared to the untreated equivalent transfection, or anti-miR negative
control, in the case of untreated anti-miRs.
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On the other hand, upregulation of FN-EDA1 gene expression was observed in
mock (14.1±3.2-fold; significant), negative control inhibitor (11.6±6.3-fold; significant),
miR-145-5p (11.3±7.1-fold; not significant) and miR-424-3p (12.2±8.9 -fold; not
significant) after TGF-β1 treatment (Figure 4.10). Knockdown of miR-424-3p caused a
small increase (not significant) in TGF-β1-induced FN-EDA1 gene expression,
compared to treated negative control inhibitor. Meanwhile, inhibition of miR-145-5p had
no effect on TGF-β1-induced FN-EDA1 gene expression.
Neither transfection with miR-424-3p inhibitor (7.1±7.0-fold) nor miR-145-5p
inhibitor (6.7±5.2-fold) caused a significant increase in TGF-β1-induced COL1A1
transcript levels (Figure 4.11). Similarly, knockdown of these inhibitors does not
significantly upregulate TGF-β1-induced COL1A1 gene expression, compared to cells
transfected with negative control inhibitor.
4.2.8 Knockdown of miR-424-3p or miR-145-5p did not alter TGF-β1-induced α-
SMA protein in NOF
To investigate the effect of miR 424-3p inhibition on TGF-β1-induced α-SMA at
the protein level, NOF were transiently transfected with a non-targeting negative control
inhibitor or miR-424-3p inhibitor or miR-145-5p inhibitor for 48 h. NOF were serum
starved overnight and treated with TGF-β1 or left untreated. NOF were harvested and
subjected to protein extraction. The total protein lysates were used for immunoblotting.
TGF-β1 caused an increase in α-SMA protein abundance in all conditions, but this did
not reach statistical significance (p<0.05) (Figure 4.12). Inhibition of miR-424-3p or
miR-145-5p had small decreases (not significant) in TGF-β1-induced α-SMA protein
abundance, compared to treated negative control inhibitor.
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Figure 4.10: Inhibition miR-145-5p or miR-424-3p had no effect on TGF-β1-
induced FN-EDA1 expression in NOF
NOF were transiently transfected with negative control inhibitor, miR-424-3p inhibitor
or miR-145-5p for 48 h. The transfected NOF were serum starved overnight before being
treated with or without TGF-β1 for 48 h. Following treatment, NOF were harvested and
subjected to RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was
done using primers designed to amplify FN-EDA1. B2M was used as a reference gene.
Each data represents the mean relative quantification of myofibroblast differentiation
markers relative to B2M ± SEM from three independent experiments, for each
transfection with or without TGF-β1 compared to untreated negative control inhibitor.
Statistical analysis was determined using two-tailed Student T-test with *p <0.05. The
significance is compared to the untreated equivalent transfection, or anti-miR negative
control, in the case of untreated anti-miRs. No significant difference between anti-miR
negative control compared to anti-miRs in TGF-β1-treated NOF.
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Figure 4.11: Inhibition miR-145-5p or miR-424-3p had no effect on TGF-β1-
induced COL1A1 expression in NOF
NOF were transiently transfected with negative control inhibitor, miR-424-3p inhibitor
or miR-145-5p for 48 h. The transfected NOF were serum starved overnight before being
treated with or without TGF-β1 for 48 h. Following treatment, NOFs were harvested and
subjected to RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was
done using primers designed to amplify COL1A1. B2M was used as a reference gene.
Each data represents the mean relative quantification of myofibroblast differentiation
markers relative to B2M ± SEM from three independent experiments, for each
transfection with or without TGF-β1 compared to untreated negative control inhibitor.
Statistical analysis was determined using two-tailed Student T-test. The significance is
compared to the untreated equivalent transfection, or anti-miR negative control, in the
case of untreated anti-miRs. No significant difference between anti-miR negative control
compared to anti-miRs in TGF-β1-treated NOF.
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Figure 4.12: Inhibition of miR 424-3p or miR-145-5p did not alter TGF-β1-induced
α-SMA protein abundance in NOF
NOF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR-145-5p inhibitor for 48 h. Then, NOF were serum starved overnight and treated
with or without TGF-β1 for 48 h. NOF were harvested and used for protein extraction.
Total protein lysates were used for immunoblotting using antibodies from mouse α-SMA
and β-actin as a loading control. (A) a representative of protein bands for immunoblot
from three independent repeats, (B) the quantified amount of protein in each sample
using Image J software. Each data represents the mean ± SEM from three independent
experiments. The significance is compared to the untreated equivalent transfection, or
anti-miR negative control, in the case of untreated anti-miRs. No significant difference
between anti-miR negative control compared to anti-miRs in TGF-β1-treated NOF.
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4.2.9 Knockdown of miR-424-3p or miR-145-5p had no effect on TGF-β1-induced
α-SMA positive stress fibres formation in NOF
To determine the effect of TGF-β1-induced miR-424-3p upregulation on the
formation of stress fibre, NOF were seeded onto coverslips and transiently transfected
with negative control inhibitor or miR-424-3p inhibitor or miR-145-5p inhibitor for 48 h
before being treated with TGF-β1 or left untreated for 48 h. As shown in Figure 4.13 (A),
TGF-β1 promotes α-SMA positive stress fibres formation in NOF transfected with
negative control inhibitor (2.1±0.1-fold; significant), miR-424-3p inhibitor (2.7±0.5-fold;
significant) or miR-145-5p inhibitor (4.3±1.3-fold; significant), as obviously seen by
striking cytoskeletal. The stress fibre was observed much clearer in the TGF-β1-treated
mock compared to NOF transfected with other two inhibitors. A small increase in mean
relative fluorescence per cell (not significant) was observed when NOF were exposed to
the miR-424-3p inhibitor and TGF-β1 in combination, compared to treated negative
control inhibitor (Figure 4.13 (B)). Similarly, treatment with TGF-β1 did not
significantly increase mean relative fluorescence per cell in miR-145-5p inhibitor-treated
NOF, compared to treated negative control inhibitor.
4.2.10 Knockdown of miR-424-3p or miR-145-5p did not alter TGF-β1-induced gel
contraction in NOF
A gel collagen contractility assay was done to determine the effect of miR-424-3p
on TGF-β1-induced contractility in NOF. NOF were transiently transfected with negative
control inhibitor or miR-424-3p inhibitor or miR-145-5p inhibitor for 48 h. Transfected
NOF were resuspended in a mixture of rat tail collagen 1 with DMEM (1:1). The mixture
was allowed to polymerise, then treated with 5 ng/ml of TGF-β1 or left untreated for 48
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Figure 4.13: Effect of inhibition of miR-424-3p or miR-145-5p on TGF-β1-induced
α-SMA positive stress fibres formation in NOF
NOF were seeded onto coverslips overnight and transiently transfected with negative
control inhibitor or miR-424-3p inhibitor or miR-145-5p inhibitor for 48 h. Following
that, NOF were serum starved overnight and treated with TGF-β1 for 48 h. The
coverslips were washed with DPBS prior to fixation with 100 % methanol for 20 min.
Then, they were permeabilised in 4 mM sodium deoxycholate for 10 min before being
blocked with 2.5 % (w/v) BSA in DPBS for 30 min. The coverslips were incubated with
a primary FITC-conjugated α-SMA antibody overnight at 4 0C. Following incubation,
they were washed with DPBS and were mounted with Dapi. The coverslips were viewed
under a fluorescence microscope using Pro-Plus 7.0 imaging software at 100x
magnification (using oil immersion). (A) Representative images of stress fibre formation
from three repeats. (B) The mean fluorescence intensity per cell ± SEM from three
independent experiments was quantified using Image J software. Statistical analysis was
determined using two-tailed Student T-test with *p < 0.05. If not shown by a bar, the
significance is compared to the untreated equivalent transfection, or anti-miR negative
control, in the case of untreated anti-miRs.
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h. TGF-β1 significantly induced gel contraction in mock (224±29.5 mm2), negative
control inhibitor (284±62.4 mm2), miR 424-3p inhibitor (295±56.1 mm2) and miR-145-
5p inhibitor (309±50.1 mm2) (Figure 4.14). However, inhibition of miR-424-3p or miR-
145-5p did not alters TGF-β1’s ability to induce contraction of gel, compared to treated
negative control inhibitor.
4.2.11 miR-424-3p effects on CAF
4.2.11.1 Overexpression of miR-424-3p did not inhibit TGF-β1-induced
myofibroblast differentiation markers in CAF
To investigate the involvement of the miR-424-3p in TGF-β1-induced
myofibroblast differentiation in CAF, CAF were transiently transfected with precursor
negative control or precursor miR-424-3p for 48 h. Following that, CAF were treated
with TGF-β1, or left untreated for 48 h and myofibroblast differentiation markers were
assessed by qRT-PCR. As shown in Figure 4.15, overexpression of miR-424-3p did not
inhibit basal α-SMA expression at mRNA level in CAF. TGF-β1 significantly increases
α-SMA transcript levels in CAF transfected with mock (78.0±31.2-fold), pre-miR
negative control (48.4±31.3-fold) and pre-miR-424-3p (44.6±19.4-fold). miR-424-3p
overexpression in CAF did not significantly decrease TGF-β1-induced α-SMA transcript
levels, compared to TGF-β1-treated cells transfected with pre-miR negative control.
Similar to α-SMA, overexpression of miR-424-3p did not inhibit basal level of FN-
EDA1 transcripts in CAF. TGF-β1 treatment significantly caused increases in FN- EDA1
transcript levels of mock (31.8±15.3-fold), pre-miR negative control (17.0±9-fold) and
pre-miR-424-3p (15.8±3.0-fold) (Figure 4.16). Overexpression of miR-424-3p had a
small decrease in TGF-β1-induced FN-EDA1 transcript levels, compared to treated pre-
miR negative control, this not significant, however. Overexpression of miR-424-3p did
not inhibit basal level of COL1A1 transcripts in CAF. Treatment with TGF-β1
124
Figure 4.14: Inhibition of miR-424-3p or miR-145-5p did not alter TGF-β1-induced
gel contraction in NOF
NOF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR-145-5p inhibitor for 48 h. Following incubation, the NOF were harvested,
counted (2.5 x 105 cells/well) and resuspended in a mixture of rat tail collagen 1 (in 0.1
M acetic acid) and DMEM (1:1). The pH was neutralised with 1M of NaOH and the
mixture was aliquoted into wells (300 µl/well) and left to polymerise in an incubator at
37 0C with 5 % CO2. After the gels had polymerised, media were added to each well and
incubated for 4 h in the incubator. After that, the media were replaced by serum free
media for overnight. The gels were detached from the sided of the wells with a scalpel
and treated with TGF-β1 or left untreated for 48 h. The images were taken and the gel
contraction was determined by measuring the surface area of the gels with Image J
software. (A) a representative of gels containing transfected NOF after 48 h of TGF-β1
treatment. (B) the quantified of gels contraction, as a mean of surface area (mm2) ± SEM
from three independent experiments, compared to untreated miRNA negative control.
Statistical analysis was determined using two-tailed Student T-test with ****p < 0.0001.
The significance is compared to the untreated equivalent transfection, or anti-miR
negative control, in the case of untreated anti-miRs. No significant difference between
anti-miR negative control compared to anti-miRs in TGF-β1-treated NOF.
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Figure 4.15: Overexpression of miR-424-3p did not inhibit TGF-β1 induced α-SMA
expression in CAF
CAF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. The transfected CAF were serum starved overnight before being treated with or
without TGF-β1 for 48 h. Following treatment, CAF were harvested and subjected to
RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was done using
primers designed to amplify α-SMA. B2M was used as a reference gene. Each data
represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated pre-miR negative control. Statistical analysis
was determined using two-tailed Student T-test with *p <0.05. The significance is
compared to the untreated equivalent transfection, or pre-miR negative control, in the
case of untreated pre-miR. No significant difference between pre-miR negative control
compared to pre-miR-424-3p in TGF-β1-treated CAF.
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Figure 4.16: Overexpression of miR-424-3p did not inhibit TGF-β1 induced FN-
EDA1 expression in CAF
CAF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. The transfected CAF were serum starved overnight before being treated with or
without TGF-β1 for 48 h. Following treatment, CAF were harvested and subjected to
RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was done using
primers designed to amplify FN-EDA1. B2M was used as a reference gene. Each data
represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated pre-miR negative control. Statistical analysis
was determined using two-tailed Student T-test with *p <0.05. The significance is
compared to the untreated equivalent transfection, or pre-miR negative control, in the
case of untreated pre-miR. No significant difference between pre-miR negative control
compared to pre-miR-424-3p in TGF-β1-treated CAF.
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significantly increased COL1A1 transcript levels in mock (3.4±0.7-fold), pre-miR
negative control (3.4±1.6-fold) and pre-miR-424-3p (2.9±1.1-fold). Overexpression of
miR-424-3p caused a small decrease (not significant) in TGF-β1-induced COL1A1 gene
expression (Figure 4.17).
4.2.11.2 Overexpression of miR-424-3p did not alter TGF-β1-induced α-SMA
protein level in CAF
The effect of over-expressing miR-424-3p on α-SMA expression was also
investigated at the protein level by measuring α-SMA abundance. CAF were transiently
transfected with pre-miR negative control or pre-miR-424-3p for 48 h. Following
incubation, they were serum starved overnight and treated with TGF-β1 or left untreated.
CAF were harvested and subjected to protein extraction. The total protein lysates were
used for western blotting. As shown in Figure 4.18, overexpression of miR-424-3p did
not inhibit basal abundance of α-SMA at protein level in CAF. TGF-β1 slightly increased
α-SMA protein level in all conditions, however, this not significant (p<0.05).
Upregulation of miR-424-3p did not alter TGF-β1-induced α-SMA protein abundance,
compared to treated pre-miR negative control.
4.2.11.3 Overexpression of miR-424-3p did not prevent the formation of TGF-
β1-induced α-SMA positive stress fibres formation in CAF
To assess the effect of miR-424-3p overexpression on stress fibres formation,
CAF were transiently transfected with a pre-miR negative control or pre-miR-424-3p for
48 h. TGF-β1 was added for 48 h and α-SMA immunocytochemistry was done to assess
the formation of stress fibre in CAF. As shown in Figure 4.19 (A), overexpression of
miR-424-3p did not inhibit basal formation of stress fibre in CAF. TGF-β1 promotes the
formation of stress fibres, as seen by intense staining of the cytoskeleton in all
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Figure 4.17: Overexpression of miR-424-3p did not inhibit TGF-β1 induced
COL1A1 expression in CAF
CAF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. The transfected CAF were serum starved overnight before being treated with or
without TGF-β1 for 48 h. Following treatment, CAF were harvested and subjected to
RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was done using
primers designed to amplify COL1A1. B2M was used as a reference gene. Each data
represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated pre-miR negative control. Statistical analysis
was determined using two-tailed Student T-test with *p < 0.05. The significance is
compared to the untreated equivalent transfection, or pre-miR negative control, in the
case of untreated pre-miR. No significant difference between pre-miR negative control
compared to pre-miR-424-3p in TGF-β1-treated CAF.
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Figure 4.18: Overexpression of miR 424-3p did not alter TGF-β1 response of α-
SMA protein abundance in CAF
CAF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. Then, CAF were serum starved overnight and treated with or without TGF-β1 for
48 h. CAF were harvested and used for protein extraction. Total protein lysates were
used for immunoblotting using antibodies from mouse α-SMA and β-actin as a loading
control. (A) a representative of protein bands for immunoblot from three independent
repeats, (B) the quantified amount of protein in each sample using Image J software.
Each data represents the mean ± SEM from three independent experiments. The
significance is compared to the untreated equivalent transfection, or pre-miR negative
control, in the case of untreated pre-miR, none of these are significant, however. No
significant difference between pre-miR negative control compared to pre-miR-424-3p in
TGF-β1-treated CAF.
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Figure 4.19: Overexpression of miR-424-3p did not prevents the formation of TGF-
β1-induced α-SMA positive stress fibres formation in CAF
CAF were seeded onto coverslips overnight and transiently transfected with pre-miR
negative control or pre-miR-424-3p for 48 h. Following that, CAF were serum starved
overnight and treated with or without TGF-β1 for 48 h. The coverslips were washed with
DPBS prior to fixation with 100 % methanol for 20 min. Then, they were permeabilised
in 4 mM sodium deoxycholate for 10 min before being blocked with 2.5 % (w/v) BSA in
DPBS for 30 min. The coverslips were incubated with a primary FITC-conjugated α-
SMA antibody overnight at 4 0C. Following incubation, they were washed with DPBS
and were mounted with Dapi. The coverslips were viewed under a fluorescence
microscope using Pro-Plus 7.0 imaging software at 100x magnification (using oil
immersion). (A) Representative images of stress fibre from three independent repeats. (B)
The mean fluorescence intensity per cell ± SEM from three independent experiments was
quantified using Image J software. Statistical analysis was determined using two-tailed
Student T-test with *p < 0.05. If not shown by a bar, the significance is compared to the
untreated equivalent transfection, or pre-miR negative control, in the case of untreated
pre-miR.
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conditions, whether transfected with pre-miRs or not. Transfection with pre-miR-424-3p
did not significantly alter the response to TGF-β1 compared to either mock or pre-miR
negative control. Overexpression of miR-424-3p attenuates TGF-β1–induced α-SMA
positive stress fibre formation, however this did not reach significance (Figure 4.19 (B)).
4.2.11.4 Overexpression of miR-424-3p did not alter TGF-β1 response on gel
contraction in CAF
To investigate the role of miR-424-3p in regulating TGF-β1-induced gel
contraction, CAF were transiently transfected with a pre-miR negative control or a pre-
miR-424-3p for 48 h. Transfected CAF were resuspended in a mixture of rat tail collagen
1 with DMEM (1:1). The mixture was allowed to polymerise, then treated with TGF-β1
or left untreated for 48 h. Overexpression of miR-424-3p did not inhibit basal gel
contraction in CAF. TGF-β1 promotes gel contraction in CAF transfected with mock
(312±26 mm2), pre-miR negative control (313±62 mm2) and pre-miR 424-3p (316±53
mm2) (Figure 4.20). miR-424-3p overexpression had no effect on TGF-β1-induced gel
contraction, compared to treated pre-miR negative control.
4.2.11.5 Knockdown of miR-145-5p or miR-424-3p did not alter TGF-β1-
induced myofibroblast markers in CAF
An attempt to knockdown the miR-424-3p or miR-145-5p expression was next
carried out. CAF were transiently transfected with a miR-424-3p inhibitor or a miR-145-
5p inhibitor. A non-targeting inhibitor was used as a negative control and a mock
transfection (transfection reagent only) was also included in this experiment. TGF-β1
was added to the culture after 48 h post-transfection. Transfected CAF were harvested for
RNA extraction, protein extraction, and immunocytochemistry. Inhibition of miR-424-3p
or miR-145-5p did not increase a basal expression of α-SMA and FN-EDA1 at
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Figure 4.20: Overexpression of miR-424-3p had no effect on TGF-β1-induced gel
contraction in CAF
CAF were transiently transfected with pre-miR negative control or pre-miR-424-3p for
48 h. Following incubation, CAF were harvested, counted (2.5 x 105 cells/well) and
resuspended in a mixture of rat tail collagen 1 (in 0.1 M acetic acid) and DMEM (1:1).
The pH was neutralised with 1M of NaOH and the mixture was aliquoted into wells (300
µl/well) and left to polymerise in an incubator at 37 0C with 5 % CO2. After the gels had
polymerised, media were added to each well and incubated for 4 h in the incubator. After
that, the media were replaced by serum-free media for overnight. The gels were detached
from the sided of the wells with a scalpel and treated with or without TGF-β1 for 48 h.
The images were taken at 48 h and the gel contraction was determined by measuring the
surface area of the gels with Image J software. (A) a representative of gels containing
transfected CAF after 48 h of TGF-β1 treatment. (B) the quantified of gels contraction,
as a surface area (mm2) compared to untreated pre-miR negative control. Each data
represents the mean ± SEM from three independent experiments. Statistical analysis was
determined using two-tailed Student T-test with ****p <0.0001, as the significance is
compared to the untreated equivalent transfection, or pre-miR negative control, in the
case of untreated pre-miR. No significant difference between pre-miR negative control
compared to pre-miR-424-3p in TGF-β1-treated CAF.
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transcripts level in CAF. TGF-β1 treatment significantly increased α-SMA transcript
levels in all conditions; mock (73.7±33.6-fold), negative control inhibitor (93.6±33.6-
fold), anti-miR-145-5p (81.0±50.5-fold) and anti-miR-424-3p (62.4±33.3-fold) (Figure
4.21). Conversely, TGF-β1 treatment did not significantly increase FN-EDA1 transcripts
levels in all conditions (Figure 4.22).
Inhibition of miR-424-3p or miR-145-5p did not increase a basal expression of
COL1A1 at mRNA level. Meanwhile, treatment of TGF-β1 significantly resulted in
increase of COL1A1 transcripts level in mock (3.6±1.4-fold) and anti-miR-424-3p
(3.3±1.2-fold) (Figure 4.23). Knockdown of miR-424-3p did not result in increase of
TGF-β1-induced myofibroblast differentiation markers, compared to treated negative
control inhibitor. On the other hand, inhibition of miR-145-3p caused a small increase
(but not significant) in TGF-β1-induced COL1A1 gene expression, compared to treated
negative control inhibitor.
4.2.11.6 Knockdown of miR-424-3p or miR-145-5p did not alter TGF-β1-
induced α-SMA protein level in CAF
Lastly, inhibition of miR-424-3p or miR-145-5p did not increase a basal
abundance of α-SMA at protein level in CAF. TGF-β1 caused a small increase (not
significant) in α-SMA at the protein level in mock (0.9±0.3-fold), anti-miR negative
control (1.5±0.7-fold), anti-miR-145-5p inhibitor (1.2±0.4-fold) and anti-miR-424-3p
(1±0.2-fold) (Figure 4.24). Knockdown of miR-424-3p or miR-145-5p did not alter TGF-
β1-induced α-SMA at protein level, compared to treated negative control inhibitor.
4.2.11.7 Knockdown of miR-424-3p, not miR-145-5p, alter TGF-β1 response
of positive stress fibres formation in CAF
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Figure 4.21: Inhibition of miR-424-3p or miR-145-5p did not alter TGF-β1-induced
α-SMA expression in CAF
CAF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR 145-5p for 48 h. The transfected CAF were serum starved overnight before being
treated with or without TGF-β1 for 48 h. Following treatment, CAF were harvested and
subjected to RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was
done using primers designed to amplify αSMA. B2M was used as a reference gene. Each
data represents the mean relative quantification of myofibroblast differentiation markers
relative to B2M ± SEM from three independent experiments, for each transfection with
or without TGF-β1 compared to untreated negative control inhibitor. Statistical analysis
was determined using two-tailed Student T-test with *p <0.05, as the significance is
compared to the untreated equivalent transfection, or anti-miR negative control, in the
case of untreated anti-miRs. No significant difference between anti-miR negative control
compared to anti-miRs in TGF-β1-treated CAF.
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Figure 4.22: Inhibition of miR-424-3p or miR-145-5p did not alter TGF-β1-induced
FN-EDA1 expression in CAF
CAF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR 145-5p for 48 h. The transfected CAF were serum starved overnight before being
treated with or without TGF-β1 for 48 h. Following treatment, CAF were harvested and
subjected to RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was
done using primers designed to amplify FN-EDA1. B2M was used as a reference gene.
Each data represents the mean relative quantification of myofibroblast differentiation
markers relative to B2M ± SEM from three independent experiments, for each
transfection with or without TGF-β1 compared to untreated negative control inhibitor.
Statistical analysis was determined using two-tailed Student T-test, as the significance is
compared to the untreated equivalent transfection, or anti-miR negative control, in the
case of untreated anti-miRs, none of these are significant, however. No significant
difference between anti-miR negative control compared to anti-miRs in TGF-β1-treated
CAF.
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Figure 4.23: Inhibition of miR-424-3p had no effect on TGF-β1-induced COL1A1
expression while knockdown of miR-145-5p did not increases TGF-β1-induced
COL1A1 expression in CAF
CAF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR 145-5p for 48 h. The transfected CAF were serum starved overnight before being
treated with or without TGF-β1 for 48 h. Following treatment, CAF were harvested and
subjected to RNA extraction and used for cDNA synthesis. The qRT-PCR analysis was
done using primers designed to amplify COL1A1. B2M was used as a reference gene.
Each data represents the mean relative quantification of myofibroblast differentiation
markers relative to B2M ± SEM from three independent experiments, for each
transfection with or without TGF-β1 compared to untreated negative control inhibitor.
Statistical analysis was determined using two-tailed Student T-test with *p < 0.05, as the
significance is compared to the untreated equivalent transfection, or anti-miR negative
control, in the case of untreated anti-miRs. No significant difference between anti-miR
negative control compared to anti-miRs in TGF-β1-treated CAF.
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Figure 4.24: Inhibition of miR 424-3p or miR-145-5p did not alter TGF-β1-induced
α-SMA protein abundance in CAF
CAF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR-145-5p inhibitor for 48 h. Then, CAF were serum starved overnight and treated
with or without TGF-β1 for 48 h. CAF were harvested and used for protein extraction.
Total protein lysates were used for immunoblotting using antibodies from mouse α-SMA
and β-actin as a loading control. (A) a representative of protein bands for immunoblot
from three independent repeats, (B) the quantified amount of protein in each sample
using Image J software. Each data represents the mean ± SEM from three independent
experiments. No significant difference between untreated equivalent transfection or anti-
miR negative control, in the case of untreated anti-miRs or anti-miR negative control
compared to anti-miRs in TGF-β1-treated CAF.
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Immunocytochemistry revealed that inhibition of miR-424-3p or miR-145-5p did
not increase basal formation of α-SMA positive stress fibre in CAF. TGF-β1 provokes α-
SMA positive stress fibre formation in CAF, as seen by the striking increase in
cytoskeletal fluorescent staining evident in all conditions following TGF-β1 treatment;
mock (35.4±6.7-fold), anti-miR negative control (23.7±3.1-fold), anti-miR-145-5p
(22.0±4.1-fold) and anti-miR-424-3p (12.0±0.8-fold) (Figure 4.25 (A)). In this study, the
formation of α-SMA positive stress fibres was greater in CAF compared to that in NOF
in response to TGF-β1. This is consistent with a previous study (Yang et al., 2014) which
showed that CAF (from gastric cancer tissue) expressed a high level of α-SMA positive
stress fibre, compared to NOF (from normal gastric mucosa). Inhibition of miR-424-3p,
not miR-145-5p alter TGF-β1-induced α-SMA positive stress fibre formation, compared
to treated negative control inhibitor (Figure 4.25 (B)).
4.2.11.8 Knockdown of miR-424-3p decreases TGF-β1-induced gel contraction;
while miR-145-5p increases TGF-β1-induced gel contraction in CAF
As shown in Figure 4.26, Inhibition of miR-424-3p or miR-145-5p did not alter
basal gel contraction in CAF. TGF-β1 significantly increased gel contraction in CAF
transfected with; mock (312±26 mm2; p<0.0001), negative control inhibitor (337±44
mm2; p<0.0001), miR-424-3p inhibitor (388±51 mm2; not significant) and miR-145-5p
inhibitor (304±40 mm2; p<0.0001). Inhibition of miR-424-3p decreases TGF-β1 effects
on gel contraction, compared to treated negative control inhibitor while inhibition of
miR-145-5p increases TGF-β1-induced gel contraction, compared to treated negative
control.
4.3 Discussion
While many studies focused on the important role of CAF in promoting tumour
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Figure 4.25: Inhibition of miR-424-3p, not miR-145-5p decreases TGF-β1-induced
α-SMA positive stress fibres formation in CAF
CAF were seeded onto coverslips overnight and transiently transfected with negative
control inhibitor or miR-424-3p inhibitor or miR-145-5p inhibitor for 48 h. Following
that, CAF were serum starved overnight and treated with TGF-β1 for 48 h. The
coverslips were washed with DPBS prior to fixation with 100 % methanol for 20 min.
Then, they were permeabilised in 4 mM sodium deoxycholate for 10 min before being
blocked with 2.5 % (w/v) BSA in DPBS for 30 min. The coverslips were incubated with
a primary FITC-conjugated α-SMA antibody overnight at 4 0C. Following incubation,
they were washed with DPBS and were mounted with Dapi. The coverslips were viewed
under a fluorescence microscope using Pro-Plus 7.0 imaging software at 100x
magnification (using oil immersion). (A) Representative images of stress fibre from three
repeats. (B) The mean fluorescence intensity per cell ± SEM from three independent
experiments was quantified using Image J software. Statistical analysis was determined
using two-tailed Student T-test with *p <0.05. If not shown by a bar, the significance is
compared to the untreated equivalent transfection, or anti-miR negative control, in the
case of untreated anti-miRs. No significant difference between anti-miR negative control
compared to anti-miR-145-5p in TGF-β1-treated CAF.
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Figure 4.26: Inhibition of miR-424-3p decreases TGF-β1-induced gel contraction;
while miR-145-5p increases TGF-β1-induced gel contraction in CAF
CAF were transiently transfected with negative control inhibitor or miR-424-3p inhibitor
or miR-145-5p inhibitor for 48 h. Following incubation, the CAF were harvested,
counted (2.5 x 105 cells/well) and resuspended in a mixture of rat tail collagen 1 (in 0.1
M acetic acid) and DMEM (1:1). The pH was neutralised with 1M of NaOH and the
mixture was aliquoted into wells (300 µl/well) and left to polymerise in an incubator at
37 0C with 5 % CO2. After the gels had polymerised, media were added to each well and
incubated for 4 h in the incubator. After that, the media were replaced by serum-free
media for overnight. The gels were detached from the sided of the wells with a scalpel
and treated with or without TGF-β1 for 48 h. The images were taken at 48 h and the gel
contraction was determined by measuring the surface area of the gels with Image J
software. (A) a representative of gels containing transfected CAF after 48 h of TGF-β1
treatment. (B) the quantified of gels contraction, as a mean of surface area (mm2) ± SEM
from three independent experiments, compared to untreated miRNA negative control.
Statistical analysis was determined using two-tailed Student T-test with *p <0.05, **p<
0.005, ****p <0.0001. If not shown by a bar, the significance is compared to the
untreated equivalent transfection, or anti-miR negative control, in the case of untreated
anti-miRs.
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progression, little is known about the role of miRNAs in CAF. As stated in Section
1.10.3, deregulation of miRNAs was observed in CAF from various type of cancer
including ovarian cancer (Mitra et al., 2012; Tang et al., 2016) and breast cancer (Zhao
et al., 2012). Little is known, however, of the role of miRNA in determining CAF
phenotype in oral cancer.
miRNA expression profiling by TLDA here provides evidence that miR-424-5p
and miR-145-5p were highly upregulated in two TGF-β1-treated primary oral fibroblasts
isolated from healthy subjects, NOF1 and NOF5. Validation by qRT-PCR further
supported these findings. Validation of miR-424-3p was done in NOF804, however, the
expression of miR-424-3p could not be validated in NOF1 and NOF5. Similar to NOF1
(as mentioned in Chapter 3), NOF5 became slow growing and died. As a result, a newly
derived NOF culture, NOF804, was mostly used for the experiments functionally
interrogating the role of candidate miRNA throughout this study. The TLDA data
showed that miR-424-3p, but not miR-424-5p, is highly upregulated in NOF804 upon
TGF-β1 treatment. Validation by qRT-PCR confirmed this finding, although the fold
change was lower than that identified by TLDA. However, it still follows the miRNA
expression pattern detected in the TLDA. The difference in the fold change between the
qPCR and the TLDA screen might reflect the fact that the TLDA screen was carried on
one sample, whereas the qPCR validation was carried out in three biological repeats.
From the TLDA data, miR-145-5p was found to be downregulated in NOF804 cells,
contradicting the findings in the other two NOF cultures (NOF1 and NOF5). This result
perhaps indicates the heterogeneity of miRNA expression in NOF cultures derived from
slightly different areas in the mouth, or might result from patient-to-patient variability.
Given the that miR-145-5p was found to be upregulated by TGF-β1 treatment in two of
three cultures, however, and has been reported in other tissues to be involved in
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myofibroblast differentiation, this was selected for further functional analyses alongside
miR-424-3p.
Two widely employed approaches to study endogenous miRNA function; the
introduction to cells of miRNA mimics (gain-of-function) and miRNA inhibitors (loss-
of-function) were used in this study. miRNA mimics are chemically modified double-
stranded RNA molecules that are processed by cells’ endogenous machinery to produce
mature miRNAs able to post-transcriptionally repress target genes. Conversely, miRNA
inhibitors are chemically modified single-stranded RNA molecules that complementary
bind to specific miRNAs (no RISC-like complex association), abrogating their ability to
bind to target genes and regulate their expression.
Increasing evidence has recently accumulated about a role for miR-424 in cancers.
miR-424-5p expression was decreased in liver cancer tissue compared to normal liver
tissue and this downregulation was associated with advanced disease progression in liver
cancer patients (Zhang et al., 2014). Conversely, Wu and co-workers (2013)
demonstrated that miR-424-5p was significantly upregulated in pancreatic cancer.
Despite these findings, little is known about the involvement of miR-424 in the tumour
microenvironment. Only one study, published in the course of this project, reported that
miR-424 potentiates TGF-β-induced myofibroblast differentiation through EMT in
human lung epithelial cells (Xiao et al., 2015). Inspection of online databases employing
target prediction algorithms, such as TargetScan (http://www.targetscan.org/vert_71/),
identified multiple predicted targets of miR-424 in TGF-β signalling. Some of these
predicted targets have been verified in the previous studies, including Smurf2 (Xiao et al.,
2015) and Smad7 (Wang et al., 2016). miR-145 has been demonstrated to negatively
regulate TGF-β signalling through Smad3 and TGF-βR2 (Megiorni et al., 2013; Yang et
al., 2013). TGF-β1 has been reported to induce miR-143/5 expression, suggesting that
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miR-145 could be part of TGF-β pathway (Long and Miano, 2011). miR-145 has been
reported in specialised differentiation e.g the gut epithelial and smooth muscle cell
maturation (Zeng, Carter, & Childs, 2009). Yang et al., (2011) demonstrated that the loss
of miR-145 in chondrocyte differentiation, as it directly targets Sox-9, a critical
transcription factor in chondrogenesis.
The present study analysed the functional relevance of miR-424-3p or miR-145-
5p in TGF-β1-induced eCAF and tumour-derived CAF, with aim of determining whether
these miRNAs contribute to the development of the myofibroblast eCAF phenotype
decribed in Chapter 3, and by extension the in vivo CAF phenotype. To determine the
involvement of these miRNA in reprogramming normal fibroblast into eCAF, NOF and
CAF were transfected with miRNA mimic or miRNA inhibitors prior to TGF-β1
treatment. Experiments were then carried out to assess the impact of this on the
myofibroblastic phenotypes of eCAF and tumour-derived CAF.
α-SMA is a well-established molecular marker for myofibroblast differentiation.
Therefore, α-SMA regulation has been widely studied, particularly at the transcriptional
level (Hinz et al., 2012). As anticipated, TGF-β1 increased α-SMA expression at both
mRNA and protein level in mock transfected NOF. This upregulation was significantly
decreased by pretreatment with pre-miR-424-3p at mRNA level. However,
overexpression of miR-424-3p did not alter TGF-β1-induced α-SMA protein abundance
in NOF; the reasons for this are unclear but perhaps relate to the time-course of this
experiment, or perhaps the existence of a compensatory mechanism.
Myofibroblast differentiation requires the combined action of α-SMA, TGF-β1
and FN-EDA1 (Tomasek et al., 2002; Gabbiani, 2003; Hinz et al., 2007). The early study
demonstrated that FN-EDA1 is crucial for the TGF-β1-induced myofibroblastic
phenotype (Serini et al., 1998). As shown in Section 3.2.2, the increase in FN-EDA1 in
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response to TGF-β1 in mock transfected cells is of a similar magnitude as in
untransfected NOF, suggesting the transfection procedure did not affect the cell’s ability
to respond to TGF-β1. Similar to α-SMA, miR-424-3p overexpression significantly
attenuates TGF-β1-induced FN-EDA1 transcript levels in NOF. On the other hand,
treatment with TGF-β1 did not significantly increase COL1A1 transcript levels in NOF.
Moreover, overexpression of miR-424-3p did not inhibit COL1A1 expression in NOF.
The data above suggest that miR-424-3p has the ability to modulate α-SMA and
FN-EDA1 expression but not COL1A1. Some studies have identified regulators of α-
SMA transcription. Smad3, a major Smad mediator associated with TGF-β signaling,
induces α-SMA expression by directly binding to two CAGA motifs of Smad3-binding
elements (SBEs), in the promoter of of the α-SMA gene (Hu et al., 2003). Fibronectin
binds to a large number of growth factors such as TGF-β (Klingberg et al., 2013), VEGF
(Wijelath et al., 2006), HGF (Rahman et al., 2005), and PDGF (Smith et al., 2009); all of
these may contribute to myofibroblast phenotype. Although FN-EDA1 is associated with
myofibroblast differentiation, the mechanisms underlying this are poorly understood.
Kohan et al., (2010) demonstrated that increased FN-EDA1 is sufficient to promote
fibroblast differentiation by binding to α4β7 integrin receptor, followed by activation of
MAPK/Erk1/2-dependent signalling. In vivo (a rat excisional model of wound repair) and
in vitro (TGFβ1-treated rat fibroblast) studies demonstrated that FN-EDA deposition
occurs before α-SMA expression (Serini et al., 1998). These findings suggest that FN-
EDA deposition occurs through FN-EDA-cell surface receptor interactions that could
transmit signals initiated by TGF-β1 and/or synergise with them and act as mediator for
the induction of myofibroblast phenotype along with α-SMA expression. Collagen type 1,
the native component of ECM, is encoded by two genes; COL1A1 and COL1A2
(Karsenty et al., 1991). The synthesis of these two collagens is controlled by TGF-β1
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signalling pathway and Smad signalling pathway (Cutroneo et al., 2007). TGF-β1
regulates COL1A1 expression by binding directly to TGF-β cis-element located between
-174 and -84 bp from the transcription start site (Jimenez et al., 1994). Taken together,
these three genes are regulated by different pathways, therefore, miR-424-3p might target
a component of one pathway, but not the other. Furthermore, computational prediction
using TargetScan revealed that miR-424-3p is not predicted to directly target α-SMA,
FN-EDA1 and COL1A1, suggesting that the regulation of these genes by miR-424-3p
may occur via modulation of upstream TGF-β signalling. As seen with untransfected
NOF in Chapter 3 (Section 3.2.4), NOF transfected with control, non-targeting
oligonucleotides displayed intense cytoskeleton staining associated with elevated α-SMA
expression after TGF-β1 treatment, suggesting that the transfection procedure does not
alter the cells’ ability to respond to TGF-β1. However, the α-SMA positive stress fibres
formation was not significantly reduced when NOF were transfected with pre-miR-424-
3p and subsequently exposed to TGF-β1.
α-SMA is important in the generation of contractile force in myofibroblasts
(Cutroneo et al., 2007). Moreover, α-SMA positive myofibroblast contracts more
compared to α-SMA negative myofibroblast, as demonstrated using stress-released
collagen gels (Hinz et al., 2001). How α-SMA regulates the contractility of
myofibroblasts remains unclear. However, it was proposed that α-SMA was incorporated
into actin stress fibres, thereby increased in contractility of myofibroblasts (Hinz et al.,
2001). In this study, TGF-β1 significantly increased gel contraction in mock transfected,
control transfected and pre-miR-424-3p transfected NOF. Overexpression of miR-424-3p,
however, significantly reduced (p<0.005) TGF-β1-induced gel contraction, in keeping
with the finding that it is able to suppress α-SMA induction.
Collectively, these data demonstrated that miR-424-3p inhibits CAF-like
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myofibroblastic phenotype, possibly through a negative feedback loop with TGF-β1. In
silico pathway analysis indicates that miR-424-3p may target genes related to cell cycle
including Cyclin D, CDK2, and CDK6, suggesting that miR-424-3p may play a role in
modulating myofibroblast phenotype thtrough a negative feedback loop with TGF-β1.
TGF-β induces reorganisation of actin cytoskeleton (a feature of myofibroblast
phenotype) through activation of non-Smad pathway, a Rho GTPase signalling (Carthy,
2017). TGF-β induced Rho GTPase in human gingival fibroblasts (Smith et al., 2006),
human lung fibroblasts (Watts et al., 2006) and mouse Swiss3T3 fibroblasts (Vardouli et
al., 2005), with most studies focused on RhoA (Johnson et al., 2014; Manickam et al.,
2014). The molecular mechanisms underlying TGF-β-induced Rho activation are poorly
understood. RhoA/p160ROCK pathway involves in the formation of stress fibre and
induction of EMT (Bhowmick et al., 2003) and myofibroblast differentiation (Smith et
al., 2006). However, how TGF-β regulates G1 of cell cycle phase through
RhoA/p160ROCK pathway in fibroblasts remains elusive. Bhowmick et al., (2003)
demonstrated that RhoA and its effector kinase, p160ROCK directly bind and further,
prevent the activity of CDC25A to promote cell cycle arrest in TGF-β-treated epithelial
cells, but not fibroblasts. Additionally, they demonstrated that TGF-β induces
p160ROCK of nuclear translocation in NMuMG epithelial cells and this relocalisation
elevates level of phosphorylated CDC25A and inhibits CDC25A phosphatase activity.
Interestingly, some miR-16 family including miR-424 targets CDC25A, probably due to
its own growth inhibitory effects (Rissland et al., 2011). CDC25A activates CDKs,
particularly CDK2 (predicted target gene of miR-424-3p) by dephosphorylating
threonine and tyrosine phosphor residues on CDK2 (Gu et al., 1992). On the other hand,
RhoA can regulate Cyclin D (miR-424-3p target gene), a positive regulator of G1 cell
cycle phase (Sherr and Roberts, 1999). Cyclin D1 transcripts level is increased in lung
fibroblast-derived from idiophatic pulmonary fibrosis, compared to normal lung
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fibroblast cell (Watts et al., 2006). Interestingly, TGF-β1 further augments Cyclin D1
expression at mRNA and protein level, suggesting that TGF-β1 can mediate Cyclin D
expression in fibroblasts. Additionally, inhibition of RhoA using both dominant negative
RhoA transfection and simvastat (a pharmacological inhibitor) decreases Cyclin D1
expression in lung fibroblasts. Cyclin D associates with CDK4/6 to promote G1 phase.
However, the phosphorylation of this complex can be inhibited by regulation of CDK
inhibitors including p15, one of INK4 family members (Sherr and Roberts, 1999).
Collectively, these findings contribute to a diverse dimension of TGF-β signalling
complexity and subsequent cell cycle arrest. In this study, overexpression of miR-424-3p
prevents TGF-β1-induced contraction in NOF and this might reflect a role of miR-424-
3p in CAF-like myofibroblast differentiation by regulating one or more pathways related
to cell cycle. The proposed signalling pathways (mentioned above) indicating how miR-
424-3p may regulates, at least in part, of TGF-β1-induced CAF-like myofibroblastic
phenotype (e.g actin cytoskeleton reorganisation) related to cell cycle regulation were
illustrated in Figure 4.27.
Members of TGF-β superfamily are implicated in many cellular processes such as
differentiation, apoptosis and proliferation (Siegel and Massague, 2003). In normal
epithelial cells, TGF-β1 acts as a potent growth inhibitor, however, it has also mitogenic
activity in some fibroblasts-derived cell line including NIH 3T3 (Koskinen et al., 1991).
The anti-proliferative effect of TGF-β involves certain regulators of G1 phase of cell
cycle, whose gene expression is mediated by Smad signalling (Massague, 2004). In
canonical Smad signalling, the binding of TGF-β receptors by TGF-β superfamily
phosphorylates Smad2 and Smad3. Once phosphorylated, Smad2/3 bind to Smad4 (a co-
mediator Smad) and in the nucleus, the heteromeric complex together with FoxO, p53
and Sp1 to induce a cell cycle inhibitor, p21 (Pardali et al., 2000; Cordenonsi et al., 2003;
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Seoane et al., 2004). p21 directly binds to active Cyclin D-CDK6 and Cyclin E-CDK2
complexes and inhibits their kinase activity, thereby caused cell cycle arrest (Geng and
Weinberg, 1993; Koff et al., 1993). Taken together, this study suggested that miR-424-
3p negatively regulating the pro-tumourigenic properties of stromal fibroblasts by two
distinct but interrelated signalling pathways; regulation of Smad activation at the first
place, and subsequent regulation of cell cycle by Smads. However, further experimental
data are needed to test this hypothesis, particularly testing the effect of miR-424-3p
modulation on proliferation.
Given that TGF-β1 upregulates miR-424-3p and miR-145-5p in NOF, an attempt
to inhibit miR-424-3p expression or miR-145-5p expression was carried out in NOF. As
seen with untransfected NOF in Section 3.2.1 and 3.2.2, mock transfected NOF displayed
increased α-SMA, FN-EDA1 and COL1A1 transcript levels when treated with TGF-β1.
In addition, TGF-β1 also promoted other expected phenotypic and morphological
changes (stress fibre formation, gel contraction and α-SMA protein expression) in mock
and control oligonucleotide transfected cells, as expected. However, inhibition of miR-
424-3p did not further increase these effects when NOF were exposed to TGF-β1 and
miR-424-3p inhibitor in combination for 48 h. Similar results were observed when NOF
were exposed to miR-145-5p inhibitor and TGF-β1 in combination. Given that the data
previously described indicates that fibroblasts express both of these miRNA, and that
overexpression of miR-424-3p suppressed features of myofibroblast differentiation, it
was expected that inhibition of this miRNA might increase expression of myofibroblast
markers in response to TGF-β1. There are possible reasons that may explain why this
result was not obtained. Given that one miRNA regulates many mRNAs and many
miRNAs can regulate one mRNA (Zhang et al., 2014), the synergistic action of multiple
miRNAs may be important for the regulation of target gene. Perhaps, several miRNAs
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Figure 4.27: miR-424-3p targets genes related to G1 of cell cycle phase
The Kyoto Encyclopedia of genes and genomes (KEGG) pathway analysis of miR-424-
3p target genes predicted by miRPath v3.0. miR-424-3p targets genes related to cell
cycle; Cyclin D, CDK2, and CDK6. The highlighted red boxes indicate miR-424-3p
target genes in G1 of cell cycle phase.
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have mild suppressive activities on several different genes, which when combined have
an effect on cell phenotype, and therefore just modulating the endogenous expression
level of one miRNA in a loss of function assay doesn’t have a measurable effect. It is
also possible that the response of the fibroblasts to TGF-β1 is maximal under the
conditions used, and while it may be inhibited by overexpression of miR-424-3p,
inhibition of endogenous activity of this miRNA is unable to further potentiate responses
to TGF-β1. A further possibility is that the miRNA inhibitors are not functioning in the
conditions used. This was difficult to assess as the inhibitors purchased from Exiqon do
not degrade their target miRNAs but sequester them in the form of stable complexes with
their target, and may therefore not influence cellular levels of the miRNA, precluding the
use of qPCR to interrogate miRNA in inhibitor-transfected cells. Additionally, qPCR
does not distinguish between functional miRNAs with non-functional miRNAs
(Thomson et al., 2013). Perhaps, another reason is inefficient transfection causing an
accumulation of oligonucleotides inside vesicles. As a result, the inhibitors and their
target are present in different subcellular compartments. This could be experimentally
tested, if given sufficient time, with fluorescently labelled anti-miRs and observing the
transfected cells under fluorescence microscope.
In this study, the effect of modulating miR-424-3p and miR-145-5p on
myofibroblast phenotype in CAF was also investigated. In gain-of-function experiments,
TGF-β1 increases α-SMA transcript levels and protein levels, α-SMA positive stress
fibre formation and gel contraction in all conditions of transfected CAF including mock.
Overexpression of miR-424-3p had no effects in reversing these myofibroblast
phenotype in CAF. Given these mixed findings, an attempt to inhibit miR-424-3p
expression or miR-145-5p expression in CAF was carried out.
Similar to NOF, TGF-β1 marked increases in myofibroblast differentiation
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markers (α-SMA, FN-EDA1 and COL1A1) at mRNA level, α-SMA positive stress fibre
formation, gel contraction and α-SMA protein level in all conditions of transfected CAF
including mock. However, knockdown of miR-424-3p decreased α-SMA positive stress
fibre formation and contractility when CAF were exposed to miR-424-3p inhibitor and
TGF-β1 in combination. Inhibition of miR-145 significantly increases TGF-β1-induced
gel contraction in CAF. There are possible reasons that contributed to these insignificant
findings. First, CAF may express the high endogenous level of miR-424-3p or miR-145-
5p, thus the effect of both miRNA inhibitors on myofibroblast phenotype may not be
detectable in CAF. Second, inefficient transfection of miRNA inhibitors might have
resulted in a small population of cells being transfected and produced the insignificant
effects. The effects of pre-miR and anti-miRs on TGF-β1-induced CAF-like
myofibroblast in NOF or CAF phenotypes in tumour-derived CAF were summarised in
Table 4.1 and Table 4.2.
4.4 Summary
Increasing evidence show that miRNAs are involved in the conversion of
fibroblasts into CAF. In this chapter, miRNA expression profile (further validated by
qPCR) revealed that miR-424-5p and miR-145-5p were upregulated in TGF-β1 induced
myofibroblast differentiation in NOF1 and NOF5. As these two cells died, miRNA
profiling was done in new patient-derived NOF, NOF804. From miRNA expression
profile, miR-424-3p was upregulated in TGF-β1-treated NOF804. The validation data
confirmed this finding. Further, miRNA mimic or miRNA inhibitors were used to
examine the role of miR-424-3p in regulating TGF-β1-induced CAF-like myofibroblasts
differentiation. The gain-of-function experiments showed that overexpression of miR-
424-3p was able to reverse myofibroblastic phenotype associated with TGF-β1 in
NOF804. Overexpression of miR-424-3p attenuates TGF-β1 response of α-SMA and
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Effect of TGF-β1 NOF CAF
α-SMA mRNA level Reduced No effect
FN-EDA1 mRNA level Reduced No effect
COL1A1 mRNA level No effect No effect
α-SMA protein level No effect No effect
α-SMA positive stress fibre formation No effect No effect
Contractility Decreased No effect
Table 4.1: Effect of miR-424-3p overexpression in TGF-β1-treated NOF or CAF
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Effect of TGF-β1
miR-145-5p miR-424-3p
NOF CAF NOF CAF
α-SMA mRNA level No effect No effect No effect No effect
FN-EDA1 mRNA
level
No effect No effect No effect No effect
COL1A1 mRNA level No effect No effect No effect No effect
α-SMA protein level No effect No effect No effect No effect
α-SMA positive stress
fibre formation
No effect No effect No effect Decreased
Contractility No effect Increased No effect Decreased
Table 4.2: Effect of inhibition of anti-miRs in TGF-β1-treated NOF or CAF
154
FN-EDA1 transcript levels in NOF804. In addition, overexpression of miR-424-3p
prevents TGF-β1’s ability to induce gel contraction in NOF804. However,
overexpression of miR-424-3p did not decrease TGF-β1 associated with α-SMA positive
stress fibres formation and α-SMA protein abundance in NOF804. Collectively, these
data suggest that miR-424-3p regulates, at least in part, TGF-β1-induced myofibroblast
differentiation, and that it might form part of a negative feedback loop to limit the effects
of TGF-β1 signalling, as has been described for SMAD7, which is upregulated by TGF-
β1 but serves to inhibit downstream phenotypic effects.
Overexpression of miR-424-3p had no effects in reversing TGF-β1-modulated
myofibroblastic phenotype in CAF. On the other hand, the loss-of-function experiments
of miR-424-3p or miR-145-5p did not work really well in NOF. Inhibition of miR-424-
3p decreased TGF-β1-induced α-SMA stress fibre formation in CAF. Inhibition of miR-
145-5p increases TGF-β1-induced gel contraction, not other myofibroblast phenotype, in
CAF. The functional analysis data presented here were inconclusive, therefore, it might
worth to look for other potentially functional miRNA that deregulated in eCAF.
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CHAPTER 5: Expression profiling
of miRNA during CAF
development
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5.1 Aim and objectives
The previous chapter provided evidence for the role for miR-424-3p and miR-
145-5p in eCAF differentiation, but the variability of the functional changes observed on
modulation of these miRNA prompted a fresh, more in depth, analysis to attempt to
identify other miRNA which might play a role in eCAF differentiation. Herein, the aim
of this chapter was to profile the expression of miRNAs in eCAF using a global miRNA
profiling strategy to identify novel miRNA regulators of CAF formation from normal
fibroblasts. Additionally, the miRNA expression profile of two subtypes of CAF
(isolated from genetically stable OSCC (GS-OSCC) and genetically unstable of OSCC
(GU-OSCC)) was determined using the same methodology. To do this, the following
objectives were addressed:
1) to determine the differential miRNA expression of eCAF compared to NOF
using TLDA, with more repeats and a more sophisticated analysis strategy
2) to determine global miRNA expression of tumour-derived CAF (GS-OSCC and
GU-OSCC), compared to NOF using TLDA.
5.2 miRNA expression profiling revealed that novel miRNAs are significantly
upregulated in eCAF
Gene expression profiling of stromal cells, predominantly performed in
fibroblasts, has been identified as a promising approach to predict markers of disease
progression (Finak et al., 2008) and therapy response (Farmer et al., 2009). Many studies
demonstrated differences in gene expression between CAF and normal fibroblasts,
particularly identifying differences in the expression of cytokines and ECM molecules
(Bauer et al., 2010; Utispan et al., 2010; Micke et al., 2007). Several studies have
identified changes in miRNA expression in myofibroblast differentiation, but less is
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known about the role of miRNA in CAF development. The expression of miR-21 was
reported to be upregulated in MRC-5 fibroblasts (human fetal fibroblast cell line) treated
with TGF-β1 or conditioned medium from ovarian cancer cells, compared to untreated
fibroblasts or without conditioned medium (Yao et al., 2011). While in CAF
development, miR-155 was reported to be upregulated in both fibroblasts isolated from
ovarian cancer tissue versus fibroblast from the normal ovarian tissue and experimentally
induced CAF (Mitra et al., 2012). miR-106b is increased in CAF derived from gastric
cancer tissues, compared with fibroblasts derived from normal gastric tissue (Yang et al.,
2014). However, as described in Chapter 4, there have been no reports regarding
differential miRNA expression associated with myofibroblast differentiation in the
context of OSCC. By using TLDA, this study analysed miRNA expression of eCAF from
two primary NOF cultures.
The miRNA expression profiles of eCAF and NOF (as described in Chapter 4)
were expanded and re-analysed with the help of a computational biologist, Dr Ryan Pink,
from Oxford Brookes University. To increase the statistical power of the data obtained,
the TLDA experiments were repeated twice for two primary NOF cultures and the data
obtained from the TLDA (two data sets from this experiment and one data set from the
previous experiment in Chapter 4) were used for analysis using DataAssist software v2.0.
The samples that are used in this analysis were summarised in Table 5.1. Quantitative
miRNA expression data were acquired based on ∆Ct values of the TLDA results.
Normalisation was performed using the mean of all the internal controls on the TLDA
cards; small nuclear RNAs (snRNA), RNU44, RNU48 and U6. The False Discovery
Rate (FDR) by Benjamini and Hochberg algorithm was applied for analysing corrected
p-values from a T-test between sample groups after normalisation. The workflow of the
TLDA interrogation of miRNA expression including computational analysis of the data
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miRNA cards
NOF5 (n=3) NOF804 (n=3)
Untreated TGF-β1-treated Untreated TGF-β1-treated
Pool A √ √ √ √
Pool B √ √ √ √
Table 5.1: NOF cultures that were used in the miRNA expression profiles and the
data were analysed using more stringent approach
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is illustrated in Figure 5.1.
As shown in Figure 5.2, using this method of analysis, only two miRNAs were
significantly upregulated in TGF-β1-treated NOF5; miR-181a (4.2-fold) and Let-7c (2.5-
fold), compared to untreated NOF5. No miRNAs were significantly downregulated in
TGF-β1-treated NOF5. The other two miRNAs that were focused on earlier in this study
(in Chapter 4) were upregulated in TGF-β1-treated NOF5, with miR-145-5p (3.6-fold)
and miR-424-3p (230-fold), but these increases did not reach significance using the
stringent statistical tests performed here. Only two miRNAs were significantly
upregulated in TGF-β1-treated NOF804; miR-503 (28.6-fold) and miR-708 (2.8-fold),
but these upregulated miRNAs were different to those upregulated miRNAs identified in
NOF5. Unlike NOF5, in which no down-regulated miRNA were identified, miR-1276
was significantly downregulated (0.1-fold) in TGF-β1-treated NOF804 (Figure 5.3).
miR-424-3p was upregulated 11.2-fold, however, this did not reach significance. While
expression of miR-145-5p was upregulated (not reaching statistical significance) in
NOF5, this miRNA was downregulated 1.1-fold (not reaching statistical significance) in
TGF-β1-treated NOF804.
5.3 Comparison of miRNA expression profile between CAF and NOF
Lim et al., (2011) demonstrated that CAF derived from GU-OSCC had a different
transcriptional profile from that of CAF derived from GS-OSCC. This difference
possibly involves specific miRNA expression profiles between the two distinct CAF
populations as miRNA are one of the regulators of gene expression. Thus, TLDA was
used to evaluate the miRNA expression profiles of these distinct CAF populations. CAF
from GU-OSCC are predominantly senescent, large and slow growing cells (Lim et al.,
2011). Three primary NOF isolates from normal oral mucosa (NOF1, NOF2 and NOF5)
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Figure 5.1: Schematic diagram of TLDA including data analysis to determine the
miRNA expression profile in NOF stimulated with TGF-β1
NOF cells were incubated with or without 5 ng/ml of TGF-β1 for 48 h. RNA was
extracted from fibroblasts and used later for cDNA synthesis. cDNA was amplified and
used for TLDA profiling. ∆Ct values obtained from qPCR were extracted using RQ
manager v1.2.1 and analysed using Data Assist software v2.0. The ∆Ct values were
normalised to average of internal controls at a Ct cut-off value of 40. Each expressed
miRNA was determined as fold change (∆∆Ct values relative to the untreated fibroblasts).
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Figure 5.2: A volcano plot of differential miRNA expression in TGF-β1-treated
NOF5 compared to untreated NOF5
NOF5 cells were incubated with or without 5 ng/ml of TGF-β1 for 48 h. Fibroblasts were
harvested and RNA was extracted for cDNA synthesis. cDNA was amplified and used
for TLDA experiment. The volcano plot shows the relationship between fold-change,
measured by Log2 (x-axis) and significance, measured by –Log10 (y-axis) between two
groups. Each dot represents one miRNA. Only miRNAs above the horizontal line are
significant (*p<0.05). The green dots denote miRNAs that are downregulated while red
dots represent miRNAs that are upregulated. The black dots are either miRNAs that are
not significant or below the fold change cut off. miRNAs identified as significant are
labelled on the plot. The miRNA expression profiles of NOF5 was produced from three
biological repeats.
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Figure 5.3: A volcano plot of differentially miRNAs expression in TGF-β1-treated
NOF804 compared to untreated NOF804
NOF804 cells were incubated with or without 5 ng/ml of TGF-β1 for 48 h. Fibroblasts
were harvested and RNA was extracted for cDNA synthesis. cDNA was amplified and
used for TLDA experiment. The volcano plot shows the relationship between fold-
change, measured by Log2 (x-axis) and significance, measured by –Log10 (y-axis)
between two groups. Each dot represents one miRNA. Only miRNAs above the
horizontal line are significant (*p<0.05). The green dots denote miRNAs that are
downregulated while red dots represent miRNAs that are upregulated. The black dots are
either miRNAs that are not significant or below the fold change cut off. miRNAs
identified as significant are labelled on the plot. The miRNA expression profiles of
NOF804 was produced from three biological repeats.
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were cultured. RNA was isolated and used to generate cDNA. Pre-amplified cDNA was
used as a template for TLDA analysis. Data analysis was performed in collaboration with
Dr Ryan Pink (Oxford Brookes University) using miRNA expression data obtained from
NOF and CAF of each subtype (generated by Genevieve Melling and Tasnuva Kabir,
former PhD students in the Lambert group; this data had not been previously analysed
nor included in other PhD theses). The samples that were used in the analysis were
summarised in Table. 5.2. Analysis revealed that 281 miRNAs displayed different
expression in CAF isolated from GS-OSCC, compared to NOF, where a log 2 of fold
change of <1 is considered downregulated and log 2 of fold change >1 is considered
upregulated (Figure 5.4 A). Out of these, only 16 miRNAs were significantly upregulated
(p<0.05) in CAF (GS-OSCC) compared to NOF while none were significantly
downregulated in CAF (GS-OSCC). miR-192 was highly upregulated (p<0.05) in CAF
(GS-OSCC) compared to NOF with a 13.8-fold increase. This was followed by miR-324-
5p and miR-484 with 6.1-fold and 5.5-fold increases, respectively. The other miRNAs
that were significantly upregulated in CAF (GS-OSCC) are listed in Figure 5.4 (B).
Fourteen miRNAs were significantly upregulated in CAF (GU-OSCC) compared
to NOF (Figure 5.5 A). miR-324-5p is highly upregulated in CAF (GU-OSCC) compared
to NOF with a 9.3-fold increase. Similar to CAF (GS-OSCC), no miRNA was identified
to be significantly downregulated in CAF (GU-OSCC) compared to NOF. Other
miRNAs that were significantly upregulated in CAF (GU-OSCC) are listed in Figure 5.5
(B). All the genes or pathways predicted to be targeted by any miRNAs mentioned in this
chapter were identified using the online target prediction tool, Diana-miRPath v3.0
(Vlachos et al., 2015). Out of 14 significantly altered miRNAs, miR-10a and miR-193b
were predicted to target genes encoding ECM components, COL4A3 and COL1A1,
respectively. The ECM is remodelled in pathological conditions such cancer and fibrosis.
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miRNA
cards
Without TGF-β1
NOF
(NOF1,NOF2,
NOF5)
CAF/GS-OSCC
(BICR70,BICR73,
BICR59)
CAF/GU-OSCC
(BICR31,BICR1
8,BICR3)
Pool A √ √ √
Pool B √ √ √
Table 5.2: NOF, CAF (GS-OSCC) and CAF (GU-OSCC) cultures that were used in
the miRNA expression profiles and the data were analysed using more stringent
approach
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Figure 5.4: Differential miRNAs expression in CAF (GS-OSCC) compared to NOF
NOF (NOF1, NOF2 and NOF5) and CAF isolated from genetically stable OSCC
(BICR70, BICR73, BICR59) were cultured, RNA was isolated and used for cDNA
synthesis. cDNA was amplified and used for TLDA experiment. (A) The volcano plot
shows the relationship between fold-change, measured by Log2 (x-axis) and significance,
measured by –Log10 (y-axis) between two groups. Each dot represents one miRNA.
Only miRNAs above the horizontal line are significant (*p<0.05). The green dots denote
miRNAs that are downregulated while red dots represent miRNAs that are upregulated.
The black dots are either miRNAs that are not significant or below the fold change cut
off. (B) miRNAs identified as significant are listed below the plot. TLDA experiments
were repeated three times.
166
Figure 5.5: Differential miRNA expression in CAF (GU-OSCC) compared to NOF
NOF (NOF1, NOF2 and NOF5) and CAF isolated from genetically unstable OSCC
(BICR31, BICR18, BICR3) were cultured, RNA was isolated and used for cDNA
synthesis. cDNA was amplified and used for TLDA experiment. (A) The volcano plot
shows the relationship between fold-change, measured by Log2 (x-axis) and significance,
measured by –Log10 (y-axis) between two groups. Each dot represents one miRNA.
Only miRNAs above the horizontal line are significant (*p<0.05). The green dots denote
miRNAs that are downregulated while red dots represent miRNAs that are upregulated.
The black dots are either miRNAs that are not significant or below the fold change cut
off. (B) miRNAs identified as significant are listed below the plot. TLDA experiments
were repeated three times.
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CAF sustain their major role in ECM remodelling as they are mainly responsible for the
synthesis of ECM proteins including collagens. Many cancers, including oral cancers,
display desmoplasia, a fibrotic state, characterised by deposition of collagens type I and
III and by a degradation of collagen type IV (Kauppila et al., 1998; Huijbers et al., 2010).
Furthermore, CAF are known to generate an abnormal ECM, including aberrant
COL1A1 expression, suggesting changes in these miRNA has the potential to modify the
CAF phenotype and the ECM of the tumour microenvironment.
miR-362-5p was predicted to target a gene related involved in the Krebs cycle,
isocitrate dehydrogenase 1 (IDH1). As mentioned in Section 1.6.3, CAF possibly secrete
metabolites (lactate or pyruvate) to fuel the growth of cancer cells. Fiaschi et al., (2012)
demonstrated that CAF secreted lactate and ketone bodies, later utilised by cancer cells
for oxidative phosphorylation. Additionally, β-hydroxybutyrate (a ketone body)
increased cancer cell proliferation by 3-fold, compared to control group, while lactate
promoted angiogenesis in a tumour model. A recent study showed that isocitrate
dehydrogenase 3α (IDH3α) downregulation causes metabolic reprogramming of
oxidative phosphorylation to glycolysis in CAF (Zhang et al., 2015). This study found
that IDH3α inhibition increased glucose uptake, lactate production and reduce oxygen
consumption in CAF. In contrast, overexpression of IDH3α inhibited TGF-β1-induced
lactate production in CAF. This data suggests these miRNAs have the potential to
regulate the metabolome of CAF and thereby influence their behaviour and that of
nearby cancer cells.
5.4 Comparison of miRNA expression profile between CAF isolated from GS-
OSCC and CAF isolated from GU-OSCC
The results described in Section 5.3 showed that both CAF from GS-OSCC and
GU-OSCC display distinct miRNA expression profiles compared to NOF. Out of these,
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the only miRNAs upregulated in both CAF (GS-OSCC) and CAF (GU-OSCC) are
indicated in a Venn diagram (Figure 5.6 A). This diagram was generated using the online
tool Data Overlapping and Area-Proportional Venn Diagram, obtained from
http://bioinforx.com/bxarrays/overlap.php. Only four miRNAs were highly expressed in
both subtypes of CAF when compared to NOF; miR-197, miR-320, miR-324-5p and
miR-376b. The fold change and statistical value for both subtypes of CAF are outlined in
Figure 5.6 (B).
5.5 Discussion
miRNA can regulate many biological processes and have shown promise as
biomarkers for various diseases (Ling et al., 2016; Iorio and Croce, 2009).
miRNAprofiling may be used to classify subgroups of tumours, especially for poorly
differentiated tumours that are difficult to distinguish by histological analysis (Dai et al.,
2014). miRNAs have attractive features for translation as biomarkers from the bench to
clinical practice; these include simple extraction (the principles of miRNA isolation is the
same as RNA extraction, except miRNA isolation was slightly modified to retain small
RNA fraction (Accerbi et al., 2010)), miRNA profiling by qRT-PCR and other analytical
methods, and resistance to degradation (Kwan et al., 2016). qRT-PCR provides absolute
miRNA quantification with dynamic range, low cost and greatest sensitivity compared to
other methods including RNA-seq (Pritchard et al., 2016). miRNA have been
demonstrated to be more stable than mRNAs in various specimen types including blood
plasma/serum (Arroyo et al., 2011) and formalin-fixed tissue blocks (Doleshal et al.,
2008).
The functional analysis data from Chapter 4 were inconclusive. Therefore, the
TLDA data were re-analysed using more samples and a more stringent analytical
approach to look for other potentially functional miRNA. The results from the second
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Figure 5.6: Commonly altered miRNAs in both CAF derived from GS-OSCC and
GU-OSCC compared to NOF
NOF and CAF (GS-OSCC and GU-OSCC) were grown, RNA was isolated and used for
cDNA synthesis. cDNA was amplified and used for TLDA experiment. (A) Venn
diagram shows that miRNAs that significantly upregulated in CAF (GS-OSCC), CAF
(GU-OSCC) and in both (B) Listed miRNAs that overlapped between two different data
sets.
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method of analysis revealed that miR-181a and Let-7c were significantly upregulated in
NOF5 cells after TGF-β1 treatment. Surprisingly, whilst miR-424-5p was upregulated, in
keeping with the findings in Chapter 4, miR-145-5p was downregulated (but not reaching
significance (p<0.05)) in TGF-β1-treated NOF5 cells in this analysis. Therefore, these
findings might explain the inconclusive results obtained from the functional analysis
experiments in Chapter 4, and suggest caution should be employed when interpreting the
findings of TLDA miRNA screening approaches. miR-181a, one of two miRNA
identified as altered in this reanalysis, belongs to the miR-181 family which includes
miR-181a, miR-181b, miR-181c and miR-181d (Giordano and Columbano, 2013). This
family of miRNA has been implicated in many cellular processes such as cell
proliferation, apoptosis, invasion and as a tumour suppressor (Shi et al., 2008; Chen et al.,
2013; Jianwei et al., 2013). miR-181a was overexpressed in cirrhosis and hepatocellular
carcinoma (Brockhausen et al., 2015). In OSCC, miR-181a was reported to be frequently
downregulated and overexpression of miR-181a decreased K-ras protein level (Shin et al.,
2011). Previous studies demonstrated that TGF-β regulates the expression of miR-181b
in hepatocytes by targeting TIMP3 (Wang et al., 2010) and p27 (Wang et al., 2012).
miR-181a promotes TGF-β-mediated EMT by suppressing Smad7 in ovarian cancer cells
(Parikh et al., 2014). TGF-β upregulates miR-181a expression to promote EMT of breast
cancer cells (Taylor et al., 2013). Taken together, these findings indicate TGF-β may be
a regulator of the expression of miR-181 family members. In agreement with this, TGF-
β1 caused upregulation of miR-181a expression in NOF5 and was predicted to target
Smad7, a negative regulator of TGF-β signalling. TGF-β activates Smad2 and Smad3
proteins (receptor-activated Smad) by reducing the association of Smad2/3 with Smad7
(one of the inhibitory Smads). However, no evidence of miR-181a involvement in
myofibroblast differentiation or fibrosis of OSCC has been reported to date, and further
functional assays are required to confirm this.
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The human Let-7 family consists of 10 miRNAs, located on different
chromosomes; Let-7a, Let-7b, Let-7c, Let-7d, Let-7e, Let-7f, Let-7g, Let-7i, miR-98 and
miR-202. The Let-7 family has been demonstrated to be involved in the control of
cellular processes; embryogenesis (R. Maller Schulman et al., 2008), tumour suppressive
functions (Zhang et al., 2007) and regulation of cell proliferation (Johnson et al., 2007).
Let-7 is commonly viewed as a tumour suppressor miRNA; increasing evidence
demonstrates that Let-7 is downregulated in various types of cancer including colon
cancer (Akao et al., 2006), gastric cancer (Zhang et al., 2007), breast cancer (Huang et
al., 2015) and lung cancer (Takamizawa et al., 2004). However, upregulation of certain
Let-7 family members has been observed in some types of human cancers such as
upregulation of Let-7b and Let-7i in lymphoma (Lawrie et al., 2009). This implies that
Let-7 family does not play as tumour suppressor role under all circumstances or in all
tissues. Only one study reported a high level of Let 7c expression in cardiac fibroblast
during EndMT (Ghosh et al., 2012). To date, no evidence of Let-7c involvement in
myofibroblast differentiation or CAF development has been reported. Interestingly, Let-
7c is predicted to target COL1A1, a key component of the ECM and one of the markers
of myofibroblast phenotype, suggesting it has the potential to modulate CAF and
myofibroblast differentiation.
miR-503 and miR-708 were highly upregulated in TGF-β1-treated NOF804 cells,
compared to unstimulated cells. The miRNA changes in response to TGF-β1 are different
between the two NOF cultures. This might be due to experimental variation including
passage number of the NOF used. Perhaps, the response could also be altered by site
specific differences where NOF are from different parts of buccal mucosa and health
status of the patient (e.g oral bacterial infection). miR-424-3p was upregulated while
miR-145-5p was downregulated in TGF-β1-treated NOF804 cells. However, these two
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miRNAs did not reach statistical significance (p<0.05).
miR-503 possesses the same seed sequence and genomic organisation of the miR-
16 family which includes miR-424 (Caporali and Emanueli, 2011). Thus, miR-503 is
considered as a part of the miR-16 family. Moreover, miR-503 promotes fibrosis in
cardiac cells (Zhou et al., 2016). In addition, miR-503 is important in myoblast
differentiation as well as myogenesis (Wang et al., 2009; Caporali et al., 2011). miR-503
is predicted to target genes related to TGF-β signaling pathway, Smad7 and Smurf1 (a
negative regulator of BMP signalling). Controlled proteolysis by Smad ubiquitination
regulatory factors (Smurfs) plays an important role in regulating cellular responses of
TGF-β signaling pathway. Smurf1 facilitates myogenic differentiation of TGF-β-treated
mouse C2C12 cells, compared to untreated cells (Ying et al., 2003). Smurf1 has been
demonstrated to interact with Smad7 (one of the inhibitory Smads), inducing the
ubiquitination-mediated degradation of the activated TGF-β receptors (Ebisawa et al.,
2001). Thus, it is possible that miR-503 may be involved functionally in myofibroblastic
differentiation.
miR-708 is located at the chromosomal locus 11q14.1 (Saini et al., 2011) and is
one of the more recently discovered miRNA to play role in cancer. miR-708 expression
is reported to be decreased in renal cancer cells and restoration of miR-708 expression
promotes apoptosis in renal cancer cells (Saini et al., 2011). However, it is unknown
whether miR-708 has any effect in tumour-stroma interaction. In this study, expression of
miR-708 was highly upregulated in eCAF. miR-708 is predicted to target genes related to
TGF-β signaling, including Smad2 (a positive regulator of TGF-β signaling) and
COL1A1. It is well accepted that Smad2/3 activation is crucial for Smad4-dependent
transcription regulation, suggesting a potential role for this miRNA is regulating
responses of fibroblasts to TGF-β1.
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In the present study, a differential miRNAs expression profile from two subtypes
of CAF (GS-OSCC and GU-OSCC) compared to NOF was determined. These two CAF
were fully characterised by Hassona and co-workers (2013). The TLDA data showed that
there were 16 miRNAs significantly deregulated in CAF (GS-OSCC). Among of these,
miR-192 is highly upregulated in CAF (GS-OSCC), compared to NOF. miR-192 was
reported to be highly expressed in mesangial cells upon TGF-β1 treatment and was
associated with elevated expression of COL1A2B by downregulating ZEB2 expression
(Kato et al., 2007). Recently, miR-192 was demonstrated to take part in cell cycle control
(Braun et al., 2008; Georges et al., 2008). miR-192 was predicted to target gene related
to cell cycle (specifically DNA damage checkpoint) by regulating CDK1. CAF (GU-
OSCC) have significantly more ROS production compared to CAF (GS-OSCC)
(Hassona et al., 2013). In agreement with this, DNA damage elicits cell cycle arrest in
CAF (GS-OSCC; wild-type TP53/p16INK4A), by regulating transcription factor p53 (G1
phase). Activated p53 is stabilised through protection from MDM2, later transactivates
the expression of genes including p21. The activated p21 inhibits G1 CDKs, resulting in
DNA repair (Barnum and O’Connell, 2014), suggesting that miR-192-mediated
regulation of CDK1 might play a role in determining the phenotype of these cells; further
experimental testing of this hypothesis is required, however.
Fourteen miRNAs were significantly upregulated in CAF (GU-OSCC),
compared to NOF with miR-324-5p showing the highest differential expression. In
cancer, miR-324-5p was found to repress transcription factor Gli-1, promoting
differentiation of medulloblastoma cells (Ferretti et al., 2008), but little else is known of
its roles. miR-324-5p is predicted to target a gene involved in glycosaminoglycan
biosynthesis (specifically heparan sulphate/heparin), exostosin glycosyltransferase 2
(EXT2). Heparan sulphate proteoglycans are macromolecules that served as a scaffold
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for the attachment of various ECM components including collagen, laminin and
fibronectin (Vlodavsky et al., 1996). In this study, three miRNAs were identified to be
involved in p53 signaling by targeting different genes in cell cycle checkpoints; miR-30b
(G1 arrest; Cyclin D, Cyclin E and CDK6), miR-376a (p53 negative feedback; MDM2)
and miR-532-3p (G1 arrest; Cyclin D and p53 negative feedback; MDM2). CAF (GU-
OSCC) is characterised by loss of TP53/p16INK4A (Hassona et al., 2013), therefore, when
DNA damage occurred in this cell, the ability to induce cell cycle arrest at specific points
in the cell cycle, particularly DNA repair mechanism was impaired, leading cells to
senesce. Furthermore, CAF (GU-OSCC) are enlarged cells, slow growing cells,
expressed genes associated with cellular senescence, and expressed more SA β-Gal
enzyme activity (marker of senescence) compared to normal oral mucosa and CAF (GS-
OSCC) (Lim et al., 2011; Hassona et al., 2013). Additionally, CAF (GU-OSCC)
accumulated with oxidative DNA damage, the number of 8-oxo-dG -positive cells was
increased in this CAF subset relative to CAF (GS-OSCC). The role of MDM2, an
ubiquitin ligase is to maintain the low level of p53 expression in unstressed cells
(Kubbutat et al., 1997). The expression of MDM2 induced by p53 caused p53
degradation, thus, MDM2-p53 serves as a negative feedback loop (Moll and Petrenko,
2003). Perhaps, the MDM2-p53 negative feedback loop acts the same manner to
maintain the status level of p53 in CAF (GU-OSCC). In this study, the miRNA
expression profile of CAF (GU-OSCC) is distinctly different from than that observed in
fibroblasts treated with cisplatin (Kabir et al., 2016), suggesting a difference between
senescent CAF and fibroblasts artificially induced to senesce. Additionally, miR-335 was
upregulated in cisplatin-treated normal fibroblasts and a miR-335/COX2/PTEN axis able
to modulate an inflammatory SASP of CAF, thus promoting tumour-supportive
microenvironment. Using the method of analysis employed here, miR-335 was not found
to be significantly up-regulated in senescent CAF.
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There were four miRNAs highly expressed in both CAF (GS-OSCC) and CAF
(GU-OSCC); miR-197, miR-320, miR-324-5p and miR-376b. miR-197 is located at the
chromosome 1p13.3 and little is known about the role of miR-197 in cancer. miR-197 is
secreted into the extracellular environment via cancer-related exosomes and is involved
in regulation of cell proliferation (Grange et al., 2011). High expression of miR-197 is
correlated with reduced Fus1 (a tumour suppressor) expression in NSCLC tumour
specimens (Du et al., 2009). Similar to miR-324-5p, miR-197 was predicted to target
gene related to glycosaminoglycan biosynthesis (specifically heparan sulphate/heparin),
exostosin glycosyltransferase 2 (EXT2). miR-320, another miRNA highly expressed in
both subtypes of CAF, is reported to be present in extracellular vesicles derived from
cancer and normal tissue (Skog et al., 2008; Guduric-Fuchs et al., 2012). miR-320-Pten-
Ets2 axis in stromal fibroblasts can modulate cancer-stroma communications and plays a
role in human breast cancer (Bronisz et al., 2012). miR-320 was predicted to be involved
in TGF-β signaling by targeting Smad3 (a positive regulator of TGF-β signaling).
Activated Smad3 is important for Smad4-dependent transcription regulation. The Smad3-
Smad4 complex was transported into the nucleus and this complexes activate specific
genes. Little is known about the involvement of miR-376b in cancer. One study
demonstrated that miR-376b was downregulated in rapamycin-induced autophagy in
MCF-7 cell and both genes related to autophagy, ATG4C and BECN1 are downstream
targets of miR-376b (Korkmaz et al., 2012). None of genes were predicted to target any
pathway related to any CAF biology, suggesting that cell-cell interactions might regulate
miR-376b expression to reflect a protective response in cellular homeostasis or a
detrimental effect in disease condition but again, this requires experimental validation.
Given that hundreds of miRNA were differentially expressed in CAF from two
subtypes of OSCC, it is not unsure whether the experiments carried out are measuring
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different miRNA expression or measuring similar miRNA expression across various
conditions. The principle component analysis (PCA), therefore, provide simplified
analysis to clearly determine the variables (samples) from the big data set that may
explain the difference in the observation (miRNA expression). Comparison between
miRNA expression using PCA will reveal distint clusters across the CAF (two suvtypes
of OSCC) and NOF. A comparison of miRNA expression profiles between CAF (GS-
OSCC) with CAF (GU-OSCC) could also be done in this experiment to compare miRNA
differentially expressed within two distinct subpopulations of CAF derived from OSCCs.
5.6 Summary
In this chapter, miR-424-5p and miR-145-5p were not significantly upregulated
in eCAF derived from NOF5, in contrast to the results of the analysis presented in
Chapter 4. Likewise, miR-424-3p was not significantly upregulated in the TGF-β1-
treated NOF804. miR-145-5p also appears to be downregulated but not significant
(p<0.05) in the TGF-β1-treated NOF804. These findings might explain the variable
results obtained from the functional analysis experiments in Chapter 4. Other potentially
functional miRNAs obtained from the analyses might emerge as interesting candidates to
control myofibroblast differentiation or CAF development. Furthermore, this study had
identified distinct miRNAs expression profile between CAF (GS-OSCC) with CAF (GU-
OSCC). This study provides information several miRNA candidates in senescent CAF, a
subpopulation of CAF that contribute to cancer progression through modulation of
secretome, termed the senescence-associated secretory phenotype (SASP) (Laberge et al.,
2015). Furthermore, the SASP comprises of elevated levels of cytokines, growth factors,
ECM proteins and other factors, which helps to create a pro-tumourigenic extracellular
milieu. The molecular mechanisms underlying the pro-tumourigenic of SASP is poorly
understood. Therefore, elucidating the mechanisms responsible for the SASP production
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(including the involvement of miRNA) could provide a new approach in therapy since
stromal fibroblasts are thought to be genetically stable (Loeffler et al., 2006) and may
therefore add to the repertoire of currently available treatments alongside those targeting
genetically unstable or drug-resistant tumour cells.
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CHAPTER 6: Discussion
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6.1 General discussion
The close relationship between cancer cells and stromal cells in the tumour
microenvironment is believed to promote cancer growth and progression. The tumour
microenvironmental milieu consists of multiple cells, including cancer associated
fibroblasts (CAF), and generates an altered extracellular matrix (ECM), cytokines,
chemokines, and pro-angiogenic factors, collectively creating a more permissive
microenvironment to encourage tumour proliferation (Pietras and Ostman, 2010) and
metastasis (Liao et al., 2009). Fibroblasts found in the tumour microenvironment are
referred to by a variety of names, but most commonly as CAF. CAF have been
demonstrated to be involved in many aspects of cancer development; invasion and
metastasis (Duda et al., 2010), ECM remodeling (Gaggioli et al., 2007), angiogenesis
(Gerber et al., 2009) and resistance to therapy. In OSCC, stromal CAF facilitate tumour
growth and progression by altering the proliferation, invasion, and metastasis of cancer
cells (Thode et al., 2011). Therefore, CAF may represent potential therapeutic targets for
anticancer therapy; this potential is amplified by their genetic stability which makes them
unlikely to develop resistance to therapy as seen with cancer cell-targeted treatments.
Myofibroblasts are generally considered not to be exactly the same as CAF but
share a number of characteristics. Myofibroblasts are found in healing wounds and have
fibroblast and smooth muscle cell characteristics. Thus, myofibroblasts express α-SMA
and are able to generate contractile force to promote wound closure (Tomasek et al.,
2002). Upon completion of wound repair, the α-SMA expression decreases, the
contractile activity of myofibroblasts is terminated and myofibroblasts undergo
programmed cell death (apoptosis) (Desmouliere et al., 1995). However, in pathological
situations resembling a healing wound such as cancer, myofibroblastic fibroblasts remain
activated, neither reverting back to normal phenotype nor being removed by apoptosis
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(Li et al., 2007). Myofibroblasts in a neoplastic stroma have been shown to be a
predictive marker of poor prognoses in various cancer including OSCC (Desmouliere et
al., 2004; Sobral et al., 2011; De-assis et al., 2012; Dourado et al., 2017).
CAF represent heterogeneous phenotypes; they exist as a varied population of
myofibroblastic cells mixed with other fibroblastic phenotypes that do not express α-
SMA but may be tumour promoting nevertheless (Desmouliere et al., 2004; Micke and
Ostman, 2004). Sugimoto et al., (2006) demonstrated that CAF comprise mixed
populations of activated fibroblasts; one subset was FSP1 positive but lacked expression
of α-SMA, whereas the other FSP1 negative subset co-expressed α-SMA. These
subpopulations of CAF might have distinct role in cancer progression. Two CAF
phenotypes were identified in genetically stable or genetically unstable OSCC; GS-
OSCC and GU-OSCC. Lim et al (2011) characterised OSCC based on the presence of
inactivating mutations/chromosomal deletions of TP53/p16INK4A. They found that
fibroblasts derived from genetically unstable OSCC (GU-OSCC; loss of TP53/p16INK4A)
were senescent and differ in transcriptional profile to fibroblasts derived from genetically
stable OSCC (GS-OSCC; wild-type TP53/p16INK4A). The development of senescent CAF
was induced by ROS associated with TGF-β1 and TGF-β2 from GU-OSCC keratinocytes
(Hassona et al., 2012). However, in this model not all the CAF are senescent, further
suggesting the presence of heterogeneity. Therefore, it is impossible to fully model the
transition to a mixed CAF phenotype in vitro, but this study at least represents a subtype
(myofibroblastic) associated with disease progression.
CAF originate from multiple origins including resident fibroblast undergoing
mesenchymal-mesenchymal transition (MMT) (Radisky et al., 2007). Morphologically,
fibroblasts are elongated cells with a spindle-like shape. Fibroblasts are the non-epithelial,
non-vascular and non-inflammatory cells of connective tissue (Tarin and Croft, 1969).
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Fibroblasts reside within the ECM and are one of the most abundant cell type in
connective tissue.
In this study, NOF extracted from human buccal mucosa were used as an in vitro
model to examine the molecular mechanisms underlying myofibroblast-like CAF
transition. It is well-known that cancer cells secrete high levels of TGF-β1 along with
other growth factors such as PDGF (Massague, 2008). These paracrine secretions are
believed to trigger a transition of resting fibroblasts to CAF phenotype with
myofibroblastic features in various cancers including OSCC (Lewis et al., 2004).
The molecular mechanisms by which TGF-β1- mediates the conversion of oral
fibroblasts to a myofibroblastic, CAF-like phenotype remain unclear. Here, it was
hypothesised that specific miRNA regulate the development of the myofibroblastic CAF
phenotype. In order to test this hypothesis, TGF-β1 was first used to differentiate NOF
into an experimentally-derived CAF phenotype (eCAF) in culture. Dose and time course
experiments were performed to optimise the appropriate TGF-β1 concentration and
treatment time needed for maximal induction of CAF-like myofibroblast differentiation,
within the physiological range of TGF-β1. TGF-β1 concentrations (0.05-5 ng/ml) were
chosen based on a previous study (Walker et al., 2004). In this study, 5 ng/ml was used
as the optimal concentration of TGF-β1 and 48 h as optimal time course for fibroblast
activation to a CAF-like myofibroblastic eCAF phenotype, as determined by increased
expression of α-SMA at mRNA and protein level. There was a biological variability
observed in all primary NOF cultures in response to TGF-β1 throughout this study,
however the majority of cultures showed at least some response, albeit of varying
magnitude. NOF5 showed greater response to TGF-β1 among other NOF as assessed by
increased α-SMA expression. The differences observed are perhaps due to the freshness
of TGF-β1 and also the condition of NOF such as the passage number (previous data
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accrued in the lab indicates that NOF cultures do not senesce within the range of
passages used, but it is impossible to exclude other phenotypic variations that may have
been induced by culture). Additionally, patient-to-patient variability contributes to these
differences such as age, smoking status and health status (e.g oral infection).
Another myofibroblast and CAF marker, FN-EDA1, was also used as CAF
marker to monitor eCAF development in this study. Unlike α-SMA, this marker is not
fully characterised in myofibroblast differentiation. FN-EDA1 has been demonstrated to
be re-expressed in various pathological processes including wound healing and liver
fibrosis (Ffrench-Constant et al., 1989; Jamagin et al., 1994). Serini and co-workers
(1999) demonstrated that FN-EDA1 plays an important role in TGF-β1-induced
myofibroblast differentiation in cultured rat subcutaneous, lung and dermis fibroblasts.
TGF-β1 induced differentiation into myofibroblasts with increased FN-EDA1 production
in cultured colonic lamina propria fibroblasts (Brenmoehl et al., 2009). Taken together,
TGF-β1 has been shown to increase FN-EDA1 production and is becoming an
established myofibroblast differentiation marker, and was hence used in this study. Here,
it was shown, for the first time to our knowledge, that TGF-β1 robustly induces FN-
EDA1 expression in oral fibroblast cultures. However, how FN-EDA1 regulates, or
participates in, myofibroblast differentiation remains unknown. In this study, similar to
α-SMA, NOF5 demonstrated the highest increase in FN-EDA1 expression in response to
TGF-β1 at mRNA level compared to the other NOF cultures.
Actin stress fibres are comprised of bundles of polymerized actin filaments
connected to modified focal adhesion complexes, thus providing the transmembrane link
to components of ECM (Goldman et al., 1975). CAF have cytoplasmic β-actin and γ-
actin isoforms which participate in actin stress fibre formation (Sandbo et al., 2011). As
mentioned above, α-SMA expression is induced in NOF under stimulation with TGF-β1.
183
α-SMA is rapidly incorporated into actin stress fibre, thereby increasing the contractility
of fibroblasts (Serini and Gabbiani, 1999). In keeping with this, in this study, TGF-β1 not
only increase gene expression of α-SMA but also promoted the development of α-SMA
positive stress fibres. Fluorescence microscopic analysis showed that TGF-β1 increased
α-SMA positive staining cells compared to untreated cells, in all NOF cultures. This
result is consistent with a highly contractile phenotype of eCAF under TGF-β1
stimulation, as assessed by collagen contraction assays. The appearance of actin stress
fibres is closely related to the generation of contractile force, particularly in intact
granulation tissue (Hinz et al., 2001). Stress fibre contraction is controlled by the Rho-
dependent regulation of non-muscle myosin together with the stress fibre (Pellegrin and
Mellor, 2007). In keeping with the findings reported here, TGF-β1 induces myofibroblast
differentiation of human gingival fibroblasts by increasing α-SMA expression and α-
SMA positive stress fibres formation, compared to untreated cells (Lewis et al., 2004). In
another study, flow cytometric analysis showed that treatment of human buccal
fibroblasts with TGF-β1 increased α-SMA production compared to unstimulated cells
(Kellermann et al., 2007). In summary, the findings reported here are in keeping with,
and add to, existing understanding of the ability of TGF-β1 to induce a myofibroblastic
CAF-like phenotype in oral fibroblasts in vitro, giving confidence that this optimised
model of CAF differentiation could be used for subsequent analysis of underlying
molecular mechanisms.
Little is known about the role of miRNAs in the tumour microenvironment,
especially in stromal cells of OSCC. Evidence in the literature suggests miRNAs are
likely to play a role in TGF-β1 signaling; most members of the TGF-β1 pathway are
known or predicted to be targeted by one or more miRNAs (Butz et al., 2012).
Furthermore, TGF-β1 directly regulates the biogenesis of miRNAs through Smads
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(Zhong et al., 2010). The expression of miR-21 was upregulated in TGF-β1-treated
fibroblast isolated from normal lung tissue, compared to untreated fibroblasts (Yao et al.,
2011). The expression of miR-31 and miR-214 were downregulated in CAF from ovarian
tumours (Mitra et al., 2012). Here it was hypothesised, therefore, that miRNA play a role
in the development of a myofibroblastic CAF. To begin to test this hypothesis, the
expression profile of miRNAs during the differentiation of normal fibroblasts to eCAF
was studied. The data presented in this study demonstrated that eCAF exhibit distinct
miRNAs expression profiles compared to corresponding NOF. A preliminary analysis of
the tiling low density array (TLDA) data accrued indicated that hundreds of miRNAs
were deregulated in TGF-β1-treated NOF culture, compared to unstimulated NOF. Out
of these, miR-424-5p and miR-145-5p were highly upregulated in eCAF from NOF1 and
NOF5 cultures while miR-424-3p was highly upregulated in eCAF from NOF804 culture.
Conversely, the miR-145-5p was downregulated in eCAF from NOF804 culture. Thus,
these three miRNAs were selected for further validation by qRT-PCR. The qRT-PCR
data generally correlated with the TLDA data, although different magnitudes of changes
were observed in some cases between the two techniques used.
To gain a further insight on how these miRNAs regulate TGF-β1-induced CAF-
like myofibroblast differentiation, both the loss-of-function and the gain-of-function
experiments were carried out. miR-145 is a miRNA previously identified to play a role in
fibroblast differentiation in different contexts. Wang and colleagues (2014) demonstrated
that miR-145 induces conversion of cardiac fibroblasts into myofibroblast. Additionally,
miR-145 plays an important role in lung myofibroblast differentiation (Yang et al., 2013).
Relatively, little is known about miR-424 in the tumour-stroma interactions; miR-424
was demonstrated to regulate myofibroblast differentiation in human lung epithelial
through EMT (Xiao et al., 2015) but otherwise its role in this context is little documented.
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In this study, the role of miR-424-5p and miR-145-5p could not be investigated further in
NOF1 and NOF5 cultures (used for the TLDA profiling) due to problems with their
culture which arose after the profiling had been carried out. Therefore, a newly-derived
NOF culture, NOF804 was mainly used throughout this study to investigate the role of
miR-424-3p and miR-145-5p in TGF-β1-induced CAF-like myofibroblast differentiation.
The present study revealed that miR-424-3p is able to modulate, at least in part,
TGF-β1-induced myofibroblast differentiation in NOF804. Overexpression of miR-424-
3p attenuated the expression of TGF-β1-induced myofibroblast markers, with
pronounced effects on α-SMA and FN-EDA1 transcript levels. In line with this finding,
overexpression of miR-424-3p prevented TGF-β1-induced contractility in NOF804.
However, overexpression of miR-424-3p had only a small effect on TGF-β1-induced α-
SMA abundance at protein level and TGF-β1-induced stress fibre formation. An attempt
to inhibit miR-424-3p and miR-145-5p (loss-of-function assays) in NOF did not work
well as the functional analysis showed unconvincing data for both inhibitors. There was
some variability in response to inhibition of miR-424-3p and miR-145-5p between
biological repeats in NOF, as indicated by large standard errors of the mean generated
from the data. These possibly due to the efficiency of individual transfections or of
variations in the NOF themselves (e.g passage number and confluency). Further
investigations would be required to determine the reasons for the variation observed,
such as transfecting fluorescently tagged inhibitors to examine transfection efficiency.
Given the changes in expression and the functional data observed in eCAF in this
study, the function of miR-424-3p and miR-145-5p in tumour-derived CAF from OSCC
was also investigated. Overexpression of miR-424-3p did not inhibit basal myofibroblast
phenotype or further TGF-β1-induced myofibroblast differentiation in CAF. Neither
inhibition of miR-424-3p nor miR-145-5p increase basal myofibroblast phenotype in
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CAF. Inhibition of miR-434-3p decreased TGF-β1-induced positive stress fibre
formation and collagen contractility in CAF. Inhibition of miR-145-5p significantly
increases TGF-β1’s ability to induced gel contraction, but not other markers of the
myofibroblast phenotype, in CAF.
As some of the functional data obtained were somewhat inconclusive (particularly
with regards to miR-145), and the original NOF cultures became unusable, NOF804 cells
were used to generate three repeats and the data re-analysed using a more sophisticated
approach. The TLDA data revealed that miR-424-3p and miR-145-5p were not
differentially expressed in eCAF from NOF804. Additionally, the re-analysed TLDA
data revealed other potential miRNA candidates differentially expressed in eCAF from
NOF804 culture; miR-503 and miR-708. miR-503 is predicted to target Smad7 and
Smurf1 (a negative regulator of TGF-β or BMP signaling pathway), while miR-708 is
predicted to target Smad2 (a positive regulator of TGF-β signaling) and COL1A1 (a
component of ECM).
This study also demonstrated the miRNA signature of CAF derived from two
subtypes of OSCC. CAF (GU-OSCC) were large, slow growing and associated with
cellular senescence (Lim et al., 2011). Furthermore, this type of CAF exhibited high SA
β-Gal expression and upregulation of p16INK4A (Hassona et al., 2013). CAF (GS-OSCC)
are wild-type TP53/p16INK4A. The present study revealed that 16 miRNAs were
significantly deregulated in CAF (GS-OSCC), with miR-192 highly upregulated in CAF
(GS-OSCC), compared to NOF. Fourteen miRNAs were significantly upregulated in
CAF (GU-OSCC), compared to NOF with miR-324-5p showed the highest expression
among the other miRNAs. Out of the 14 altered miRNAs, three miRNAs are predicted to
target genes related to G1 cell cycle or p53 negative feedback; miR-30b (Cyclin D,
Cyclin E and CDK6), miR-376a (MDM2) and miR-532-3p (Cyclin D and MDM2). All
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of these genes might be involved in maintaining the phenotype of CAF (GU-OSCC)
which are predominantly senescent and slow growing in culture. Both types of CAF
share common miRNAs expression changes; miR-197, miR-320, miR-324-5p and miR-
376b. miR-197, miR-320 and miR-376b are predicted to target different genes related to
CAF biology (e.g TGF-β signaling, ECM component) or regulation of autophagy. Thus,
targeting these miRNAs might have translational benefits in clinical therapy of either
genetically stable or unstable tumours of OSCC.
6.2 Limitations of the study
The present study optimised the generation of eCAF by assessing two molecular
markers of myofibroblast differentiation; α-SMA and FN-EDA1, as well as stress fibre
formation and fibroblast contractility. Although these findings are sufficient to confirm
the cells are CAF-like cells but within the same type of tissue, CAF markers are not
uniquely expressed on these cells, suggesting distinct CAF subpopulations exist.
Sugimoto and co-workers (2006) demonstrated that one CAF-subtype characterized by
co-expression of α-SMA, PDGFRβ, and NG2, while another subtype expressed FSP-1.
Furthermore, FSP-1-positive fibroblast was identified as being mostly non-
myofibroblast-rich cell populations of CAF and was demonstrated to accelerate
tumourigenesis in vivo and human tumour xenograft model (Trimboli et al., 2009; Erez
et al., 2010; O’Connell et al., 2011). Collectively, it would be interesting to examine
other myofibroblast markers, to confirm the faithfulness of the phenotype observed in
this study to CAF in vivo. For example, FAP, which is reported to be highly expressed by
CAF in various human epithelial cancers such as breast, ovarian and lung cancers (Cheng
et al., 2005), could have been analysed if more time had been available.
Immunocytochemistry of stress fibre formation can be improved by including a
red Phalloidin antibody that stained F-actin. This could highlight the cytoplasm and
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fibroblasts, relative to α-SMA expression.
The gel collagen contraction assay demonstrated that the cells assessed in this
study were CAF-like cells. Giving that CAF exist from various fibroblast populations,
this method is limited as it only gives quantitative contraction for populations of cells,
not individual cells. In addition, matrix tension alone is unable to complete myofibroblast
differentiation. The matrix tension transferred to fibroblast is modulated by integrins,
found in focal adhesion complex (Arora et al., 1999) and these focal adhesions could be
assessed by scanning electron microscopy. Furthermore, matrix tension is important to
generate the intermediate cells that are thought to transform into differentiated
myofibroblasts, termed proto-myofibroblasts (Tomasek et al., 2002).
In this study, NOF cultures seem to be quite heterogenous in their level of α-SMA
expression in response to TGF-β1. This could be explained by demonstrating whether the
NOF cultures used in this study respond to canonical TGF-β signaling e.g Smad7 gene
expression by qRT-PCR. Other approach, a single cell RNA-seq might be useful to look
for the heterogeneity within NOF cultures.
qPCR is a commonly used method for studying miRNA function upon
transfection with miRNA mimics or miRNA inhibitors. However, this method does not
accurately determine the level of miRNA. In theory, for a miRNA to be functional,
miRNA must be incorporated into RISC complex. Thus, qPCR does not distinguish
between functional miRNA or non-functional miRNA. In addition, miRNA inhibitors
can give a false positive result because, after cell lysis, most of the inhibitors released
from cellular vesicles can directly interfere with the PCR reaction (Thomson et al., 2013).
Better approaches to measure the effectiveness of transfection are the use of miRNA
reporter assay or measurement of miRNA level by Argonaute immunoprecipitation (a
key component of the RISC complex).
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CAF are possibly derived from various origins with specific transitions. CAF
might arise from resident fibroblasts through MMT while epithelial cells acquire EMT to
become CAF (Cirri and Chiarugi, 2011). In this study, it is unsure whether CAF from
OSCC originate from resident fibroblasts or cancer cells. A karyotypic analysis should be
done to exclude CAF that originate from cancer cells through EMT. CAF have a stable
diploid karyotype while cancer cells are polyploid (Aprelikova et al., 2010). Therefore,
the role of miR-424-3p in TGF-β1-induced myofibroblast differentiation can be fairly
compared between eCAF with real CAF.
6.3 Future work
The findings obtained from this study have raised many questions in the context
of myofibroblast differentiation or CAF development. As mentioned in Section 6.2, some
of the experiments could be carried out to further characterise eCAF.
Although miR-424-3p was partially involved in TGF-β1-induced CAF-like
myofibroblast differentiation, its pro-tumorigenic roles in the cancer progression should
be investigated in various aspects including hypoxia and angiogenesis. miR-424 is a
hypoxia-induced miRNA and targets HIFs, transcription factors that regulate tumour cell
survival and angiogenesis (Ghosh et al., 2010). Moreover, miR-424 regulates tumour
metabolism by upregulation of glycolysis through regulation of IDH3α during TGF-β1-
induced CAF formation (Zhang et al., 2015).
The significantly upregulated miRNAs (re-analysed TLDA data) in eCAF from
NOF804 should be validated by qRT-PCR. The roles of selected miRNAs could be
studied by both gain-of-function and loss-of-function experiment. For the loss-of-
function study, another method should be implemented such as miRNA sponges. This
method uses plasmid constructs either transiently or stably transfected into the cells
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containing multiple miRNA binding sites for a selected miRNA. Once the functional role
of miRNAs was established, downstream cytokines, chemokines and growth factors can
be predicted using target prediction tools such as TargetScan and Diana-microT.
The role of selected miRNAs could be studied in the context of tumour-stroma
interactions. This can be achieved by 3D models of co-culturing cancer cells with CAF
or fibroblasts stably transfected with miRNA mimics or miRNA inhibitors, to see the
effects of those miRNAs in cancer progression such as invasion and angiogenesis.
Giving that TGF-β1 regulates myofibroblast differentiation, a study could be carried out
to assess whether the selected miRNAs are downstream of TGF-β signaling.
Certain exosome-secreted miRNAs can be transferred from stromal cells to
cancer cells. Vanpoucke and co-workers (2004) demonstrated that miR-223 is highly
expressed in IL-4-induced TAMs, not in breast cancer cells. This miRNA can be
transmitted from TAMs to cancer cells and inhibits Myocyte-specific enhancer factor 2C
(Mef2C), a transcription factor that promotes cell migration. Therefore, a study could be
conducted to determine the transmission of selected miRNAs between associated stromal
cells with oral cancer cells and examining the tumour promoting effects of these selected
miRNAs.
6.4 Conclusions and clinical significance
This study identified miR-424-3p as a regulator, at least in part, of TGF-β1-
induced CAF-like myofibroblast differentiation. miR-424-3p overexpression was able to
prevent TGF-β1-induced CAF-like myofibroblastic phenotype. However, more in-depth
investigations are needed to better understand the exact mechanisms and the tumour-
promoting role of miR-424-3p in oral stroma-cancer interactions.
This study emphasised the exciting potential of other miRNA candidates that
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differentially expressed in eCAF and these miRNAs might reverse the myofibroblastic
phenotype in the fibrosis and in the tumour microenvironment. Additionally, this study
has highlighted the miRNA signatures of CAF from two subtypes of OSCC. These
miRNA signatures have valuable indicators in clinical diagnosis, prognosis and
therapeutic targets in OSCC. Cancer cells and CAF have different biological
characteristics, thus the same miRNAs might play different roles in them. Although there
is distinct miRNAs expression profile in CAF from some type of cancer, some miRNAs
are shown to have a common role in CAF from different cancers. miR-21 is highly
upregulated in the CAF from various cancer tissues and this indicates poor prognoses
(Bullock et al., 2013; Li et al., 2013; Nielsen et al., 2011). The ability to manipulate
miRNA expression currently predominantly involves the use of miRNA inhibitors or
miRNA mimic. However, the successful delivery in vivo is still challenging. The nature
of naked miRNAs; hydrophilicity, polyanionic nature and high molecular weight, makes
them unable to cross the cell membrane (Wang et al., 2010). Furthermore, administration
of miRNAs by intravenous resulted in poor tissue distribution due to renal bypass. All of
these technical challenges need to be overcome before translating the mechanistic insight
gained in studies such as this to a clinical setting.
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APPENDICES
Appendix 1: miRNAs were differentially expressed in TGF-β1-treated NOF5 and
NOF804, compared to unstimulated cells
NOF5
miRNA
POOL A
miRNA
POOL B
Fold change relative
to endogenous
control
Fold change relative
to endogenous
control
ath-miR159a-
4373390 23.5205
ath-miR159a-
000338 693379.4241
has-miR-155-
4395459 39.3471 dme-miR-7-000268 1355.7923
hsa-let-7a-
4373169 0.8503 hsa-let-7a#-002307 767.943
hsa-let-7b-
4395446 13.9199 hsa-let-7b#-002404 556.2827
hsa-let-7c-
4373167 7.9977 hsa-let-7c#-002405 412.044
hsa-let-7d-
4395394 3.1351 hsa-let-7e#-002407 286.1412
hsa-let-7e-
4395517 11.1247
hsa-let-7f-1#-
002417 270.8893
hsa-let-7f-
4373164 0.8015
hsa-let-7f-2#-
002418 166.4621
hsa-let-7g-
4395393 3.672 hsa-let-7g#-002118 151.9676
hsa-miR-100-
4373160 9.6295 hsa-let-7i#-002172 149.7065
hsa-miR-101-
4395364 4.8569
hsa-miR-100#-
002142 139.7136
hsa-miR-103-
4373158 10.0458
hsa-miR-101#-
002143 133.549
hsa-miR-105-
4395278 23.5205
hsa-miR-105#-
002168 122.1013
hsa-miR-106a-
4395280 8.5705
hsa-miR-106a#-
002170 121.1873
hsa-miR-106b-
4373155 42.3921
hsa-miR-106b#-
002380 118.8496
hsa-miR-107-
4373154 51.3527
hsa-miR-10a#-
002288 108.9179
hsa-miR-10a-
4373153 40.3904
hsa-miR-10b#-
002315 105.6101
hsa-miR-10b-
4395329 23.5205
hsa-miR-1178-
002777 102.0158
hsa-miR-122-
4395356 47.5434
hsa-miR-1179-
002776 99.5907
hsa-miR-124-
4373295 190.9864
hsa-miR-1180-
002847 98.5417
hsa-miR-125a-3p-
4395310 30.3056
hsa-miR-1182-
002830 80.0651
hsa-miR-125a-5p-
4395309 18.7463
hsa-miR-1183-
002841 64.6361
hsa-miR-125b-
4373148 18.4361
hsa-miR-1184-
002842 59.5174
hsa-miR-126-
4395339 0.9604
hsa-miR-1197-
002810 58.781
hsa-miR-127-3p-
4373147 12.5434
hsa-miR-1200-
002829 55.6967
hsa-miR-127-5p-
4395340 0.2717
hsa-miR-1201-
002781 51.9416
hsa-miR-128-
4395327 17.9875
hsa-miR-1203-
002877 48.4198
hsa-miR-129-3p-
4373297 4.3416
hsa-miR-1204-
002872 47.5712
hsa-miR-129-5p-
4373171 23.5205
hsa-miR-1205-
002778 40.4702
hsa-miR-130a-
4373145 10.1969
hsa-miR-1206-
002878 37.9526
hsa-miR-130b-
4373144 12.5966
hsa-miR-1208-
002880 33.418
hsa-miR-132-
4373143 1.1433
hsa-miR-122#-
002130 29.7438
hsa-miR-133a-
4395357 23.5205
hsa-miR-1224-3P-
002752 29.4284
hsa-miR-133b-
4395358 23.5205
hsa-miR-1225-3P-
002766 28.731
hsa-miR-134-
4373299 14.5511
hsa-miR-1226#-
002758 26.8033
hsa-miR-135a-
4373140 23.5205
hsa-miR-1227-
002769 25.0383
hsa-miR-135b-
4395372 23.5205
hsa-miR-1228#-
002763 24.2924
hsa-miR-136-
4373173 23.5205
hsa-miR-1233-
002768 24.2065
hsa-miR-137-
4373301 8.8141
hsa-miR-1236-
002761 23.4883
hsa-miR-138-
4395395 4.1264
hsa-miR-1238-
002927 23.359
hsa-miR-139-3p-
4395424 23.5205
hsa-miR-124#-
002197 23.1468
hsa-miR-139-5p-
4395400 23.5205
hsa-miR-1243-
002854 21.8261
hsa-miR-140-3p-
4395345 23.5205
hsa-miR-1244-
002791 21.7244
hsa-miR-140-5p-
4373374 6.6558
hsa-miR-1245-
002823 21.5804
hsa-miR-141-
4373137 23.5205
hsa-miR-1247-
002893 21.4227
hsa-miR-142-3p-
4373136 23.5205
hsa-miR-1248-
002870 18.818
hsa-miR-142-5p-
4395359 23.5205
hsa-miR-1249-
002868 17.5877
hsa-miR-143-
4395360 11.8463
hsa-miR-1250-
002887 17.5877
hsa-miR-1-
4395333 4.6237
hsa-miR-1251-
002820 17.5877
hsa-miR-145-
4395389 15.882
hsa-miR-1252-
002860 17.5877
hsa-miR-146a-
4373132 3.4807
hsa-miR-1253-
002894 17.5877
hsa-miR-146b-
3p-4395472 23.5205
hsa-miR-1254-
002818 17.5877
hsa-miR-146b-
5p-4373178 4.7002
hsa-miR-1255A-
002805 17.5877
hsa-miR-147-
4373131 80.0484
hsa-miR-1255B-
002801 17.5877
hsa-miR-147b-
4395373 0.9086
hsa-miR-1256-
002850 17.5877
hsa-miR-148a-
4373130 7.6001
hsa-miR-1257-
002910 17.5877
hsa-miR-148b-
4373129 23.5205
hsa-miR-1259-
002796 17.5877
hsa-miR-149-
4395366 2.6512
hsa-miR-125b-1#-
002378 17.5877
hsa-miR-150-
4373127 5.4383
hsa-miR-125b-2#-
002158 17.5877
hsa-miR-152-
4395170 7.4918
hsa-miR-126#-
000451 17.5877
hsa-miR-153-
4373305 0.4288
hsa-miR-1260-
002896 17.5877
hsa-miR-154-
4373270 23.5205
hsa-miR-1262-
002852 17.5877
hsa-miR-15a-
4373123 21.6382
hsa-miR-1263-
002784 17.5877
hsa-miR-15b-
4373122 6.0544
hsa-miR-1264-
002799 17.5877
hsa-miR-16-
4373121 3.7566
hsa-miR-1265-
002790 17.5877
hsa-miR-17-
4395419 7.6342
hsa-miR-1267-
002885 17.5877
hsa-miR-181a-
4373117 9.1514
hsa-miR-1269-
002789 17.5877
hsa-miR-181c-
4373115 23.5205
hsa-miR-1270-
002807 17.5877
hsa-miR-182-
4395445 23.5205
hsa-miR-1271-
002779 17.5877
hsa-miR-183-
4395380 23.5205
hsa-miR-1272-
002845 17.5877
hsa-miR-184-
4373113 23.5205
hsa-miR-1274A-
002883 17.5877
hsa-miR-185-
4395382 12.071
hsa-miR-1274B-
002884 17.5877
hsa-miR-186-
4395396 122.5838
hsa-miR-1275-
002840 17.5877
hsa-miR-187-
4373307 23.5205
hsa-miR-1276-
002843 17.5877
hsa-miR-188-3p-
4395217 23.5205
hsa-miR-1278-
002851 17.5877
hsa-miR-18a-
4395533 4.4586
hsa-miR-1282-
002803 17.5877
hsa-miR-18b-
4395328 8.1728
hsa-miR-1283-
002890 17.5877
hsa-miR-190-
4373110 23.5205
hsa-miR-1284-
002903 17.5877
hsa-miR-191-
4395410 4.9801
hsa-miR-1285-
002822 17.5877
hsa-miR-192-
4373108 185.8343
hsa-miR-1286-
002773 17.5877
hsa-miR-193a-3p-
4395361 2.7188
hsa-miR-1288-
002832 17.5877
hsa-miR-193a-5p-
4395392 15.4677
hsa-miR-1289-
002871 17.5877
hsa-miR-193b-
4395478 7.3966
hsa-miR-129#-
002298 17.5877
hsa-miR-194-
4373106 121.7636
hsa-miR-1290-
002863 17.5877
hsa-miR-195-
4373105 0.7559
hsa-miR-1291-
002838 17.5877
hsa-miR-196b-
4395326 23.5205
hsa-miR-1292-
002824 17.5877
hsa-miR-197-
4373102 15.1103
hsa-miR-1293-
002905 17.5877
hsa-miR-198-
4395384 247.8456
hsa-miR-1294-
002785 17.5877
hsa-miR-199a-3p-
4395415 4.3626
hsa-miR-1296-
002908 17.5877
hsa-miR-199a-5p-
4373272 46.254
hsa-miR-1298-
002861 17.5877
hsa-miR-199b-
5p-4373100 19.5191
hsa-miR-1300-
002902 17.5877
hsa-miR-19a-
4373099 7.2889
hsa-miR-1301-
002827 17.5877
hsa-miR-19b-
4373098 8.1775
hsa-miR-1302-
002901 17.5877
hsa-miR-200a-
4378069 23.5205
hsa-miR-1303-
002792 17.5877
hsa-miR-200b-
4395362 14.1055
hsa-miR-1304-
002874 17.5877
hsa-miR-200c-
4395411 206.7585
hsa-miR-1305-
002867 17.5877
hsa-miR-202-
4395474 148.5199
hsa-miR-130a#-
002131 17.5877
hsa-miR-203-
4373095 13.9715
hsa-miR-130b#-
002114 17.5877
hsa-miR-204-
4373094 1.44
hsa-miR-132#-
002132 17.5877
hsa-miR-205-
4373093 23.5205
hsa-miR-1324-
002815 17.5877
hsa-miR-208-
4373091 23.5205
hsa-miR-135b#-
002159 17.5877
hsa-miR-208b-
4395401 23.5205
hsa-miR-136#-
002100 17.5877
hsa-miR-20a-
4373286 5.418
hsa-miR-138-2#-
002144 17.5877
hsa-miR-20b-
4373263 8.4131
hsa-miR-141#-
002145 17.5877
hsa-miR-210-
4373089 6.3306
hsa-miR-143#-
002146 17.5877
hsa-miR-211-
4373088 23.5205
hsa-miR-144#-
002148 17.5877
hsa-miR-212-
4373087 5.4215
hsa-miR-144-
002676 17.5877
hsa-miR-21-
4373090 14.67
hsa-miR-145#-
002149 17.5877
hsa-miR-214-
4395417 12.8408
hsa-miR-146a#-
002163 17.5877
hsa-miR-215-
4373084 23.5205
hsa-miR-148a#-
002134 17.5877
hsa-miR-216a-
4395331 23.5205
hsa-miR-148b#-
002160 17.5877
hsa-miR-216b-
4395437 23.5205
hsa-miR-149#-
002164 17.5877
hsa-miR-217-
4395448 23.5205
hsa-miR-151-3p-
002254 17.5877
hsa-miR-218-
4373081 2.2986
hsa-miR-151-5P-
002642 17.5877
hsa-miR-219-1-
3p-4395206 23.5205
hsa-miR-154#-
000478 17.5877
hsa-miR-219-2-
3p-4395501 23.5205
hsa-miR-155#-
002287 17.5877
hsa-miR-219-5p-
4373080 23.5205
hsa-miR-15a#-
002419 17.5877
hsa-miR-220-
4373078 23.5205
hsa-miR-15b#-
002173 17.5877
hsa-miR-220b-
4395317 23.5205
hsa-miR-16-1#-
002420 17.5877
hsa-miR-220c-
4395322 23.5205
hsa-miR-16-2#-
002171 17.5877
hsa-miR-221-
4373077 6.8815
hsa-miR-17#-
002421 17.5877
hsa-miR-222-
4395387 4.8118
hsa-miR-181a-2#-
002317 17.5877
hsa-miR-223-
4395406 1.0642
hsa-miR-181c#-
002333 17.5877
hsa-miR-22-
4373079 4.6465
hsa-miR-182#-
000483 17.5877
hsa-miR-224-
4395210 8.7645
hsa-miR-1825-
002907 17.5877
hsa-miR-23a-
4373074 18.9632
hsa-miR-1826-
002873 17.5877
hsa-miR-23b-
4373073 5.5586
hsa-miR-183#-
002270 17.5877
hsa-miR-24-
4373072 4.0199
hsa-miR-185#-
002104 17.5877
hsa-miR-25-
4373071 15.2134
hsa-miR-186#-
002105 17.5877
hsa-miR-26a-
4395166 3.1261
hsa-miR-18a#-
002423 17.5877
hsa-miR-26b-
4395167 3.0542
hsa-miR-18b#-
002310 17.5877
hsa-miR-27a-
4373287 12.2575
hsa-miR-190b-
002263 17.5877
hsa-miR-27b-
4373068 16.2697
hsa-miR-191#-
002678 17.5877
hsa-miR-28-3p-
4395557 5.4701
hsa-miR-192#-
002272 17.5877
hsa-miR-28-5p-
4373067 9.3106
hsa-miR-193b#-
002366 17.5877
hsa-miR-296-3p-
4395212 23.5205
hsa-miR-194#-
002379 17.5877
hsa-miR-296-5p-
4373066 6.238
hsa-miR-195#-
002107 17.5877
hsa-miR-298-
4395301 23.5205
hsa-miR-196a#-
002336 17.5877
hsa-miR-299-3p-
4373189 68.7081
hsa-miR-19a#-
002424 17.5877
hsa-miR-299-5p-
4373188 23.5205
hsa-miR-19b-1#-
002425 17.5877
hsa-miR-29a-
4395223 4.1143
hsa-miR-200a#-
001011 17.5877
hsa-miR-29b-
4373288 7.5818
hsa-miR-200b#-
002274 17.5877
hsa-miR-29c-
4395171 24.8781
hsa-miR-200c#-
002286 17.5877
hsa-miR-301a-
4373064 9.8173
hsa-miR-202#-
002362 17.5877
hsa-miR-301b-
4395503 8.7546
hsa-miR-206-
000510 17.5877
hsa-miR-302a-
4378070 38.7632
hsa-miR-20a#-
002437 17.5877
hsa-miR-302b-
4378071 23.5205
hsa-miR-20b#-
002311 17.5877
hsa-miR-302c-
4378072 35.131
hsa-miR-21#-
002438 17.5877
hsa-miR-30b-
4373290 1.9462
hsa-miR-213-
000516 17.5877
hsa-miR-30c-
4373060 1.624
hsa-miR-214#-
002293 17.5877
hsa-miR-31-
4395390 6.3657
hsa-miR-218-1#-
002094 17.5877
hsa-miR-320-
4395388 9.0689
hsa-miR-218-2#-
002294 17.5877
hsa-miR-323-3p-
4395338 1.6552
hsa-miR-22#-
002301 17.5877
hsa-miR-32-
4395220 11.4333
hsa-miR-221#-
002096 17.5877
hsa-miR-324-3p-
4395272 16.3936
hsa-miR-222#-
002097 17.5877
hsa-miR-324-5p-
4373052 28.1596
hsa-miR-223#-
002098 17.5877
hsa-miR-325-
4373051 23.5205
hsa-miR-23a#-
002439 17.5877
hsa-miR-326-
4373050 23.5205
hsa-miR-23b#-
002126 17.5877
hsa-miR-328-
4373049 4.0228
hsa-miR-24-1#-
002440 17.5877
hsa-miR-329-
4373191 23.5205
hsa-miR-24-2#-
002441 17.5877
hsa-miR-330-3p-
4373047 46.239
hsa-miR-25#-
002442 17.5877
hsa-miR-330-5p-
4395341 36.2309
hsa-miR-26a-1#-
002443 17.5877
hsa-miR-331-3p-
4373046 0.3498
hsa-miR-26a-2#-
002115 17.5877
hsa-miR-331-5p-
4395344 23.5205
hsa-miR-26b#-
002444 17.5877
hsa-miR-335-
4373045 7.634
hsa-miR-27a#-
002445 17.5877
hsa-miR-337-5p-
4395267 5.467
hsa-miR-27b#-
002174 17.5877
hsa-miR-338-3p-
4395363 23.5205
hsa-miR-29a#-
002447 17.5877
hsa-miR-339-3p-
4395295 16.8844
hsa-miR-29b-1#-
002165 17.5877
hsa-miR-339-5p-
4395368 17.9011
hsa-miR-29b-2#-
002166 17.5877
hsa-miR-33b-
4395196 0.0394
hsa-miR-302a#-
002381 17.5877
hsa-miR-340-
4395369 19.3061
hsa-miR-302b#-
002119 17.5877
hsa-miR-342-3p-
4395371 0.1507
hsa-miR-302c#-
000534 17.5877
hsa-miR-342-5p-
4395258 23.5205
hsa-miR-302d#-
002120 17.5877
hsa-miR-345-
4395297 5.256
hsa-miR-302d-
000535 17.5877
hsa-miR-346-
4373038 23.5205
hsa-miR-30a-3p-
000416 17.5877
hsa-miR-34a-
4395168 11.4531
hsa-miR-30a-5p-
000417 17.5877
hsa-miR-34c-5p-
4373036 7.9793
hsa-miR-30b#-
002129 17.5877
hsa-miR-361-5p-
4373035 47.7995
hsa-miR-30c-1#-
002108 17.5877
hsa-miR-362-3p-
4395228 23.5205
hsa-miR-30c-2#-
002110 17.5877
hsa-miR-362-5p-
4378092 4.1255
hsa-miR-30d#-
002305 17.5877
hsa-miR-363-
4378090 61.2089
hsa-miR-30d-
000420 17.5877
hsa-miR-365-
4373194 2.508
hsa-miR-30e-3p-
000422 17.5877
hsa-miR-367-
4373034 562.7276
hsa-miR-31#-
002113 17.5877
hsa-miR-369-3p-
4373032 23.5205
hsa-miR-32#-
002111 17.5877
hsa-miR-369-5p-
4373195 23.5205
hsa-miR-320B-
002844 17.5877
hsa-miR-370-
4395386 10.0491
hsa-miR-335#-
002185 17.5877
hsa-miR-371-3p-
4395235 23.5205
hsa-miR-337-3p-
002157 17.5877
hsa-miR-372-
4373029 93.103
hsa-miR-338-5P-
002658 17.5877
hsa-miR-373-
4378073 23.5205
hsa-miR-33a#-
002136 17.5877
hsa-miR-374a-
4373028 3.0311
hsa-miR-33a-
002135 17.5877
hsa-miR-374b-
4381045 0.1215
hsa-miR-340#-
002259 17.5877
hsa-miR-375-
4373027 23.5205
hsa-miR-34a#-
002316 17.5877
hsa-miR-376a-
4373026 11.2752
hsa-miR-34b-
000427 17.5877
hsa-miR-376b-
4373196 6.9329
hsa-miR-34b-
002102 17.5877
hsa-miR-376c-
4395233 4.78
hsa-miR-361-3p-
002116 17.5877
hsa-miR-377-
4373025 20.4803
hsa-miR-363#-
001283 17.5877
hsa-miR-379-
4373349 8.0854
hsa-miR-367#-
002121 17.5877
hsa-miR-380-
4373022 23.5205
hsa-miR-374a#-
002125 17.5877
hsa-miR-381-
4373020 169.2748
hsa-miR-374b#-
002391 17.5877
hsa-miR-382-
4373019 7.8411
hsa-miR-376a#-
002127 17.5877
hsa-miR-383-
4373018 1.2196
hsa-miR-377#-
002128 17.5877
hsa-miR-384-
4373017 23.5205
hsa-miR-378-
000567 17.5877
hsa-miR-409-5p-
4395442 44.4965
hsa-miR-378-
002243 17.5877
hsa-miR-410-
4378093 5.0206
hsa-miR-380-5p-
000570 17.5877
hsa-miR-411-
4381013 5.3804
hsa-miR-409-3p-
002332 17.5877
hsa-miR-412-
4373199 23.5205
hsa-miR-411#-
002238 17.5877
hsa-miR-422a-
4395408 102.4424
hsa-miR-424#-
002309 17.5877
hsa-miR-423-5p-
4395451 24.8356
hsa-miR-425#-
002302 17.5877
hsa-miR-424-5p-
4373201 158.4425
hsa-miR-431#-
002312 17.5877
hsa-miR-425-
4380926 7.0499
hsa-miR-432#-
001027 17.5877
hsa-miR-429-
4373203 23.5205
hsa-miR-432-
001026 17.5877
hsa-miR-431-
4395173 23.5205
hsa-miR-452#-
002330 17.5877
hsa-miR-433-
4373205 8.0084
hsa-miR-454#-
001996 17.5877
hsa-miR-448-
4373206 23.5205
hsa-miR-483-3p-
002339 17.5877
hsa-miR-449a-
4373207 23.5205
hsa-miR-488-
001106 17.5877
hsa-miR-449b-
4381011 23.5205
hsa-miR-497#-
002368 17.5877
hsa-miR-450a-
4395414 9.6866
hsa-miR-497-
001043 17.5877
hsa-miR-450b-
3p-4395319 1.2294
hsa-miR-500-
001046 17.5877
hsa-miR-450b-
5p-4395318 23.5205
hsa-miR-505#-
002087 17.5877
hsa-miR-451-
4373360 23.5205
hsa-miR-513B-
002757 17.5877
hsa-miR-452-
4395440 30.3581
hsa-miR-513C-
002756 17.5877
hsa-miR-453-
4395429 23.5205
hsa-miR-516-3p-
001149 17.5877
hsa-miR-454-
4395434 5.5653
hsa-miR-517#-
001113 17.5877
hsa-miR-455-3p-
4395355 4.1149
hsa-miR-518c#-
001158 17.5877
hsa-miR-455-5p-
4378098 14.5077
hsa-miR-518e#-
002371 17.5877
hsa-miR-483-5p-
4395449 36.766
hsa-miR-518f#-
002387 17.5877
hsa-miR-484-
4381032 6.2973
hsa-miR-519b-3p-
002384 17.5877
hsa-miR-485-3p-
4378095 7.0485
hsa-miR-519e#-
001166 17.5877
hsa-miR-485-5p-
4373212 23.5205
hsa-miR-520c-3p-
002400 17.5877
hsa-miR-486-3p-
4395204 4.6161
hsa-miR-520D-3P-
002743 17.5877
hsa-miR-486-5p-
4378096 17.4468
hsa-miR-520h-
001170 17.5877
hsa-miR-487a-
4378097 46.6
hsa-miR-524-
001173 17.5877
hsa-miR-487b-
4378102 5.687
hsa-miR-541#-
002200 17.5877
hsa-miR-488-
4395468 23.5205
hsa-miR-543-
002376 17.5877
hsa-miR-489-
4395469 500.201
hsa-miR-545#-
002266 17.5877
hsa-miR-490-3p-
4373215 1.8807
hsa-miR-548E-
002881 17.5877
hsa-miR-491-3p-
4395471 23.5205
hsa-miR-548G-
002879 17.5877
hsa-miR-491-5p-
4381053 5.0725
hsa-miR-548H-
002816 17.5877
hsa-miR-492-
4373217 23.5205
hsa-miR-548I-
002909 17.5877
hsa-miR-493-
4395475 10.7538
hsa-miR-548J-
002783 17.5877
hsa-miR-494-
4395476 38.4501
hsa-miR-548K-
002819 17.5877
hsa-miR-495-
4381078 3.4779
hsa-miR-548L-
002904 17.5877
hsa-miR-496-
4386771 23.5205
hsa-miR-548M-
002775 17.5877
hsa-miR-499-3p-
4395538 23.5205
hsa-miR-548N-
002888 17.5877
hsa-miR-499-5p-
4381047 23.5205
hsa-miR-548P-
002798 17.5877
hsa-miR-500-
4395539 11.233
hsa-miR-549-
001511 17.5877
hsa-miR-501-3p-
4395546 23.5205
hsa-miR-550-
001544 17.5877
hsa-miR-501-5p-
4373226 23.5205
hsa-miR-550-
002410 17.5877
hsa-miR-502-3p-
4395194 23.5205
hsa-miR-551a-
001519 17.5877
hsa-miR-502-5p-
4373227 23.5205
hsa-miR-551b#-
002346 17.5877
hsa-miR-503-
4373228 1.4747
hsa-miR-552-
001520 17.5877
hsa-miR-504-
4395195 23.5205
hsa-miR-553-
001521 17.5877
hsa-miR-505-
4395200 11.5745
hsa-miR-554-
001522 17.5877
hsa-miR-506-
4373231 23.5205
hsa-miR-555-
001523 17.5877
hsa-miR-507-
4373232 23.5205
hsa-miR-557-
001525 17.5877
hsa-miR-508-3p-
4373233 23.5205
hsa-miR-558-
001526 17.5877
hsa-miR-508-5p-
4395203 23.5205
hsa-miR-559-
001527 17.5877
hsa-miR-509-3-
5p-4395266 23.5205
hsa-miR-562-
001529 17.5877
hsa-miR-509-5p-
4395346 270.9502
hsa-miR-563-
001530 17.5877
hsa-miR-510-
4395352 23.5205
hsa-miR-564-
001531 17.5877
hsa-miR-511-
4373236 23.5205
hsa-miR-566-
001533 17.5877
hsa-miR-512-3p-
4381034 23.5205
hsa-miR-567-
001534 17.5877
hsa-miR-512-5p-
4373238 23.5205
hsa-miR-569-
001536 17.5877
hsa-miR-513-5p-
4395201 23.5205
hsa-miR-571-
001613 17.5877
hsa-miR-515-3p-
4395480 23.5205
hsa-miR-572-
001614 17.5877
hsa-miR-515-5p-
4373242 23.5205
hsa-miR-573-
001615 17.5877
hsa-miR-516a-5p-
4395527 23.5205
hsa-miR-575-
001617 17.5877
hsa-miR-516b-
4395172 23.5205
hsa-miR-577-
002675 17.5877
hsa-miR-517a-
4395513 23.5205
hsa-miR-578-
001619 17.5877
hsa-miR-517b-
4373244 23.5205
hsa-miR-580-
001621 17.5877
hsa-miR-517c-
4373264 3.5539
hsa-miR-581-
001622 17.5877
hsa-miR-518a-3p-
4395508 23.5205
hsa-miR-583-
001623 17.5877
hsa-miR-518a-5p-
4395507 23.5205
hsa-miR-584-
001624 17.5877
hsa-miR-518b-
4373246 65.5054
hsa-miR-585-
001625 17.5877
hsa-miR-518c-
4395512 23.5205
hsa-miR-586-
001539 17.5877
hsa-miR-518d-
3p-4373248 47.8956
hsa-miR-587-
001540 17.5877
hsa-miR-518d-
5p-4395500 23.5205
hsa-miR-588-
001542 17.5877
hsa-miR-518e-
4395506 23.5205
hsa-miR-589-
001543 17.5877
hsa-miR-518f-
4395499 31.8641
hsa-miR-590-3P-
002677 17.5877
hsa-miR-519a-
4395526 211.2811
hsa-miR-591-
001545 17.5877
hsa-miR-519c-3p-
4373251 23.5205
hsa-miR-592-
001546 17.5877
hsa-miR-519d-
4395514 23.5205
hsa-miR-593-
001547 17.5877
hsa-miR-519e-
4395481 23.5205
hsa-miR-593-
002411 17.5877
hsa-miR-520a-3p-
4373268 35.2142
hsa-miR-595-
001987 17.5877
hsa-miR-520a-5p-
4378085 23.5205
hsa-miR-596-
001550 17.5877
hsa-miR-520b-
4373252 23.5205
hsa-miR-599-
001554 17.5877
hsa-miR-520d-
5p-4395504 23.5205
hsa-miR-600-
001556 17.5877
hsa-miR-520e-
4373255 23.5205
hsa-miR-601-
001558 17.5877
hsa-miR-520f-
4373256 23.5205
hsa-miR-603-
001566 17.5877
hsa-miR-520g-
4373257 23.5205
hsa-miR-604-
001567 17.5877
hsa-miR-521-
4373259 1864.6731
hsa-miR-605-
001568 17.5877
hsa-miR-522-
4395524 23.5205
hsa-miR-606-
001569 17.5877
hsa-miR-523-
4395497 806.6315
hsa-miR-607-
001570 17.5877
hsa-miR-524-5p-
4395174 23.5205
hsa-miR-608-
001571 17.5877
hsa-miR-525-3p-
4395496 23.5205
hsa-miR-609-
001573 17.5877
hsa-miR-525-5p-
4378088 23.5205
hsa-miR-613-
001586 17.5877
hsa-miR-526b-
4395493 23.5205
hsa-miR-614-
001587 17.5877
hsa-miR-532-3p-
4395466 3.4478
hsa-miR-616-
001589 17.5877
hsa-miR-532-5p-
4380928 3.0169
hsa-miR-617-
001591 17.5877
hsa-miR-539-
4378103 1.1272
hsa-miR-620-
002672 17.5877
hsa-miR-541-
4395312 23.5205
hsa-miR-621-
001598 17.5877
hsa-miR-542-3p-
4378101 307.2191
hsa-miR-622-
001553 17.5877
hsa-miR-542-5p-
4395351 100.6068
hsa-miR-623-
001555 17.5877
hsa-miR-544-
4395376 23.5205
hsa-miR-624-
001557 17.5877
hsa-miR-545-
4395378 23.5205
hsa-miR-625#-
002432 17.5877
hsa-miR-548a-3p-
4380948 14.2504
hsa-miR-626-
001559 17.5877
hsa-miR-548a-5p-
4395523 23.5205
hsa-miR-628-3p-
002434 17.5877
hsa-miR-548b-
3p-4380951 23.5205
hsa-miR-629-
001562 16.9567
hsa-miR-548b-
5p-4395519 23.5205
hsa-miR-630-
001563 16.7116
hsa-miR-548c-3p-
4380993 33.458
hsa-miR-631-
001564 15.6464
hsa-miR-548c-5p-
4395540 23.5205
hsa-miR-633-
001574 15.1656
hsa-miR-548d-
3p-4381008 23.5205
hsa-miR-634-
001576 13.3539
hsa-miR-548d-
5p-4395348 29.4464
hsa-miR-635-
001578 13.1963
hsa-miR-551b-
4380945 23.5205
hsa-miR-637-
001581 13.1451
hsa-miR-556-3p-
4395456 23.5205
hsa-miR-638-
001582 13.0142
hsa-miR-556-5p-
4395455 23.5205
hsa-miR-639-
001583 12.9851
hsa-miR-561-
4380938 5.7754
hsa-miR-640-
001584 12.1378
hsa-miR-570-
4395458 23.5205
hsa-miR-641-
001585 12.0803
hsa-miR-574-3p-
4395460 4.3002
hsa-miR-643-
001594 11.3221
hsa-miR-576-3p-
4395462 7.6028
hsa-miR-644-
001596 10.8864
hsa-miR-576-5p-
4395461 23.5205
hsa-miR-645-
001597 10.7479
hsa-miR-579-
4395509 3.8765
hsa-miR-646-
001599 10.4608
hsa-miR-582-3p-
4395510 23.5205
hsa-miR-647-
001600 10.1779
hsa-miR-582-5p-
4395175 23.5205
hsa-miR-648-
001601 9.9725
hsa-miR-589-
4395520 23.5205
hsa-miR-649-
001602 9.8514
hsa-miR-590-5p-
4395176 4.8888
hsa-miR-650-
001603 9.6578
hsa-miR-597-
4380960 8.8643
hsa-miR-656-
001510 9.3012
hsa-miR-598-
4395179 6.9868
hsa-miR-657-
001512 8.9936
hsa-miR-615-3p-
4386777 23.5205
hsa-miR-658-
001513 8.6393
hsa-miR-615-5p-
4395464 23.5205
hsa-miR-659-
001514 8.3493
hsa-miR-616-
4395525 23.5205
hsa-miR-661-
001606 8.2315
hsa-miR-618-
4380996 36.1117
hsa-miR-662-
001607 8.0731
hsa-miR-624-
4395541 23.5205
hsa-miR-663B-
002857 7.9636
hsa-miR-625-
4395542 23.5205
hsa-miR-664-
002897 7.2388
hsa-miR-627-
4380967 23.5205
hsa-miR-665-
002681 6.7298
hsa-miR-628-5p-
4395544 31.848
hsa-miR-668-
001992 6.1211
hsa-miR-629-
4395547 23.5205
hsa-miR-675-
002005 6.0426
hsa-miR-636-
4395199 21.4634
hsa-miR-7-2#-
002314 6.0367
hsa-miR-642-
4380995 1.2197
hsa-miR-708#-
002342 5.9833
hsa-miR-651-
4381007 23.5205
hsa-miR-720-
002895 5.7528
hsa-miR-652-
4395463 23.5205
hsa-miR-744#-
002325 5.5783
hsa-miR-653-
4395403 23.5205
hsa-miR-765-
002643 5.4235
hsa-miR-654-3p-
4395350 23.5205
hsa-miR-766-
001986 5.4105
hsa-miR-654-5p-
4381014 23.5205
hsa-miR-767-3p-
001995 5.4043
hsa-miR-655-
4381015 5.9068
hsa-miR-767-5p-
001993 5.3756
hsa-miR-660-
4380925 6.1259
hsa-miR-769-3p-
002003 5.1785
hsa-miR-671-3p-
4395433 8.4804
hsa-miR-769-5p-
001998 5.0678
hsa-miR-672-
4395438 23.5205
hsa-miR-770-5p-
002002 4.9669
hsa-miR-674-
4395193 23.5205
hsa-miR-802-
002004 4.767
hsa-miR-708-
4395452 45.8284
hsa-miR-875-5p-
002203 4.7057
hsa-miR-744-
4395435 16.7737
hsa-miR-888#-
002213 4.3947
hsa-miR-758-
4395180 6.7678
hsa-miR-892b-
002214 4.2836
hsa-miR-871-
4395465 0.6495
hsa-miR-9#-
002231 4.1696
hsa-miR-872-
4395375 23.5205
hsa-miR-920-
002150 4.0391
hsa-miR-873-
4395467 23.5205
hsa-miR-921-
002151 4.0108
hsa-miR-874-
4395379 23.5205
hsa-miR-922-
002152 3.7473
hsa-miR-875-3p-
4395315 23.5205
hsa-miR-924-
002154 3.6158
hsa-miR-876-3p-
4395336 139.3249
hsa-miR-92a-1#-
002137 3.3763
hsa-miR-876-5p-
4395316 2.1509
hsa-miR-92a-2#-
002138 3.2164
hsa-miR-885-3p-
4395483 23.5205
hsa-miR-92b#-
002343 3.1413
hsa-miR-885-5p-
4395407 13.3061
hsa-miR-93#-
002139 3.0077
hsa-miR-886-3p-
4395305 93.4103
hsa-miR-933-
002176 2.9857
hsa-miR-886-5p-
4395304 119.6733
hsa-miR-934-
002177 2.7396
hsa-miR-887-
4395485 23.5205
hsa-miR-935-
002178 2.6577
hsa-miR-888-
4395323 0.24
hsa-miR-936-
002179 2.5506
hsa-miR-889-
4395313 1.8714
hsa-miR-937-
002180 2.3409
hsa-miR-890-
4395320 23.5205
hsa-miR-938-
002181 2.2432
hsa-miR-891a-
4395302 23.5205
hsa-miR-939-
002182 1.7178
hsa-miR-891b-
4395321 23.5205
hsa-miR-941-
002183 1.6038
hsa-miR-892a-
4395306 23.5205
hsa-miR-942-
002187 1.4808
hsa-miR-92a-
4395169 9.1218
hsa-miR-943-
002188 1.2127
hsa-miR-93-
4373302 7.9923
hsa-miR-944-
002189 1.1105
hsa-miR-9-
4373285 2.8102
hsa-miR-96#-
002140 1.0071
hsa-miR-95-
4373011 23.5205
hsa-miR-99b#-
002196 0.8998
hsa-miR-96-
4373372 23.5205
mmu-let-7d#-
001178 0.7703
hsa-miR-98-
4373009 23.5205
rno-miR-29c#-
001818 0.5758
hsa-miR-99a-
4373008 8.5819
rno-miR-7#-
001338 0.5347
NOF804
miRNA
POOL A POOL B
Fold change relative
to endogenous
control miRNA
Fold change relative
to endogenous
control
ath-miR159a-
000338 0.6997 ath-miR159a-000338 1.6749
hsa-let-7a-
000377 1.5291 dme-miR-7-000268 1.6749
hsa-let-7b-
002619 0.8121 hsa-let-7a#-002307 1.6749
hsa-let-7c-
000379 0.7327 hsa-let-7b#-002404 1.6749
hsa-let-7d-
002283 0.8825 hsa-let-7c#-002405 1.6749
hsa-let-7e-
002406 1.3711 hsa-let-7e#-002407 1.6749
hsa-let-7f-
000382 1.0097 hsa-let-7f-1#-002417 1.6749
hsa-let-7g-
002282 0.7353 hsa-let-7f-2#-002418 1.6749
hsa-miR-100-
000437 1.0874 hsa-let-7g#-002118 1.6749
hsa-miR-1-
002222 0.6997 hsa-let-7i#-002172 1.6749
hsa-miR-101-
002253 2.8332
hsa-miR-100#-
002142 1.6749
hsa-miR-103-
000439 0.5841
hsa-miR-101#-
002143 1.6749
hsa-miR-105-
002167 0.6997
hsa-miR-105#-
002168 1.6749
hsa-miR-106a-
002169 0.7933
hsa-miR-106a#-
002170 1.6749
hsa-miR-106b-
000442 1.118
hsa-miR-106b#-
002380 1.4418
hsa-miR-107-
000443 0.6997
hsa-miR-10a#-
002288 1.6749
hsa-miR-10a-
000387 6.0443
hsa-miR-10b#-
002315 1.6749
hsa-miR-10b-
002218 0.6997
hsa-miR-1179-
002776 1.6749
hsa-miR-122-
002245 0.6997
hsa-miR-1180-
002847 1.7378
hsa-miR-125a- 1.4514 hsa-miR-1182- 1.6749
3p-002199 002830
hsa-miR-125a-
5p-002198 0.4159
hsa-miR-1183-
002841 0.601
hsa-miR-125b-
000449 0.6847
hsa-miR-1184-
002842 1.6749
hsa-miR-126-
002228 0.5668
hsa-miR-1197-
002810 1.6749
hsa-miR-127-
000452 0.4637
hsa-miR-1200-
002829 1.6749
hsa-miR-127-5p-
002229 6.6082
hsa-miR-1201-
002781 1.276
hsa-miR-128a-
002216 0.5219
hsa-miR-1203-
002877 1.6749
hsa-miR-129-
000590 0.6997
hsa-miR-1204-
002872 1.6749
hsa-miR-130a-
000454 0.7438
hsa-miR-1205-
002778 1.6749
hsa-miR-130b-
000456 0.3083
hsa-miR-1206-
002878 1.6749
hsa-miR-132-
000457 0.5206
hsa-miR-1208-
002880 1.5875
hsa-miR-133a-
002246 0.8089
hsa-miR-122#-
002130 1.6749
hsa-miR-133b-
002247 0.6997
hsa-miR-1224-3P-
002752 1.6749
hsa-miR-135a-
000460 0.6997
hsa-miR-1225-3P-
002766 1.6749
hsa-miR-135b-
002261 1.3636
hsa-miR-1226#-
002758 1.6749
hsa-miR-136-
000592 0.6997
hsa-miR-1227-
002769 1.6749
hsa-miR-138-
002284 0.5721
hsa-miR-1228#-
002763 1.6749
hsa-miR-139-3p-
002313 0.6997
hsa-miR-1233-
002768 0.7897
hsa-miR-139-5p-
002289 0.6025
hsa-miR-1236-
002761 1.6749
hsa-miR-140-3p-
002234 0.6721
hsa-miR-1238-
002927 1.6749
hsa-miR-141-
000463 0.6997
hsa-miR-124#-
002197 1.6749
hsa-miR-142-3p-
000464 0.6997
hsa-miR-1243-
002854 0.0233
hsa-miR-142-5p-
002248 0.6835
hsa-miR-1244-
002791 1.6749
hsa-miR-143-
002249 0.5008
hsa-miR-1245-
002823 1.6749
hsa-miR-145-
002278 0.8488
hsa-miR-1247-
002893 0.6303
hsa-miR-146a-
000468 0.2853
hsa-miR-1248-
002870 1.6749
hsa-miR-146b-
001097 0.2396
hsa-miR-1249-
002868 3.0697
hsa-miR-146b-
3p-002361 1.0784
hsa-miR-1250-
002887 1.6749
hsa-miR-147-
000469 0.6997
hsa-miR-1251-
002820 1.6749
hsa-miR-147b-
002262 0.6997
hsa-miR-1252-
002860 0.8318
hsa-miR-148a-
000470 2.3594
hsa-miR-1253-
002894 1.6749
hsa-miR-148b-
000471 0.6997
hsa-miR-1254-
002818 2.4443
hsa-miR-149-
002255 0.4322
hsa-miR-1255A-
002805 1.6749
hsa-miR-150-
000473 2.4744
hsa-miR-1255B-
002801 1.4136
hsa-miR-152-
000475 0.6534
hsa-miR-1256-
002850 1.6749
hsa-miR-154-
000477 0.6997
hsa-miR-1257-
002910 1.6749
hsa-miR-155-
002623 0.4708
hsa-miR-1259-
002796 1.6749
hsa-miR-15a-
000389 9.5846
hsa-miR-125b-1#-
002378 3.3217
hsa-miR-15b-
000390 1.3393
hsa-miR-125b-2#-
002158 1.6749
hsa-miR-16-
000391 0.7199
hsa-miR-126#-
000451 0.3467
hsa-miR-17-
002308 0.7947
hsa-miR-1260-
002896 1.8033
hsa-miR-181a-
000480 0.7446
hsa-miR-1262-
002852 0.6785
hsa-miR-181c-
000482 0.6997
hsa-miR-1263-
002784 1.6749
hsa-miR-182-
002334 0.6997
hsa-miR-1264-
002799 1.6749
hsa-miR-183-
002269 0.6997
hsa-miR-1265-
002790 1.6749
hsa-miR-184-
000485 0.1677
hsa-miR-1267-
002885 1.6749
hsa-miR-185-
002271 0.2892
hsa-miR-1269-
002789 1.6749
hsa-miR-186-
002285 0.4078
hsa-miR-1270-
002807 0.4201
hsa-miR-188-3p-
002106 0.0067
hsa-miR-1271-
002779 2.2591
hsa-miR-18a-
002422 0.0875
hsa-miR-1272-
002845 1.6749
hsa-miR-18b-
002217 0.6997
hsa-miR-1274A-
002883 0.7443
hsa-miR-190-
000489 0.6997
hsa-miR-1274B-
002884 2.5995
hsa-miR-191-
002299 0.4024
hsa-miR-1275-
002840 1.77
hsa-miR-192-
000491 0.6997
hsa-miR-1276-
002843 0.9254
hsa-miR-193a-
3p-002250 1.447
hsa-miR-1278-
002851 1.6749
hsa-miR-193a-
5p-002281 0.8241
hsa-miR-1282-
002803 3.6572
hsa-miR-193b-
002367 0.8436
hsa-miR-1283-
002890 1.6749
hsa-miR-194-
000493 2.562
hsa-miR-1284-
002903 1.6749
hsa-miR-195-
000494 0.8325
hsa-miR-1285-
002822 1.8009
hsa-miR-196b-
002215 0.6997
hsa-miR-1286-
002773 1.6749
hsa-miR-197-
000497 0.7679
hsa-miR-1288-
002832 1.6749
hsa-miR-198-
002273 2.4384
hsa-miR-1289-
002871 1.6749
hsa-miR-199a-
000498 0.5757
hsa-miR-129#-
002298 1.6749
hsa-miR-199a-
3p-002304 1.8781
hsa-miR-1290-
002863 0.6104
hsa-miR-199b-
000500 0.6997
hsa-miR-1291-
002838 0.2716
hsa-miR-19a-
000395 0.3332
hsa-miR-1292-
002824 1.6749
hsa-miR-19b-
000396 0.5962
hsa-miR-1293-
002905 1.6749
hsa-miR-200a-
000502 0.6997
hsa-miR-1294-
002785 1.6749
hsa-miR-200b-
002251 0.6997
hsa-miR-1296-
002908 1.6749
hsa-miR-200c-
002300 0.6997
hsa-miR-1298-
002861 10.1843
hsa-miR-202-
002363 3.1571
hsa-miR-1300-
002902 0.5826
hsa-miR-203-
000507 0.6997
hsa-miR-1301-
002827 1.6749
hsa-miR-204-
000508 0.4223
hsa-miR-1302-
002901 1.6749
hsa-miR-205-
000509 0.6997
hsa-miR-1303-
002792 1.6749
hsa-miR-208-
000511 0.6997
hsa-miR-1304-
002874 1.6749
hsa-miR-208b-
002290 0.6997
hsa-miR-1305-
002867 2.0474
hsa-miR-20a-
000580 0.9346
hsa-miR-130a#-
002131 1.6749
hsa-miR-20b-
001014 1.504
hsa-miR-130b#-
002114 1.6749
hsa-miR-210-
000512 1.2569
hsa-miR-132#-
002132 1.6749
hsa-miR-21-
000397 2.1622
hsa-miR-1324-
002815 1.6749
hsa-miR-211-
000514 0.6997
hsa-miR-135b#-
002159 1.6749
hsa-miR-212-
000515 0.7791
hsa-miR-136#-
002100 1.062
hsa-miR-214-
002306 0.7622
hsa-miR-138-2#-
002144 1.6749
hsa-miR-215-
000518 0.6997
hsa-miR-141#-
002145 1.6749
hsa-miR-216a-
002220 0.6997
hsa-miR-143#-
002146 1.6749
hsa-miR-216b-
002326 0.6997
hsa-miR-144#-
002148 1.6749
hsa-miR-217-
002337 0.6997 hsa-miR-144-002676 1.6749
hsa-miR-218-
000521 0.5959
hsa-miR-145#-
002149 0.2771
hsa-miR-219-
000522 0.0499
hsa-miR-146a#-
002163 1.6749
hsa-miR-219-1-
3p-002095 0.6997
hsa-miR-148a#-
002134 1.6749
hsa-miR-219-2-
3p-002390 0.6997
hsa-miR-148b#-
002160 1.6749
hsa-miR-220-
000523 0.6997
hsa-miR-149#-
002164 0.499
hsa-miR-22-
000398 0.6997
hsa-miR-151-3p-
002254 1.7156
hsa-miR-220b-
002206 0.6997
hsa-miR-151-5P-
002642 1.066
hsa-miR-220c-
002211 0.6997
hsa-miR-154#-
000478 1.6749
hsa-miR-221-
000524 0.4726
hsa-miR-155#-
002287 1.6749
hsa-miR-222-
002276 0.5334
hsa-miR-15a#-
002419 1.6749
hsa-miR-223-
002295 0.6997
hsa-miR-15b#-
002173 1.6749
hsa-miR-224-
002099 0.8512
hsa-miR-16-1#-
002420 1.6749
hsa-miR-23a-
000399 0.6997
hsa-miR-16-2#-
002171 1.6749
hsa-miR-23b-
000400 0.6264 hsa-miR-17#-002421 1.6749
hsa-miR-24-
000402 0.7368
hsa-miR-181a-2#-
002317 2.8195
hsa-miR-25-
000403 0.5669
hsa-miR-181c#-
002333 1.6749
hsa-miR-26a-
000405 0.5968
hsa-miR-182#-
000483 1.6749
hsa-miR-26b-
000407 0.6235
hsa-miR-1825-
002907 11.2466
hsa-miR-27a-
000408 0.9981
hsa-miR-1826-
002873 0
hsa-miR-27b-
000409 1.0066
hsa-miR-183#-
002270 1.6749
hsa-miR-28-
000411 0.591
hsa-miR-185#-
002104 1.6749
hsa-miR-28-3p-
002446 0.7206
hsa-miR-186#-
002105 1.6749
hsa-miR-296-
000527 0.8984
hsa-miR-18a#-
002423 2.117
hsa-miR-296-3p-
002101 1.5573
hsa-miR-18b#-
002310 1.6749
hsa-miR-298-
002190 0.6997
hsa-miR-190b-
002263 0.2706
hsa-miR-299-3p-
001015 0.6997
hsa-miR-191#-
002678 1.1866
hsa-miR-299-5p-
000600 0.6997
hsa-miR-192#-
002272 2.2811
hsa-miR-29a-
002112 0.5384
hsa-miR-193b#-
002366 4.6207
hsa-miR-29b-
000413 0.1487
hsa-miR-194#-
002379 1.6749
hsa-miR-29c-
000587 0.4146
hsa-miR-195#-
002107 1.6749
hsa-miR-301-
000528 3.7665
hsa-miR-196a#-
002336 1.6749
hsa-miR-301b-
002392 0.6997
hsa-miR-19a#-
002424 1.6749
hsa-miR-302a-
000529 3.3068
hsa-miR-19b-1#-
002425 6.1045
hsa-miR-302b-
000531 0.6997
hsa-miR-200a#-
001011 1.6749
hsa-miR-302c-
000533 0.6997
hsa-miR-200b#-
002274 1.6749
hsa-miR-30b-
000602 0.7406
hsa-miR-200c#-
002286 1.6749
hsa-miR-30c-
000419 1.5614
hsa-miR-202#-
002362 1.6749
hsa-miR-31-
002279 0.7296 hsa-miR-206-000510 3.123
hsa-miR-320-
002277 0.6453
hsa-miR-20a#-
002437 1.6749
hsa-miR-32-
002109 0.6997
hsa-miR-20b#-
002311 1.6749
hsa-miR-323-3p-
002227 0.2792 hsa-miR-21#-002438 1.6749
hsa-miR-324-3p-
002161 0.7198 hsa-miR-213-000516 1.6749
hsa-miR-324-5p-
000539 0.6015
hsa-miR-214#-
002293 1.497
hsa-miR-325-
000540 0.6997
hsa-miR-218-1#-
002094 1.6749
hsa-miR-326-
000542 0.6997
hsa-miR-218-2#-
002294 1.6749
hsa-miR-328-
000543 0.7301 hsa-miR-22#-002301 1.4548
hsa-miR-329-
001101 0.6997
hsa-miR-221#-
002096 1.6749
hsa-miR-330-
000544 0.9414
hsa-miR-222#-
002097 1.6749
hsa-miR-330-5p-
002230 0.6997
hsa-miR-223#-
002098 1.6749
hsa-miR-331-
000545 1.7596
hsa-miR-23a#-
002439 1.6749
hsa-miR-331-5p-
002233 0.6997
hsa-miR-23b#-
002126 1.6749
hsa-miR-335-
000546 0.6997
hsa-miR-24-1#-
002440 1.6749
hsa-miR-337-5p-
002156 0.5613
hsa-miR-24-2#-
002441 1.6749
hsa-miR-338-3p-
002252 0.6997 hsa-miR-25#-002442 0.5825
hsa-miR-339-3p-
002184 0.5215
hsa-miR-26a-1#-
002443 1.6749
hsa-miR-339-5p-
002257 0.6568
hsa-miR-26a-2#-
002115 1.6749
hsa-miR-33b-
002085 0.6997
hsa-miR-26b#-
002444 1.2274
hsa-miR-340-
002258 0.6997
hsa-miR-27a#-
002445 3.3541
hsa-miR-342-3p-
002260 0.5818
hsa-miR-27b#-
002174 2.5356
hsa-miR-342-5p-
002147 0.6997
hsa-miR-29a#-
002447 1.6749
hsa-miR-345-
002186 0.3677
hsa-miR-29b-1#-
002165 1.6749
hsa-miR-346-
000553 0.6997
hsa-miR-29b-2#-
002166 1.6749
hsa-miR-34a-
000426 0.9894
hsa-miR-302a#-
002381 1.6749
hsa-miR-34c-
000428 0.2774
hsa-miR-302b#-
002119 1.6749
hsa-miR-361-
000554 2.5859
hsa-miR-302c#-
000534 1.6749
hsa-miR-362-
001273 1.5385
hsa-miR-302d#-
002120 1.6749
hsa-miR-362-3p-
002117 0.6997
hsa-miR-302d-
000535 1.6749
hsa-miR-363-
001271 0.8406
hsa-miR-30a-3p-
000416 1.0249
hsa-miR-365-
001020 0.7871
hsa-miR-30a-5p-
000417 1.7889
hsa-miR-367-
000555 0.6997
hsa-miR-30b#-
002129 1.6749
hsa-miR-369-3p-
000557 11.3433
hsa-miR-30c-1#-
002108 1.6749
hsa-miR-369-5p-
001021 0.6997
hsa-miR-30c-2#-
002110 1.6749
hsa-miR-370-
002275 0.1519
hsa-miR-30d#-
002305 1.6749
hsa-miR-371-3p-
002124 0.6997 hsa-miR-30d-000420 2.115
hsa-miR-372-
000560 0.6997
hsa-miR-30e-3p-
000422 0.5474
hsa-miR-373-
000561 0.6997 hsa-miR-31#-002113 2.5438
hsa-miR-374-
000563 0.2971 hsa-miR-32#-002111 1.6749
hsa-miR-375-
000564 0.6997
hsa-miR-320B-
002844 2.1975
hsa-miR-376a-
000565 0.7629
hsa-miR-335#-
002185 1.6749
hsa-miR-376b-
001102 0.6997
hsa-miR-337-3p-
002157 1.6749
hsa-miR-376c-
002122 0.8157
hsa-miR-338-5P-
002658 1.747
hsa-miR-377-
000566 0.6997
hsa-miR-33a#-
002136 1.6749
hsa-miR-380-3p-
000569 0.6997 hsa-miR-33a-002135 1.6749
hsa-miR-381-
000571 0.3631
hsa-miR-340#-
002259 0.5812
hsa-miR-382-
000572 0.9969
hsa-miR-34a#-
002316 0.575
hsa-miR-383-
000573 0.6997 hsa-miR-34b-000427 1.6749
hsa-miR-384-
000574 0.6997 hsa-miR-34b-002102 0.9085
hsa-miR-409-5p-
002331 0.6997
hsa-miR-361-3p-
002116 1.6749
hsa-miR-410-
001274 0.5501
hsa-miR-363#-
001283 1.6749
hsa-miR-411-
001610 0.1462
hsa-miR-367#-
002121 1.6749
hsa-miR-412-
001023 0.6997
hsa-miR-374a#-
002125 1.6749
hsa-miR-422a-
002297 0.6997
hsa-miR-374b#-
002391 1.6749
hsa-miR-423-5p-
002340 0.3625
hsa-miR-376a#-
002127 1.6749
hsa-miR-424-5p-
000604 2.2683
hsa-miR-377#-
002128 1.6964
hsa-miR-425-5p-
001516 0.8478 hsa-miR-378-000567 1.6749
hsa-miR-429-
001024 0.6997 hsa-miR-378-002243 4.0845
hsa-miR-431-
001979 0.6997
hsa-miR-380-5p-
000570 1.6749
hsa-miR-433-
001028 0.5603
hsa-miR-409-3p-
002332 0.8199
hsa-miR-448-
001029 0.6997
hsa-miR-411#-
002238 1.6749
hsa-miR-449-
001030 1.9075
hsa-miR-424#-
002309 77.692
hsa-miR-449b-
001608 0.6997
hsa-miR-425#-
002302 1.1146
hsa-miR-450a-
002303 8.2843
hsa-miR-431#-
002312 1.6749
hsa-miR-450b-
3p-002208 0.6997
hsa-miR-432#-
001027 0.2326
hsa-miR-450b-
5p-002207 0.6997 hsa-miR-432-001026 1.1377
hsa-miR-452-
002329 0.7628
hsa-miR-452#-
002330 1.6749
hsa-miR-453-
002318 0.6997
hsa-miR-454#-
001996 1.6749
hsa-miR-454-
002323 0.5841
hsa-miR-483-3p-
002339 1.0858
hsa-miR-455-
001280 0.5855 hsa-miR-488-001106 1.6749
hsa-miR-455-3p-
002244 0.956
hsa-miR-497#-
002368 1.6749
hsa-miR-483-5p-
002338 0.5919 hsa-miR-497-001043 1.6749
hsa-miR-484-
001821 0.613 hsa-miR-500-001046 0.5512
hsa-miR-485-3p-
001277 0.7478
hsa-miR-505#-
002087 2.4169
hsa-miR-485-5p-
001036 0.2511
hsa-miR-513B-
002757 1.6749
hsa-miR-486-
001278 0.7229
hsa-miR-513C-
002756 1.6749
hsa-miR-486-3p-
002093 0.6997
hsa-miR-516-3p-
001149 0.5444
hsa-miR-487a-
001279 0.6997
hsa-miR-517#-
001113 1.6749
hsa-miR-487b-
001285 0.6337
hsa-miR-518c#-
001158 1.6749
hsa-miR-488-
002357 0.6997
hsa-miR-518e#-
002371 1.6749
hsa-miR-489-
002358 0.6997
hsa-miR-518f#-
002387 1.6749
hsa-miR-490-
001037 0.1556
hsa-miR-519b-3p-
002384 1.6749
hsa-miR-491-3p-
002360 0.6997
hsa-miR-519e#-
001166 1.6749
hsa-miR-492-
001039 0.6997
hsa-miR-520c-3p-
002400 0.7957
hsa-miR-493-
002364 0.6001
hsa-miR-520D-3P-
002743 1.4857
hsa-miR-494-
002365 0.6051
hsa-miR-520h-
001170 1.6749
hsa-miR-499-3p-
002427 0.6997 hsa-miR-524-001173 1.6749
hsa-miR-500-
002428 0.0883
hsa-miR-541#-
002200 1.6749
hsa-miR-501-
001047 10.8236 hsa-miR-543-002376 1.2367
hsa-miR-501-3p-
002435 0.6997
hsa-miR-545#-
002266 1.6749
hsa-miR-502-
001109 0.6997
hsa-miR-548E-
002881 1.6749
hsa-miR-502-3p-
002083 0.6997
hsa-miR-548G-
002879 1.6749
hsa-miR-503-
001048 10.2227
hsa-miR-548H-
002816 1.6749
hsa-miR-504-
002084 0.6997
hsa-miR-548I-
002909 1.6749
hsa-miR-505-
002089 0.6997
hsa-miR-548J-
002783 1.6749
hsa-miR-506-
001050 0.6997
hsa-miR-548K-
002819 1.6749
hsa-miR-507-
001051 0.6997
hsa-miR-548L-
002904 1.6749
hsa-miR-508-
001052 0.6997
hsa-miR-548M-
002775 1.6749
hsa-miR-508-5p-
002092 0.6997
hsa-miR-548N-
002888 1.6749
hsa-miR-509-3-
5p-002155 0.6997
hsa-miR-548P-
002798 1.6749
hsa-miR-509-5p-
002235 0.6997 hsa-miR-549-001511 1.6749
hsa-miR-510-
002241 0.6997 hsa-miR-550-001544 1.6749
hsa-miR-511-
001111 0.6997 hsa-miR-550-002410 1.3621
hsa-miR-512-3p-
001823 0.6997
hsa-miR-551a-
001519 1.6749
hsa-miR-512-5p-
001145 0.6997
hsa-miR-551b#-
002346 1.6749
hsa-miR-513-5p-
002090 0.6997 hsa-miR-552-001520 1.6749
hsa-miR-515-3p-
002369 0.6997 hsa-miR-553-001521 1.6749
hsa-miR-515-5p-
001112 0.6997 hsa-miR-554-001522 1.6749
hsa-miR-516a-
5p-002416 0.6997 hsa-miR-555-001523 1.6749
hsa-miR-516b-
001150 0.6997 hsa-miR-557-001525 1.6749
hsa-miR-517a-
002402 13.928 hsa-miR-558-001526 1.6749
hsa-miR-517b-
001152 1.1642 hsa-miR-559-001527 1.6749
hsa-miR-517c-
001153 0.6997 hsa-miR-562-001529 1.6749
hsa-miR-518a-
3p-002397 0.6997 hsa-miR-563-001530 1.6749
hsa-miR-518a-
5p-002396 0.6997 hsa-miR-564-001531 0.5713
hsa-miR-518b-
001156 0.6997 hsa-miR-566-001533 1.6749
hsa-miR-518c-
002401 0.6997 hsa-miR-567-001534 1.6749
hsa-miR-518d-
001159 1.3102 hsa-miR-569-001536 1.6749
hsa-miR-518d-
5p-002389 0.6997 hsa-miR-571-001613 0.1488
hsa-miR-518e-
002395 0.6997 hsa-miR-572-001614 1.6749
hsa-miR-518f-
002388 0.6997 hsa-miR-573-001615 0.354
hsa-miR-519a-
002415 1.7681 hsa-miR-575-001617 1.6749
hsa-miR-519c-
001163 0.6997 hsa-miR-577-002675 1.6749
hsa-miR-519d-
002403 0.6997 hsa-miR-578-001619 1.6749
hsa-miR-519e-
002370 0.6997 hsa-miR-580-001621 1.6749
hsa-miR-520a#-
001168 0.6997 hsa-miR-581-001622 1.6749
hsa-miR-520a-
001167 0.6997 hsa-miR-583-001623 1.6749
hsa-miR-520b-
001116 0.6997 hsa-miR-584-001624 1.6749
hsa-miR-520d-
5p-002393 0.6997 hsa-miR-585-001625 0.3207
hsa-miR-520e-
001119 0.6997 hsa-miR-586-001539 1.6749
hsa-miR-520f-
001120 0.6997 hsa-miR-587-001540 1.6749
hsa-miR-520g-
001121 1.2846 hsa-miR-588-001542 1.6749
hsa-miR-521-
001122 4.9327 hsa-miR-589-001543 1.6749
hsa-miR-522-
002413 0.6997
hsa-miR-590-3P-
002677 1.6749
hsa-miR-523-
002386 0.1598 hsa-miR-591-001545 0.0322
hsa-miR-524-5p-
001982 0.6997 hsa-miR-592-001546 0.5099
hsa-miR-525-
001174 0.6997 hsa-miR-593-001547 1.6749
hsa-miR-525-3p-
002385 0.6997 hsa-miR-593-002411 1.6749
hsa-miR-526b-
002382 0.6997 hsa-miR-595-001987 1.6749
hsa-miR-532-
001518 0.7981 hsa-miR-596-001550 1.2906
hsa-miR-532-3p-
002355 0.549 hsa-miR-599-001554 1.6749
hsa-miR-539-
001286 1.308 hsa-miR-600-001556 1.6749
hsa-miR-541-
002201 0.6997 hsa-miR-601-001558 2.1635
hsa-miR-542-3p-
001284 0.6997 hsa-miR-603-001566 0.5978
hsa-miR-542-5p-
002240 4.0347 hsa-miR-604-001567 1.6749
hsa-miR-544-
002265 0.6997 hsa-miR-605-001568 1.6749
hsa-miR-545-
002267 0.6997 hsa-miR-606-001569 1.6749
hsa-miR-548a-
001538 0.6997 hsa-miR-607-001570 1.6749
hsa-miR-548a-
5p-002412 0.6997 hsa-miR-608-001571 1.6749
hsa-miR-548b-
001541 0.6997 hsa-miR-609-001573 1.6749
hsa-miR-548b-
5p-002408 0.6997 hsa-miR-613-001586 1.6749
hsa-miR-548c-
001590 0.6997 hsa-miR-614-001587 1.6749
hsa-miR-548c-
5p-002429 0.6997 hsa-miR-616-001589 1.6749
hsa-miR-548d-
001605 0.6997 hsa-miR-617-001591 0.448
hsa-miR-548d-
5p-002237 0.6997 hsa-miR-620-002672 1.6749
hsa-miR-551b-
001535 0.6997 hsa-miR-621-001598 1.6749
hsa-miR-556-3p-
002345 0.6997 hsa-miR-622-001553 1.6749
hsa-miR-556-5p-
002344 0.6997 hsa-miR-623-001555 1.6749
hsa-miR-561-
001528 0.5065 hsa-miR-624-001557 13.9503
hsa-miR-570-
002347 0.6997
hsa-miR-625#-
002432 1.4797
hsa-miR-574-3p-
002349 0.0001 hsa-miR-626-001559 1.6749
hsa-miR-576-3p-
002351 0.1049
hsa-miR-628-3p-
002434 1.6749
hsa-miR-576-5p-
002350 0.6997 hsa-miR-629-001562 2.4453
hsa-miR-579-
002398 0.6997 hsa-miR-630-001563 1.6749
hsa-miR-582-3p-
002399 0.6997 hsa-miR-631-001564 1.6749
hsa-miR-582-5p-
001983 0.6997 hsa-miR-633-001574 1.6749
hsa-miR-589-
002409 0.6997 hsa-miR-634-001576 1.6749
hsa-miR-590-5p-
001984 0.6997 hsa-miR-635-001578 1.6749
hsa-miR-597-
001551 0.2946 hsa-miR-637-001581 1.6749
hsa-miR-598-
001988 1.7128 hsa-miR-638-001582 1.3407
hsa-miR-615-5p-
002353 0.6997 hsa-miR-639-001583 1.6749
hsa-miR-616-
002414 0.2522 hsa-miR-640-001584 1.6749
hsa-miR-618-
001593 0.8567 hsa-miR-641-001585 1.6749
hsa-miR-624-
002430 0.6997 hsa-miR-643-001594 1.6749
hsa-miR-625-
002431 0.9207 hsa-miR-644-001596 1.6749
hsa-miR-627-
001560 0.6997 hsa-miR-645-001597 1.4103
hsa-miR-628-5p-
002433 1.0034 hsa-miR-646-001599 1.6749
hsa-miR-629-
002436 0.8592 hsa-miR-647-001600 1.6749
hsa-miR-636-
002088 0.6997 hsa-miR-648-001601 1.6749
hsa-miR-642-
001592 1.0664 hsa-miR-649-001602 1.6749
hsa-miR-651-
001604 0.6997 hsa-miR-650-001603 1.6749
hsa-miR-652-
002352 22.9203 hsa-miR-656-001510 1.6749
hsa-miR-653-
002292 0.6997 hsa-miR-657-001512 1.6749
hsa-miR-654-
001611 0.808 hsa-miR-658-001513 1.6749
hsa-miR-654-3p-
002239 0.2657 hsa-miR-659-001514 1.6749
hsa-miR-655-
001612 0.6997 hsa-miR-661-001606 1.6749
hsa-miR-660-
001515 0.6997 hsa-miR-662-001607 1.6749
hsa-miR-671-3p-
002322 1.0865
hsa-miR-663B-
002857 1.6749
hsa-miR-672-
002327 0.6997 hsa-miR-664-002897 0.1321
hsa-miR-674-
002021 0.6997 hsa-miR-665-002681 1.6749
hsa-miR-708-
002341 0.842 hsa-miR-668-001992 1.6749
hsa-miR-744-
002324 0.6076 hsa-miR-675-002005 1.6749
hsa-miR-758-
001990 0.6997
hsa-miR-708#-
002342 1.6749
hsa-miR-871-
002354 0.6997
hsa-miR-7-2#-
002314 1.6749
hsa-miR-872-
002264 0.6997 hsa-miR-720-002895 6.3641
hsa-miR-873-
002356 0.6997
hsa-miR-744#-
002325 1.6749
hsa-miR-874-
002268 0.6997 hsa-miR-765-002643 1.6749
hsa-miR-875-3p-
002204 0.6997 hsa-miR-766-001986 2.6832
hsa-miR-876-3p-
002225 0.6997
hsa-miR-767-3p-
001995 1.6749
hsa-miR-876-5p-
002205 0.6997
hsa-miR-767-5p-
001993 1.6749
hsa-miR-885-3p-
002372 0.6997
hsa-miR-769-3p-
002003 1.6749
hsa-miR-885-5p-
002296 0.6997
hsa-miR-769-5p-
001998 1.2843
hsa-miR-886-3p-
002194 0.8041
hsa-miR-770-5p-
002002 0.3295
hsa-miR-886-5p-
002193 0.9361 hsa-miR-802-002004 1.6749
hsa-miR-887-
002374 0.6997
hsa-miR-875-5p-
002203 2.1144
hsa-miR-888-
002212 143.2352
hsa-miR-888#-
002213 0.1604
hsa-miR-889-
002202 0.6997
hsa-miR-892b-
002214 1.6749
hsa-miR-890-
002209 0.6997 hsa-miR-9#-002231 1.6749
hsa-miR-891a-
002191 0.6997 hsa-miR-920-002150 1.6749
hsa-miR-891b-
002210 0.6997 hsa-miR-921-002151 1.6749
hsa-miR-892a-
002195 0.6997 hsa-miR-922-002152 1.6749
hsa-miR-9-
000583 0.6997 hsa-miR-924-002154 1.6749
hsa-miR-92a-
000431 1.5482
hsa-miR-92a-1#-
002137 1.6749
hsa-miR-95-
000433 0.9421
hsa-miR-92a-2#-
002138 1.6749
hsa-miR-98-
000577 0.6997
hsa-miR-92b#-
002343 1.6749
hsa-miR-99a-
000435 0.4961 hsa-miR-93#-002139 3.5192
hsa-miR-99b-
000436 0.5992 hsa-miR-933-002176 1.6749
mmu-miR-124a-
001182 0.6997 hsa-miR-934-002177 1.6749
mmu-miR-129-
3p-001184 0.0645 hsa-miR-935-002178 1.6749
mmu-miR-134-
001186 0.4112 hsa-miR-936-002179 1.6749
mmu-miR-137-
001129 0.6997 hsa-miR-937-002180 1.6749
mmu-miR-140-
001187 0.5022 hsa-miR-938-002181 1.6749
mmu-miR-153-
001191 0.6997 hsa-miR-939-002182 1.6749
mmu-miR-187-
001193 0.6997 hsa-miR-941-002183 2.7411
mmu-miR-374-
5p-001319 0.7849 hsa-miR-942-002187 0.9784
mmu-miR-379-
001138 1.5525 hsa-miR-943-002188 1.6749
mmu-miR-451-
001141 0.6997 hsa-miR-944-002189 1.6749
mmu-miR-491-
001630 0.4735 hsa-miR-96#-002140 1.0779
mmu-miR-495-
001663 0.458
hsa-miR-99a#-
002141 0.0339
mmu-miR-496-
001953 0.6997
hsa-miR-99b#-
002196 1.646
mmu-miR-499-
001352 0.6997 mmu-let-7d#-001178 1.6749
mmu-miR-615-
001960 0.6997
rno-miR-29c#-
001818 0.4655
mmu-miR-93-
001090 0.2517 rno-miR-7#-001338 0.7349
B2M Ct value U6 Ct value
Untreated Mock 20.71
21.73
21.03
16.54
17.45
16.78
Untreated pre-miR Negative Control 20.35
20.76
20.64
16.88
17.7
17.06
Untreated pre-miR-424-3p 20.72
20.56
20.74
16.44
17.44
18.12
TGF-β1-treated Mock 21.41
22.12
21.39
16.64
16.43
17.1
TGF-β1-treated pre-miR Negative
Control
20.50
21.53
21.44
19.36
18.99
19.54
TGF-β1-treated pre-miR-424-3p 20.67
20.99
21.34
17.4
17.44
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Appendix 2: Comparison of CT values between B2M with U6 in NOF804
NOF804 cells were seeded and transfected with 50 nM of pre-miR negative control or 50
nM of pre-miR-424-3p for 48 h. Following that, cells were serum starved and treated
with TGF-β1 or left untreated. RNA was isolated from fibroblasts and later used for
cDNA synthesis. The qRT-PCR analysis was done using primers designed to amplify
B2M and U6. This table shows B2M has the least variable in CT values between samples
than that U
